Orange Book Companion
Patent Expiration View
Products whose next patent expiration is in 2020

Patents whose numbers are in italics have been extended under 35 USC 156. All expiration dates include applicable Sec. 156 and pediatric (PED) extensions.

Products tagged as GENERIC have had a generic equivalent approved for at least one strength of the product.


CLARINEX (TABLET) (ORAL) DESLORATADINE [GENERIC AB]
Drug Classes: histamine-1 (H1) receptor antagonist
NDA Applicant: MERCK SHARP DOHME      NDA No.: 021165  Prod. No.: 001 RX (5MG)
PatentsExpirationPatented Use
Pat. No. 6100274 8-chloro-6,11-dihydro-11-](4-piperidylidine)-5H-benzo [5,6]cyclohepta[1,2-bpyridine oral compositions
Claim Types: Formulation
Pat. Sub. Date(s): 001: None
Jan 7, 2020 *PED 
Pat. No. 7405223 Treating allergic and inflammatory conditions
Claim Types: Method of administration; Method of use
Pat. Sub. Date(s): 001: None
Jan 7, 2020 *PEDU-886: Administering desloratadine to treat the symptoms of perennial allergic rhinitis, seasonal allergic rhinitis, or chronic idiopathic urticaria

CLARINEX (TABLET, ORALLY DISINTEGRATING) (ORAL) DESLORATADINE [GENERIC AB]
Drug Classes: histamine-1 (H1) receptor antagonist
NDA Applicant: MERCK SHARP DOHME      NDA No.: 021312  Prod. No.: 001 RX (5MG); 002 RX (2.5MG)
PatentsExpirationPatented Use
Pat. No. 6100274 DP* 8-chloro-6,11-dihydro-11-](4-piperidylidine)-5H-benzo [5,6]cyclohepta[1,2-bpyridine oral compositions
Claim Types: Formulation
Pat. Sub. Date(s): All strengths: None
Jan 7, 2020 *PED 
Pat. No. 7618649 DP* Extended release oral dosage composition
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): All strengths: None
Jun 19, 2021 *PEDU-1017: A method of treating nasal and non-nasal symptoms of seasonal allergic rhinitis

CLARINEX-D 12 HOUR (TABLET, EXTENDED RELEASE) (ORAL) DESLORATADINE; PSEUDOEPHEDRINE SULFATE
Drug Classes: histamine-1 (H1) receptor antagonist; alpha adrenergic agonist
NDA Applicant: MERCK SHARP DOHME      NDA No.: 021313  Prod. No.: 001 RX (2.5MG;120MG)
PatentsExpirationPatented Use
Pat. No. 6100274 DP* 8-chloro-6,11-dihydro-11-](4-piperidylidine)-5H-benzo [5,6]cyclohepta[1,2-bpyridine oral compositions
Claim Types: Formulation
Pat. Sub. Date(s): 001: None
Jan 7, 2020 *PED 
Pat. No. 8187630 DP* Extended release oral dosage composition
Claim Types: Formulation; Method of administration
Pat. Sub. Date(s): 001: Jun 28, 2012
Dec 19, 2020U-1017: A method of treating nasal and non-nasal symptoms of seasonal allergic rhinitis
Pat. No. 6709676 DP* Extended release oral dosage composition
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): 001: None
Feb 18, 2021U-707: Allergic rhinitis
Pat. No. 7618649 DP* Extended release oral dosage composition
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): 001: None
Jun 19, 2021 *PEDU-1017: A method of treating nasal and non-nasal symptoms of seasonal allergic rhinitis

CLARINEX D 24 HOUR (TABLET, EXTENDED RELEASE) (ORAL) DESLORATADINE; PSEUDOEPHEDRINE SULFATE [GENERIC AB]
Drug Classes: histamine-1 (H1) receptor antagonist; alpha adrenergic agonist
NDA Applicant: MERCK SHARP DOHME      NDA No.: 021605  Prod. No.: 001 RX (5MG;240MG)
PatentsExpirationPatented Use
Pat. No. 6100274 DP* 8-chloro-6,11-dihydro-11-](4-piperidylidine)-5H-benzo [5,6]cyclohepta[1,2-bpyridine oral compositions
Claim Types: Formulation
Pat. Sub. Date(s): 001: None
Jan 7, 2020 *PED 
Pat. No. 7618649 DP* Extended release oral dosage composition
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): 001: None
Jun 19, 2021 *PEDU-1017: A method of treating nasal and non-nasal symptoms of seasonal allergic rhinitis
Pat. No. 6979463 DP* Stable extended release oral dosage composition
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): 001: None
Mar 28, 2022 
Pat. No. 7820199 DP* Stable extended release oral dosage composition
Claim Types: Formulation
Pat. Sub. Date(s): 001: Nov 23, 2010
Sep 28, 2022 *PED 

MICARDIS (TABLET) (ORAL) TELMISARTAN [GENERIC AB]
Drug Classes: angiotensin II receptor blocker
NDA Applicant: BOEHRINGER INGELHEIM      NDA No.: 020850  Prod. No.: 001 RX (40MG); 003 RX (20MG)
PatentsExpirationPatented Use
Pat. No. 6358986 Polymorphs of telmisartan
Claim Types: Formulation
Pat. Sub. Date(s): All strengths: None
Jan 10, 2020 

MICARDIS (TABLET) (ORAL) TELMISARTAN [GENERIC AB]
Drug Classes: angiotensin II receptor blocker
NDA Applicant: BOEHRINGER INGELHEIM      NDA No.: 020850  Prod. No.: 002 RX (80MG)
PatentsExpirationPatented Use
Pat. No. 6358986 Polymorphs of telmisartan
Claim Types: Formulation
Pat. Sub. Date(s): 002: None
Jan 10, 2020 
Pat. No. 7998953 Use of inhibitors of the renin-angiotensin system
Claim Types: Method of use
Pat. Sub. Date(s): 002: Sep 9, 2011
Jun 6, 2020U-1177: Reduction of cardiac tissue damage associated with myocardial infarction
Pat. No. 8003679 Use of inhibitors of the renin-angiotensin system
Claim Types: Method of use
Pat. Sub. Date(s): 002: Sep 9, 2011
Oct 6, 2022U-1176: Treatment or prevention of stroke

MICARDIS HCT (TABLET) (ORAL) HYDROCHLOROTHIAZIDE; TELMISARTAN [GENERIC AB]
Drug Classes: thiazide diuretic; angiotensin II receptor blocker
NDA Applicant: BOEHRINGER INGELHEIM      NDA No.: 021162  Prod. No.: 001 RX (12.5MG;40MG); 002 RX (12.5MG;80MG)
PatentsExpirationPatented Use
Pat. No. 6358986 Polymorphs of telmisartan
Claim Types: Formulation
Pat. Sub. Date(s): All strengths: None
Jan 10, 2020 

NEXAVAR (TABLET) (ORAL) SORAFENIB TOSYLATE
Drug Classes: kinase inhibitor
NDA Applicant: BAYER HLTHCARE      NDA No.: 021923  Prod. No.: 001 RX (EQ 200MG BASE)
PatentsExpirationPatented Use
Pat. No. 7235576 DS* DP* Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
Claim Types: Compound; Method of use
Pat. Sub. Date(s): 001: None
Jan 12, 2020 
Pat. No. 7351834 DS* [Extended 898 days (2.5 years)]
.omega.-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
Claim Types: Compound; New polymorph, salt or hydrate
Pat. Sub. Date(s): 001: None
Jan 12, 2020 
Pat. No. 7897623 DP* Omega-carboxyl aryl substituted ureas as P38 kinase inhibitors
Claim Types: Composition; Formulation
Pat. Sub. Date(s): 001: None
Jan 12, 2020 
Pat. No. 8124630 .omega.-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
Claim Types: Method of use
Pat. Sub. Date(s): 001: Dec 16, 2013
Jan 12, 2020U-1459: Treatment of carcinoma of the thyroid
Pat. No. 8841330 Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
Claim Types: Method of use
Pat. Sub. Date(s): 001: May 15, 2015
Jan 12, 2020U-1696: Treatment of unresectable hepatocellular carcinoma
Pat. No. 8618141 Aryl ureas with angiogenesis inhibiting activity
Claim Types: Method of use
Pat. Sub. Date(s): 001: Jan 30, 2014
Feb 11, 2023U-1480: Treatment of advanced renal cell carcinoma
Pat. No. 8877933 DS* DP* Thermodynamically stable form of a tosylate salt
Claim Types: New polymorph, salt or hydrate; Process; Composition; Formulation; Method of use; Product-by-process
Pat. Sub. Date(s): 001: Dec 22, 2014
Dec 24, 2027U-1624: Treatment of unresectable hepatocellular carcinoma, advanced renal cell carcinoma, or differentiated thyroid carcinoma.
Pat. No. 9737488 DP* Pharmaceutical composition for the treatment of cancer
Claim Types: Formulation; Process
Pat. Sub. Date(s): 001: Sep 20, 2017
Sep 10, 2028U-1480: Treatment of advanced renal cell carcinoma
U-1696: Treatment of unresectable hepatocellular carcinoma
U-2107: Treatment of locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment
ExclusivityExpirationExclusivity Description
Exclusivity Code: ODE - Orphan drug exclusivityNov 22, 2020ODE-56: Treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DCT) that is refractory to radioactive iodine treatment.

TRIESENCE (INJECTABLE) (INTRAVITREAL) TRIAMCINOLONE ACETONIDE
Drug Classes: corticosteroid
NDA Applicant: NOVARTIS      NDA No.: 022048  Prod. No.: 001 RX (40MG/ML (40MG/ML))
PatentsExpirationPatented Use
Pat. No. 6395294 DP* Method of visualization of the vitreous during vitrectomy
Claim Types: Diagnostic or surgical method
Pat. Sub. Date(s): 001: None
Jan 13, 2020U-846: Use for delineation (visualization) during a vitrectomy surgical procedure
Pat. No. 8211880 Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection
Claim Types: Method of use; Diagnostic or surgical method
Pat. Sub. Date(s): 001: Aug 6, 2012
Mar 10, 2029U-1257: Treatment of ophthalmic disorders
U-1258: Visualization during vitrectomy procedures
Pat. No. 8128960 DP* Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection
Claim Types: Formulation
Pat. Sub. Date(s): 001: None
Dec 17, 2029 

BYDUREON (FOR SUSPENSION, EXTENDED RELEASE) (SUBCUTANEOUS) EXENATIDE SYNTHETIC
Drug Classes: glucagon-like peptide-1 (GLP-1) receptor agonist
NDA Applicant: ASTRAZENECA AB      NDA No.: 022200  Prod. No.: 001 RX (2MG/VIAL)
PatentsExpirationPatented Use
Pat. No. 6872700 Methods for glucagon suppression
Claim Types: Method of use
Pat. Sub. Date(s): 001: None
Jan 14, 2020U-2588: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with dapagliflozin and metformin
U-2589: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin
U-2590: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies
U-2591: Lowering plasma glucagon in adults with Type 2 diabetes mellitus by administering exenatide as an adjunct to diet and exercise
Pat. No. 6495164 DP* Preparation of injectable suspensions having improved injectability
Claim Types: Formulation; Process; Method of use; Product-by-process
Pat. Sub. Date(s): 001: None
May 25, 2020 
Pat. No. 6667061 DP* Preparation of injectable suspensions having improved injectability
Claim Types: Formulation
Pat. Sub. Date(s): 001: None
May 25, 2020 
Pat. No. 6479065 DP* Process for the preparation of polymer-based sustained release compositions
Claim Types: Formulation; Method of administration
Pat. Sub. Date(s): 001: None
Aug 10, 2020 
Pat. No. 6414126 DS* DP* C-aryl glucoside SGLT2 inhibitors and method
Claim Types: Compound; Composition; Formulation; Method of use
Pat. Sub. Date(s): 001: Nov 17, 2017
Oct 4, 2020U-2588: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with dapagliflozin and metformin
Pat. No. 6515117 DS* DP* C-aryl glucoside SGLT2 inhibitors and method
Claim Types: Compound; Composition; Formulation; Method of use
Pat. Sub. Date(s): 001: Nov 17, 2017
Oct 4, 2020U-2588: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with dapagliflozin and metformin
Pat. No. 6936590 C-aryl glucoside SGLT2 inhibitors and method
Claim Types: Method of use
Pat. Sub. Date(s): 001: Nov 17, 2017
Oct 4, 2020U-2588: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with dapagliflozin and metformin
Pat. No. 9198925 Pharmaceutical formulations containing an SGLT2 inhibitor
Claim Types: Method of use
Pat. Sub. Date(s): 001: Nov 17, 2017
Oct 4, 2020U-2588: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with dapagliflozin and metformin
Pat. No. 7223440 DP* Residual solvent extraction method and microparticles produced thereby
Claim Types: Product-by-process; Process
Pat. Sub. Date(s): 001: None
Aug 31, 2021 
Pat. No. 6824822 DP* Residual solvent extraction method and microparticles produced thereby
Claim Types: Product-by-process; Process
Pat. Sub. Date(s): 001: None
Oct 9, 2022 
Pat. No. 7563871 DP* Polymer-based sustained release device
Claim Types: Formulation
Pat. Sub. Date(s): 001: None
Apr 15, 2024 
Pat. No. 9238076 DP* Polymer-based sustained release device
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): 001: Feb 17, 2016
Apr 15, 2024U-2588: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with dapagliflozin and metformin
U-2589: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin
U-2590: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies
U-2599: Improving glycemic control in adults with Type 2 diabetes mellitus by administering an exenatide formulation as an adjunct to diet and exercise to provide a release profile having a ratio of C-max to C-avg of about 3 or less
Pat. No. 7612176 DP* Polymer-based sustained release device
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): 001: None
Apr 13, 2025U-2588: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with dapagliflozin and metformin
U-2589: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin
U-2590: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies
U-2592: Improving glycemic control in adults with Type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise
Pat. No. 8431685 DP* Polymer-based sustained release device
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): 001: May 29, 2013
Apr 13, 2025U-2588: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with dapagliflozin and metformin
U-2589: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin
U-2590: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies
U-2598: Improving glycemic control in adults with Type 2 diabetes mellitus by administering an injectable sustained release formulation of exenatide as an adjunct to diet and exercise
Pat. No. 8461105 DP* Polymer-based sustained release device
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): 001: Jul 10, 2013
Apr 13, 2025U-2588: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with dapagliflozin and metformin
U-2589: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin
U-2590: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies
U-2598: Improving glycemic control in adults with Type 2 diabetes mellitus by administering an injectable sustained release formulation of exenatide as an adjunct to diet and exercise
Pat. No. 7456254 DP* Polymer-based sustained release device
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): 001: None
Jun 30, 2025U-2588: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with dapagliflozin and metformin
U-2589: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin
U-2590: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies
U-2592: Improving glycemic control in adults with Type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise
Pat. No. 8329648 Methods for treating diabetes and reducing body weight
Claim Types: Method of use
Pat. Sub. Date(s): 001: Jan 10, 2013
Aug 18, 2026U-2588: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with dapagliflozin and metformin
U-2589: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin
U-2590: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies
U-2593: Improving glycemic control in adults with Type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml
U-2594: Reducing fasting plasma glucose in adults with Type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml
U-2595: Reducing body weight in adults with Type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml
U-2596: Reducing HBA1C in adults with Type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml
Pat. No. 8906851 Method for treating diabetes
Claim Types: Method of use
Pat. Sub. Date(s): 001: Jan 6, 2015
Aug 18, 2026U-2588: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with dapagliflozin and metformin
U-2589: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin
U-2590: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies
U-2593: Improving glycemic control in adults with Type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml
Pat. No. 9884092 Methods for treating diabetes and reducing body weight
Claim Types: Method of use
Pat. Sub. Date(s): 001: Mar 6, 2018
Aug 18, 2026U-2588: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with dapagliflozin and metformin
U-2589: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin
U-2590: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies
U-2593: Improving glycemic control in adults with Type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml
U-2594: Reducing fasting plasma glucose in adults with Type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml
U-2595: Reducing body weight in adults with Type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml
U-2596: Reducing HBA1C in adults with Type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml
Pat. No. 8501698 DP* Crystal structures of SGLT2 inhibitors and processes for preparing same
Claim Types: New polymorph, salt or hydrate; Composition; Formulation; Method of use
Pat. Sub. Date(s): 001: Nov 17, 2017
Jun 20, 2027U-2588: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with dapagliflozin and metformin
Pat. No. 8361972 Pharmaceutical formulations containing an SGLT2 inhibitor
Claim Types: Method of use
Pat. Sub. Date(s): 001: Nov 17, 2017
Mar 21, 2028U-2588: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with dapagliflozin and metformin
ExclusivityExpirationExclusivity Description
Exclusivity Code: M - MiscellaneousOct 20, 2020M-212: Information added to the labeling regarding the safety and efficacy of dapagliflozin in patients with Type 2 diabetes who have inadequate glycemic control on a background combination of metformin and exenatide extended release
Exclusivity Code: M - MiscellaneousApr 2, 2021M-224: Information added to the labeling regarding the safety and efficacy of exenatide extended release as add-on in patients with Type 2 diabetes who have inadequate glycemic control on basal insulin glargine with or without metformin

BYDUREON BCISE (SUSPENSION, EXTENDED RELEASE) (SUBCUTANEOUS) EXENATIDE
Drug Classes: glucagon-like peptide-1 (GLP-1) receptor agonist
NDA Applicant: ASTRAZENECA AB      NDA No.: 209210  Prod. No.: 001 RX (2MG/0.85ML (2MG/0.85ML))
PatentsExpirationPatented Use
Pat. No. 6872700 Methods for glucagon suppression
Claim Types: Method of use
Pat. Sub. Date(s): 001: Nov 3, 2017
Jan 14, 2020U-2589: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin
U-2590: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies
U-2591: Lowering plasma glucagon in adults with Type 2 diabetes mellitus by administering exenatide as an adjunct to diet and exercise
Pat. No. 6667061 DP* Preparation of injectable suspensions having improved injectability
Claim Types: Formulation
Pat. Sub. Date(s): 001: Nov 3, 2017
May 25, 2020 
Pat. No. 6479065 DP* Process for the preparation of polymer-based sustained release compositions
Claim Types: Formulation; Method of administration
Pat. Sub. Date(s): 001: Nov 3, 2017
Aug 10, 2020 
Pat. No. 6414126 C-aryl glucoside SGLT2 inhibitors and method
Claim Types: Compound; Composition; Formulation; Method of use
Pat. Sub. Date(s): 001: Aug 21, 2019
Oct 4, 2020U-2588: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with dapagliflozin and metformin
Pat. No. 6515117 C-aryl glucoside SGLT2 inhibitors and method
Claim Types: Compound; Composition; Formulation; Method of use
Pat. Sub. Date(s): 001: Aug 21, 2019
Oct 4, 2020U-2588: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with dapagliflozin and metformin
Pat. No. 6936590 C-aryl glucoside SGLT2 inhibitors and method
Claim Types: Method of use
Pat. Sub. Date(s): 001: Aug 21, 2019
Oct 4, 2020U-2588: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with dapagliflozin and metformin
Pat. No. 9198925 Pharmaceutical formulations containing an SGLT2 inhibitor
Claim Types: Method of use
Pat. Sub. Date(s): 001: Aug 21, 2019
Oct 4, 2020U-2588: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with dapagliflozin and metformin
Pat. No. 7223440 DP* Residual solvent extraction method and microparticles produced thereby
Claim Types: Product-by-process; Process
Pat. Sub. Date(s): 001: Nov 3, 2017
Aug 31, 2021 
Pat. No. 6824822 DP* Residual solvent extraction method and microparticles produced thereby
Claim Types: Product-by-process; Process
Pat. Sub. Date(s): 001: Nov 3, 2017
Oct 9, 2022 
Pat. No. 7563871 DP* Polymer-based sustained release device
Claim Types: Formulation
Pat. Sub. Date(s): 001: Nov 3, 2017
Apr 15, 2024 
Pat. No. 9238076 DP* Polymer-based sustained release device
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): 001: Nov 3, 2017
Apr 15, 2024U-2589: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin
U-2590: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies
U-2597: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with dapagliflozin as add-on to metformin
U-2599: Improving glycemic control in adults with Type 2 diabetes mellitus by administering an exenatide formulation as an adjunct to diet and exercise to provide a release profile having a ratio of C-max to C-avg of about 3 or less
Pat. No. 7612176 DP* Polymer-based sustained release device
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): 001: Nov 3, 2017
Apr 13, 2025U-2589: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin
U-2590: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies
U-2592: Improving glycemic control in adults with Type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise
Pat. No. 8431685 DP* Polymer-based sustained release device
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): 001: Nov 3, 2017
Apr 13, 2025U-2589: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin
U-2590: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies
U-2597: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with dapagliflozin as add-on to metformin
U-2598: Improving glycemic control in adults with Type 2 diabetes mellitus by administering an injectable sustained release formulation of exenatide as an adjunct to diet and exercise
Pat. No. 8461105 DP* Polymer-based sustained release device
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): 001: Nov 3, 2017
Apr 13, 2025U-2589: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin
U-2590: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies
U-2597: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with dapagliflozin as add-on to metformin
U-2598: Improving glycemic control in adults with Type 2 diabetes mellitus by administering an injectable sustained release formulation of exenatide as an adjunct to diet and exercise
Pat. No. 7456254 DP* Polymer-based sustained release device
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): 001: Nov 3, 2017
Jun 30, 2025U-2588: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with dapagliflozin and metformin
U-2589: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin
U-2590: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies
U-2592: Improving glycemic control in adults with Type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise
Pat. No. 8329648 Methods for treating diabetes and reducing body weight
Claim Types: Method of use
Pat. Sub. Date(s): 001: Nov 3, 2017
Aug 18, 2026U-2588: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with dapagliflozin and metformin
U-2589: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin
U-2590: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies
U-2593: Improving glycemic control in adults with Type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml
U-2594: Reducing fasting plasma glucose in adults with Type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml
U-2595: Reducing body weight in adults with Type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml
U-2596: Reducing HBA1C in adults with Type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml
Pat. No. 8906851 Method for treating diabetes
Claim Types: Method of use
Pat. Sub. Date(s): 001: Nov 3, 2017
Aug 18, 2026U-2589: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin
U-2590: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies
U-2593: Improving glycemic control in adults with Type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml
U-2597: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with dapagliflozin as add-on to metformin
Pat. No. 9884092 Methods for treating diabetes and reducing body weight
Claim Types: Method of use
Pat. Sub. Date(s): 001: Mar 6, 2018
Aug 18, 2026U-2589: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin
U-2590: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies
U-2593: Improving glycemic control in adults with Type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml
U-2594: Reducing fasting plasma glucose in adults with Type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml
U-2595: Reducing body weight in adults with Type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml
U-2596: Reducing HBA1C in adults with Type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml
U-2597: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with dapagliflozin as add-on to metformin
Pat. No. 8501698 Crystal structures of SGLT2 inhibitors and processes for preparing same
Claim Types: New polymorph, salt or hydrate; Composition; Formulation; Method of use
Pat. Sub. Date(s): 001: Aug 21, 2019
Jun 20, 2027U-2588: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with dapagliflozin and metformin
Pat. No. 8361972 Pharmaceutical formulations containing an SGLT2 inhibitor
Claim Types: Method of use
Pat. Sub. Date(s): 001: Aug 21, 2019
Mar 21, 2028U-2588: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with dapagliflozin and metformin
Pat. No. 8895033 DP* Sustained release formulations using non-aqueous carriers
Claim Types: Formulation; Method of use; Kit
Pat. Sub. Date(s): 001: Nov 3, 2017
Oct 4, 2030U-2589: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin
U-2590: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies
U-2597: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with dapagliflozin as add-on to metformin
U-2600: Improving glycemic control in adults with Type 2 diabetes mellitus by administering a pre-mixed exenatide formulation as an adjunct to diet and exercise
U-2601: Stimulating insulin release in adults with Type 2 diabetes mellitus by administering a pre-mixed exenatide formulation as an adjunct to diet and exercise
U-2602: Delaying gastric emptying in adults with Type 2 diabetes mellitus by administering a pre-mixed exenatide formulation as an adjunct to diet and exercise
ExclusivityExpirationExclusivity Description
Exclusivity Code: NP - New productOct 20, 2020 

BYDUREON PEN (FOR SUSPENSION, EXTENDED RELEASE) (SUBCUTANEOUS) EXENATIDE SYNTHETIC
Drug Classes: glucagon-like peptide-1 (GLP-1) receptor agonist
NDA Applicant: ASTRAZENECA AB      NDA No.: 022200  Prod. No.: 002 RX (2MG)
PatentsExpirationPatented Use
Pat. No. 6872700 Methods for glucagon suppression
Claim Types: Method of use
Pat. Sub. Date(s): 002: None
Jan 14, 2020U-2588: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with dapagliflozin and metformin
U-2589: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin
U-2590: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies
U-2591: Lowering plasma glucagon in adults with Type 2 diabetes mellitus by administering exenatide as an adjunct to diet and exercise
Pat. No. 6495164 DP* Preparation of injectable suspensions having improved injectability
Claim Types: Formulation; Process; Method of use; Product-by-process
Pat. Sub. Date(s): 002: Mar 28, 2014
May 25, 2020 
Pat. No. 6667061 DP* Preparation of injectable suspensions having improved injectability
Claim Types: Formulation
Pat. Sub. Date(s): 002: Mar 28, 2014
May 25, 2020 
Pat. No. 6479065 DP* Process for the preparation of polymer-based sustained release compositions
Claim Types: Formulation; Method of administration
Pat. Sub. Date(s): 002: Mar 28, 2014
Aug 10, 2020 
Pat. No. 6414126 DS* DP* C-aryl glucoside SGLT2 inhibitors and method
Claim Types: Compound; Composition; Formulation; Method of use
Pat. Sub. Date(s): 002: Nov 15, 2017
Oct 4, 2020U-2588: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with dapagliflozin and metformin
Pat. No. 6515117 DS* DP* C-aryl glucoside SGLT2 inhibitors and method
Claim Types: Compound; Composition; Formulation; Method of use
Pat. Sub. Date(s): 002: Nov 15, 2017
Oct 4, 2020U-2588: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with dapagliflozin and metformin
Pat. No. 6936590 C-aryl glucoside SGLT2 inhibitors and method
Claim Types: Method of use
Pat. Sub. Date(s): 002: Nov 15, 2017
Oct 4, 2020U-2588: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with dapagliflozin and metformin
Pat. No. 9198925 Pharmaceutical formulations containing an SGLT2 inhibitor
Claim Types: Method of use
Pat. Sub. Date(s): 002: Nov 15, 2017
Oct 4, 2020U-2588: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with dapagliflozin and metformin
Pat. No. 7223440 DP* Residual solvent extraction method and microparticles produced thereby
Claim Types: Product-by-process; Process
Pat. Sub. Date(s): 002: Mar 28, 2014
Aug 31, 2021 
Pat. No. 6824822 DP* Residual solvent extraction method and microparticles produced thereby
Claim Types: Product-by-process; Process
Pat. Sub. Date(s): 002: Mar 28, 2014
Oct 9, 2022 
Pat. No. 7563871 DP* Polymer-based sustained release device
Claim Types: Formulation
Pat. Sub. Date(s): 002: Mar 28, 2014
Apr 15, 2024 
Pat. No. 9238076 DP* Polymer-based sustained release device
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): 002: Feb 17, 2016
Apr 15, 2024U-2588: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with dapagliflozin and metformin
U-2589: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin
U-2590: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies
U-2599: Improving glycemic control in adults with Type 2 diabetes mellitus by administering an exenatide formulation as an adjunct to diet and exercise to provide a release profile having a ratio of C-max to C-avg of about 3 or less
Pat. No. 7612176 DP* Polymer-based sustained release device
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): 002: Mar 28, 2014
Apr 13, 2025U-2588: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with dapagliflozin and metformin
U-2589: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin
U-2590: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies
U-2592: Improving glycemic control in adults with Type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise
Pat. No. 8431685 DP* Polymer-based sustained release device
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): 002: Mar 28, 2014
Apr 13, 2025U-2588: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with dapagliflozin and metformin
U-2589: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin
U-2590: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies
U-2598: Improving glycemic control in adults with Type 2 diabetes mellitus by administering an injectable sustained release formulation of exenatide as an adjunct to diet and exercise
Pat. No. 8461105 DP* Polymer-based sustained release device
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): 002: Mar 28, 2014
Apr 13, 2025U-2588: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with dapagliflozin and metformin
U-2589: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin
U-2590: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies
U-2598: Improving glycemic control in adults with Type 2 diabetes mellitus by administering an injectable sustained release formulation of exenatide as an adjunct to diet and exercise
Pat. No. 7456254 DP* Polymer-based sustained release device
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): 002: Mar 28, 2014
Jun 30, 2025U-2588: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with dapagliflozin and metformin
U-2589: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin
U-2590: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies
U-2592: Improving glycemic control in adults with Type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise
Pat. No. 8329648 Methods for treating diabetes and reducing body weight
Claim Types: Method of use
Pat. Sub. Date(s): 002: Mar 28, 2014
Aug 18, 2026U-2588: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with dapagliflozin and metformin
U-2589: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin
U-2590: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies
U-2593: Improving glycemic control in adults with Type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml
U-2594: Reducing fasting plasma glucose in adults with Type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml
U-2595: Reducing body weight in adults with Type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml
U-2596: Reducing HBA1C in adults with Type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml
Pat. No. 8906851 Method for treating diabetes
Claim Types: Method of use
Pat. Sub. Date(s): 002: Jan 6, 2015
Aug 18, 2026U-2588: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with dapagliflozin and metformin
U-2589: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin
U-2590: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies
U-2593: Improving glycemic control in adults with Type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml
Pat. No. 9884092 Methods for treating diabetes and reducing body weight
Claim Types: Method of use
Pat. Sub. Date(s): 002: Mar 6, 2018
Aug 18, 2026U-2588: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with dapagliflozin and metformin
U-2589: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin
U-2590: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies
U-2593: Improving glycemic control in adults with Type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml
U-2594: Reducing fasting plasma glucose in adults with Type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml
U-2595: Reducing body weight in adults with Type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml
U-2596: Reducing HBA1C in adults with Type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml
Pat. No. 8501698 DP* Crystal structures of SGLT2 inhibitors and processes for preparing same
Claim Types: New polymorph, salt or hydrate; Composition; Formulation; Method of use
Pat. Sub. Date(s): 002: Nov 15, 2017
Jun 20, 2027U-2588: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with dapagliflozin and metformin
Pat. No. 8758292 DP* Administering apparatus with functional drive element
Claim Types: Device
Pat. Sub. Date(s): 002: Nov 15, 2017
Nov 12, 2027 
Pat. No. 8216180 DP* Administering apparatus with functional drive element
Claim Types: Device
Pat. Sub. Date(s): 002: Mar 28, 2014
Jan 12, 2028 
Pat. No. 8361972 Pharmaceutical formulations containing an SGLT2 inhibitor
Claim Types: Method of use
Pat. Sub. Date(s): 002: Nov 15, 2017
Mar 21, 2028U-2588: As an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in combination with dapagliflozin and metformin
Pat. No. 8439864 DP* Device for administering fluid from a multi-chamber ampoule in incremental steps
Claim Types: Device
Pat. Sub. Date(s): 002: Mar 28, 2014
Mar 25, 2028 
Pat. No. 9320853 DP* Method for administering a fluid active substance from a multi-chamber ampoule
Claim Types: Device; Process
Pat. Sub. Date(s): 002: Nov 15, 2017
Mar 25, 2028 
Pat. No. 8827963 DP* Administering device with holding mechanism
Claim Types: Device
Pat. Sub. Date(s): 002: Nov 15, 2017
Feb 4, 2029 
Pat. No. 8690837 DP* Mixing device for a two-chamber ampoule
Claim Types: Device
Pat. Sub. Date(s): 002: Nov 15, 2017
May 19, 2029 
Pat. No. 8998876 DP* Ampoule comprising an ampoule holder
Claim Types: Device
Pat. Sub. Date(s): 002: Nov 15, 2017
Jan 7, 2030 
Pat. No. 8721615 DP* Ampoule comprising an ampoule holder
Claim Types: Device
Pat. Sub. Date(s): 002: Nov 15, 2017
Jan 18, 2030 
ExclusivityExpirationExclusivity Description
Exclusivity Code: M - MiscellaneousApr 2, 2021M-224: Information added to the labeling regarding the safety and efficacy of exenatide extended release as add-on in patients with Type 2 diabetes who have inadequate glycemic control on basal insulin glargine with or without metformin

BYETTA (INJECTABLE) (SUBCUTANEOUS) EXENATIDE SYNTHETIC
Drug Classes: glucagon-like peptide-1 (GLP-1) receptor agonist
NDA Applicant: ASTRAZENECA AB      NDA No.: 021773  Prod. No.: 001 RX (300MCG/1.2ML (250MCG/ML)); 002 RX (600MCG/2.4ML (250MCG/ML))
PatentsExpirationPatented Use
Pat. No. 6872700 Methods for glucagon suppression
Claim Types: Method of use
Pat. Sub. Date(s): All strengths: None
Jan 14, 2020U-654: Lowering plasma glucagon in a subject in need thereof, including one with Type 2 diabetes, by administering an exendin or analog, such as exendin-4
Pat. No. 6902744 DP* Exendin agonist formulations and methods of administration thereof
Claim Types: Formulation
Pat. Sub. Date(s): All strengths: None
Jan 14, 2020 

GLUCOVANCE (TABLET) (ORAL) GLYBURIDE; METFORMIN HYDROCHLORIDE
Drug Classes: sulfonylurea; biguanide
NDA Applicant: BRISTOL MYERS SQUIBB      NDA No.: 021178  Prod. No.: 001 DISC (1.25MG;250MG**); 002 DISC (2.5MG;500MG**); 003 DISC (5MG;500MG**)
PatentsExpirationPatented Use
Pat. No. 6303146 Solid oral dosage form comprising a combination of metformin and glibenclamide
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): All strengths: None
Jan 14, 2020 *PEDU-412: Treatment of Type 2 diabetes

LEXIVA (TABLET) (ORAL) FOSAMPRENAVIR CALCIUM [GENERIC AB]
NDA Applicant: VIIV HLTHCARE      NDA No.: 021548  Prod. No.: 001 RX (EQ 700MG BASE)
PatentsExpirationPatented Use
Pat. No. 6514953 DS* DP* Calcium (3S) tetrahydro-3-furanyl(1S,2R)-3-[[(4-aminophenyl) sulfonyl](isobutyl)amino]-1-benzyl- 2-(phosphonooxy)propylcarbamate
Claim Types: New polymorph, salt or hydrate; Process; Method of use;
Pat. Sub. Date(s): 001: None
Jan 15, 2020 *PEDU-257: Treatment of HIV infection

LUZU (CREAM) (TOPICAL) LULICONAZOLE
Drug Classes: azole antifungal
NDA Applicant: MEDICIS      NDA No.: 204153  Prod. No.: 001 RX (1%)
PatentsExpirationPatented Use
Pat. No. 5900488 DS* DP* [Extended 1291 days (3.5 years)]
Method for treating mycosis using imidazolylacetonitrile derivatives
Claim Types: Compound; Composition; Process; Method of use
Pat. Sub. Date(s): 001: Dec 6, 2013
Jan 18, 2020 
Pat. No. 9012484 DS* DP* Crystal and pharmaceutical preparation containing the same crystal
Claim Types: New polymorph, salt or hydrate; Product-by-process; Method of use; Process
Pat. Sub. Date(s): 001: Apr 22, 2015
Sep 6, 2033U-540: Treatment of fungal infections
Pat. No. 9199977 DS* DP* Crystal having crystal habits and pharmaceutical composition obtained by processing the crystal
Claim Types: New polymorph, salt or hydrate; Process
Pat. Sub. Date(s): 001: Feb 5, 2016
Sep 6, 2033 
Pat. No. 9453006 DS* Crystalline form having specific crystal habit and pharmaceutical composition containing this crystalline form as active ingredient
Claim Types: New polymorph, salt or hydrate; Process; Method of use
Pat. Sub. Date(s): 001: Sep 29, 2016
Sep 6, 2033 
Pat. No. 8980931 DP* Method of evaluating pharmaceutical preparation containing luliconazole and index substance
Claim Types: Formulation
Pat. Sub. Date(s): 001: Mar 23, 2015
Apr 28, 2034 
ExclusivityExpirationExclusivity Description
Exclusivity Code: NPP - New patient populationFeb 20, 2021 

TECHNIVIE (TABLET) (ORAL) OMBITASVIR; PARITAPREVIR; RITONAVIR
Drug Classes: hepatitis C virus (HCV) NS5A inhibitor; hepatitis C virus (HCV) NS3/4A protease inhibitor; CYP3A inhibitor; HIV protease inhibitor
NDA Applicant: ABBVIE INC      NDA No.: 207931  Prod. No.: 001 DISC (12.5MG;75MG;50MG)
PatentsExpirationPatented Use
Pat. No. 7148359 DP* Polymorph of a pharmaceutical
Claim Types: Compound; Composition
Pat. Sub. Date(s): 001: Aug 6, 2015
Jan 19, 2020 *PED 
Pat. No. 7364752 DP* Solid dispersion pharamaceutical formulations
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): 001: Aug 6, 2015
May 10, 2021 *PED 
Pat. No. 8268349 DP* Solid pharmaceutical dosage form
Claim Types: Formulation
Pat. Sub. Date(s): 001: Aug 6, 2015
Feb 25, 2025 *PED 
Pat. No. 8399015 DP* Solid pharmaceutical dosage form
Claim Types: Formulation
Pat. Sub. Date(s): 001: Aug 6, 2015
Feb 25, 2025 *PED 
Pat. No. 8642538 DS* DP* Macrocyclic hepatitis C serine protease inhibitors
Claim Types: Compound; Composition; Method of use
Pat. Sub. Date(s): 001: Aug 6, 2015
Sep 10, 2029U-1638: Treatment of HCV infection using paritaprevir
Pat. No. 9006387 Anti-viral compounds
Claim Types: Method of use
Pat. Sub. Date(s): 001: Aug 6, 2015
Jun 10, 2030U-1687: Treatment of hcv infection using ombitasvir
Pat. No. 9044480 Compositions and methods for treating HCV
Claim Types: Method of use
Pat. Sub. Date(s): 001: Aug 6, 2015
Apr 10, 2031U-1638: Treatment of HCV infection using paritaprevir
Pat. No. 8686026 DP* Solid compositions
Claim Types: Formulation
Pat. Sub. Date(s): 001: Aug 6, 2015
Jun 9, 2031 
Pat. No. 8420596 DS* DP* Macrocyclic hepatitis C serine protease inhibitors
Claim Types: Compound; Composition
Pat. Sub. Date(s): 001: Aug 6, 2015
Oct 10, 2031 *PED 
Pat. No. 8691938 DS* DP* Anti-viral compounds
Claim Types: Compound; Composition
Pat. Sub. Date(s): 001: Aug 6, 2015
Apr 13, 2032 

BELBUCA (FILM) (BUCCAL) BUPRENORPHINE HYDROCHLORIDE
Drug Classes: partial opioid agonist
NDA Applicant: BDSI      NDA No.: 207932  Prod. No.: 001 RX (EQ 0.075MG BASE); 002 RX (EQ 0.15MG BASE); 003 RX (EQ 0.3MG BASE); 004 RX (EQ 0.45MG BASE); 005 RX (EQ 0.6MG BASE); 006 RX (EQ 0.75MG BASE); 007 RX (EQ 0.9MG BASE)
PatentsExpirationPatented Use
Pat. No. 7579019 Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces
Claim Types: Method of administration
Pat. Sub. Date(s): All strengths: Nov 20, 2015
Jan 22, 2020U-1769: Treatement [sic, Treatment] of pain by transmucosal delivery of buprenorphine
Pat. No. 8147866 DP* Transmucosal delivery devices with enhanced uptake
Claim Types: Method of administration; Formulation
Pat. Sub. Date(s): All strengths: Nov 20, 2015
Jul 23, 2027U-1769: Treatement [sic, Treatment] of pain by transmucosal delivery of buprenorphine
Pat. No. 9655843 DP* Transmucosal delivery devices with enhanced uptake
Claim Types: Method of administration; Formulation; Method of use
Pat. Sub. Date(s): All strengths: Jun 13, 2017
Jul 23, 2027U-1556: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Pat. No. 9901539 Transmucosal drug delivery devices for use in chronic pain relief
Claim Types: Method of use
Pat. Sub. Date(s): All strengths: Mar 28, 2018
Dec 21, 2032U-1556: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

BUNAVAIL (FILM) (BUCCAL) BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE
Drug Classes: partial opioid agonist; opioid antagonist
NDA Applicant: BDSI      NDA No.: 205637  Prod. No.: 001 DISC (EQ 2.1MG BASE;EQ 0.3MG BASE); 002 DISC (EQ 4.2MG BASE;EQ 0.7MG BASE); 003 DISC (EQ 6.3MG BASE;EQ 1MG BASE)
PatentsExpirationPatented Use
Pat. No. 7579019 Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces
Claim Types: Method of administration
Pat. Sub. Date(s): All strengths: Jun 20, 2014
Jan 22, 2020U-1521: Maintenance treatment of opioid dependence
Pat. No. 8147866 DP* Transmucosal delivery devices with enhanced uptake
Claim Types: Method of administration; Formulation
Pat. Sub. Date(s): All strengths: Jun 20, 2014
Jul 23, 2027U-1521: Maintenance treatment of opioid dependence
Pat. No. 9655843 DP* Transmucosal delivery devices with enhanced uptake
Claim Types: Method of administration; Formulation; Method of use
Pat. Sub. Date(s): All strengths: Jun 13, 2017
Jul 23, 2027U-2017: Treatment of opioid dependence
Pat. No. 8703177 DP* Abuse-resistant mucoadhesive devices for delivery of buprenorphine
Claim Types: Formulation
Pat. Sub. Date(s): All strengths: Jun 20, 2014
Aug 20, 2032 
Pat. No. 9522188 DP* Abuse resistant transmucosal drug delivery device
Claim Types: Formulation
Pat. Sub. Date(s): All strengths: Dec 20, 2016
Apr 24, 2035 

ONSOLIS (FILM) (BUCCAL) FENTANYL CITRATE
Drug Classes: opioid agonist
NDA Applicant: BDSI      NDA No.: 022266  Prod. No.: 001 DISC (EQ 0.2MG BASE); 002 DISC (EQ 0.4MG BASE); 003 DISC (EQ 0.6MG BASE); 004 DISC (EQ 0.8MG BASE); 005 DISC (EQ 1.2MG BASE)
PatentsExpirationPatented Use
Pat. No. 7579019 Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces
Claim Types: Method of administration
Pat. Sub. Date(s): All strengths: None
Jan 22, 2020U-767: Management of breakthrough pain in patients with cancer
Pat. No. 9597288 DP* Transmucosal delivery devices with enhanced uptake
Claim Types: Method of administration; Formulation; Method of use
Pat. Sub. Date(s): All strengths: Apr 3, 2017
Jul 23, 2027U-767: Management of breakthrough pain in patients with cancer

DALIRESP (TABLET) (ORAL) ROFLUMILAST [GENERIC AB]
Drug Classes: phosphodiesterase 4 inhibitor
NDA Applicant: ASTRAZENECA PHARMS      NDA No.: 022522  Prod. No.: 001 RX (500MCG)
PatentsExpirationPatented Use
Pat. No. 5712298 DS* DP* [Extended 5 years]
Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors
Claim Types: Compound; Composition; Method of use; Process
Pat. Sub. Date(s): 001: None
Jan 27, 2020U-1115: Treatment to reduce the risk of copd exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations
Pat. No. 8431154 DP* Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidone as excipient
Claim Types: Product-by-process
Pat. Sub. Date(s): 001: None
Feb 19, 2023 
Pat. No. 9468598 DP* Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient
Claim Types: Formulation
Pat. Sub. Date(s): 001: Nov 3, 2016
Feb 19, 2023 
Pat. No. 8536206 Process for the preparation of roflumilast
Claim Types: Method of use
Pat. Sub. Date(s): 001: Oct 15, 2013
Mar 8, 2024U-1115: Treatment to reduce the risk of copd exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations
Pat. No. 8604064 Process for the preparation of roflumilast
Claim Types: Method of use
Pat. Sub. Date(s): 001: Jan 8, 2014
Mar 8, 2024U-1115: Treatment to reduce the risk of copd exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations
Pat. No. 8618142 DP* Process for the preparation of roflumilast
Claim Types: Formulation
Pat. Sub. Date(s): 001: Jan 30, 2014
Mar 8, 2024 
ExclusivityExpirationExclusivity Description
Exclusivity Code: D - New Dosing ScheduleJan 23, 2021D-171: Revised dosing to include up-titration as a strategy to improve tolerability and thereby reduce treatment discontinuation for roflumilast maintenance dosage of 500 mcg daily
Exclusivity Code: M - MiscellaneousAug 31, 2020M-208: Information added to the labeling to include results of a randomized, double-blind, placebo-controlled study in patients with severe COPD associated with chronic bronchitis and a history of exacerbations

DALIRESP (TABLET) (ORAL) ROFLUMILAST
Drug Classes: phosphodiesterase 4 inhibitor
NDA Applicant: ASTRAZENECA PHARMS      NDA No.: 022522  Prod. No.: 002 RX (250MCG)
PatentsExpirationPatented Use
Pat. No. 5712298 DS* DP* [Extended 5 years]
Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors
Claim Types: Compound; Composition; Method of use; Process
Pat. Sub. Date(s): 002: Mar 14, 2018
Jan 27, 2020U-1115: Treatment to reduce the risk of copd exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations
Pat. No. 8431154 DP* Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidone as excipient
Claim Types: Product-by-process
Pat. Sub. Date(s): 002: Mar 14, 2018
Feb 19, 2023 
Pat. No. 9468598 DP* Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient
Claim Types: Formulation
Pat. Sub. Date(s): 002: Mar 14, 2018
Feb 19, 2023 
Pat. No. 8536206 Process for the preparation of roflumilast
Claim Types: Method of use
Pat. Sub. Date(s): 002: Mar 14, 2018
Mar 8, 2024U-1115: Treatment to reduce the risk of copd exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations
Pat. No. 8604064 Process for the preparation of roflumilast
Claim Types: Method of use
Pat. Sub. Date(s): 002: Mar 14, 2018
Mar 8, 2024U-1115: Treatment to reduce the risk of copd exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations
Pat. No. 8618142 DP* Process for the preparation of roflumilast
Claim Types: Formulation
Pat. Sub. Date(s): 002: Mar 14, 2018
Mar 8, 2024 
ExclusivityExpirationExclusivity Description
Exclusivity Code: NS - New strengthJan 23, 2021 

ENSTILAR (AEROSOL, FOAM) (TOPICAL) BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE
Drug Classes: corticosteroid; vitamin D analog
NDA Applicant: LEO PHARMA AS      NDA No.: 207589  Prod. No.: 001 RX (0.064%;0.005%)
PatentsExpirationPatented Use
Pat. No. 6753013 DP* Pharmaceutical composition
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): 001: Nov 12, 2015
Jan 27, 2020U-1761: Plaque psoriasis
U-2627: Topical treatment of plaque psoriasis in patients 12 years and older
Pat. No. 9566286 DP* Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
Claim Types: Device
Pat. Sub. Date(s): 001: Nov 15, 2019
Jun 10, 2031 
Pat. No. 10617698 DP* Pharmaceutical spray composition comprising a vitamind D analogue and a corticosteroid
Claim Types: Formulation
Pat. Sub. Date(s): 001: Apr 15, 2020
Jun 10, 2031 
Pat. No. 10660908 DP* Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): 001: Jun 17, 2020
Jun 10, 2031U-2627: Topical treatment of plaque psoriasis in patients 12 years and older
Pat. No. 9119781 DP* Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): 001: Nov 12, 2015
Dec 10, 2031 *PEDU-1761: Plaque psoriasis
U-2627: Topical treatment of plaque psoriasis in patients 12 years and older
Pat. No. 10130640 DP* Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid
Claim Types: Formulation
Pat. Sub. Date(s): 001: Dec 6, 2018
Dec 10, 2031 *PED 
ExclusivityExpirationExclusivity Description
Exclusivity Code: NPP - New patient populationJan 30, 2023 PED 

TACLONEX (OINTMENT) (TOPICAL) BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE [GENERIC AB]
Drug Classes: corticosteroid; vitamin D analog
NDA Applicant: LEO PHARMA AS      NDA No.: 021852  Prod. No.: 001 RX (0.064%;0.005%)
PatentsExpirationPatented Use
Pat. No. 6753013 DP* Pharmaceutical composition
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): 001: None
Jan 27, 2020U-193: Psoriasis
U-88: Treatment of moderate plaque psoriasis

TACLONEX (SUSPENSION) (TOPICAL) BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE [GENERIC AB]
Drug Classes: corticosteroid; vitamin D analog
NDA Applicant: LEO PHARMA AS      NDA No.: 022185  Prod. No.: 001 RX (0.064%;0.005%)
PatentsExpirationPatented Use
Pat. No. 6753013 DP* Pharmaceutical composition
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): 001: None
Jan 27, 2020U-1761: Plaque psoriasis
U-193: Psoriasis
U-88: Treatment of moderate plaque psoriasis
Pat. No. 6787529 DP* Topical composition
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): 001: None
Jan 27, 2020U-1761: Plaque psoriasis
U-193: Psoriasis
U-88: Treatment of moderate plaque psoriasis
ExclusivityExpirationExclusivity Description
Exclusivity Code: NPP - New patient populationJan 25, 2023 PED 

VASCEPA (CAPSULE) (ORAL) ICOSAPENT ETHYL [GENERIC AB]
NDA Applicant: AMARIN PHARMS      NDA No.: 202057  Prod. No.: 001 RX (1GM)
PatentsExpirationPatented Use
Pat. No. 8188146 DS* DP* Highly purified ethyl EPA and other EPA derivatives
Claim Types: Formulation
Pat. Sub. Date(s): 001: None
Jan 27, 2020 
Pat. No. 9700537 Composition for preventing the occurrence of cardiovascular event in multiple risk patient
Claim Types: Method of use
Pat. Sub. Date(s): 001: Jan 10, 2020
May 31, 2027U-2707: Use of VASCEPA as an adjunct to statin therapy to reduce the occurrence of a cardiovascular event in an adult patient with hypercholesterolemia
Pat. No. 9198892 Composition and/or method for preventing onset and/or recurrence of cardiovascular events
Claim Types: Method of improving a treatment
Pat. Sub. Date(s): 001: Jan 10, 2020
Sep 25, 2027U-2706: Use of VASCEPA as an adjunct to statin therapy to reduce the risk of onset and/or recurrence of cardiovascular events in a patient who has escaped the unstable period after cardiovascular angioplasty
Pat. No. 8293727 Methods of treating hypertriglyceridemia
Claim Types: Method of use
Pat. Sub. Date(s): 001: None
Feb 9, 2030U-1287: Method of reducing tg levels in patient suffering from severe hypertriglyceridemia
Pat. No. 8293728 Methods of treating hypertriglyceridemia
Claim Types: Method of use
Pat. Sub. Date(s): 001: None
Feb 9, 2030U-1287: Method of reducing tg levels in patient suffering from severe hypertriglyceridemia
Pat. No. 8314086 Methods of treating hypertriglyceridemia
Claim Types: Method of use
Pat. Sub. Date(s): 001: None
Feb 9, 2030U-1287: Method of reducing tg levels in patient suffering from severe hypertriglyceridemia
Pat. No. 8318715 Methods of treating hypertriglyceridemia
Claim Types: Method of use
Pat. Sub. Date(s): 001: Nov 29, 2012
Feb 9, 2030U-1287: Method of reducing tg levels in patient suffering from severe hypertriglyceridemia
Pat. No. 8357677 Methods of treating hypertriglyceridemia
Claim Types: Method of use
Pat. Sub. Date(s): 001: None
Feb 9, 2030U-1287: Method of reducing tg levels in patient suffering from severe hypertriglyceridemia
Pat. No. 8367652 Methods of treating hypertriglyceridemia
Claim Types: Method of administration
Pat. Sub. Date(s): 001: Feb 7, 2013
Feb 9, 2030U-1287: Method of reducing tg levels in patient suffering from severe hypertriglyceridemia
Pat. No. 8377920 Methods of treating hypertriglyceridemia
Claim Types: Method of use
Pat. Sub. Date(s): 001: None
Feb 9, 2030U-1287: Method of reducing tg levels in patient suffering from severe hypertriglyceridemia
Pat. No. 8399446 Methods of treating hypertriglyceridemia
Claim Types: Method of use
Pat. Sub. Date(s): 001: Apr 17, 2013
Feb 9, 2030U-1287: Method of reducing tg levels in patient suffering from severe hypertriglyceridemia
Pat. No. 8415335 Methods of treating hypertriglyceridemia
Claim Types: Method of administration
Pat. Sub. Date(s): 001: Apr 17, 2013
Feb 9, 2030U-1287: Method of reducing tg levels in patient suffering from severe hypertriglyceridemia
Pat. No. 8426399 Methods of treating hypertriglyceridemia
Claim Types: Method of use
Pat. Sub. Date(s): 001: None
Feb 9, 2030U-1287: Method of reducing tg levels in patient suffering from severe hypertriglyceridemia
Pat. No. 8431560 Methods of treating hypertriglyceridemia
Claim Types: Method of use
Pat. Sub. Date(s): 001: None
Feb 9, 2030U-1287: Method of reducing tg levels in patient suffering from severe hypertriglyceridemia
Pat. No. 8440650 Methods of treating hypertriglyceridemia
Claim Types: Method of use
Pat. Sub. Date(s): 001: None
Feb 9, 2030U-1287: Method of reducing tg levels in patient suffering from severe hypertriglyceridemia
Pat. No. 8518929 Methods of treating hypertriglyceridemia
Claim Types: Method of use
Pat. Sub. Date(s): 001: None
Feb 9, 2030U-1287: Method of reducing tg levels in patient suffering from severe hypertriglyceridemia
Pat. No. 8524698 Methods of treating hypertriglyceridemia
Claim Types: Method of administration
Pat. Sub. Date(s): 001: Sep 11, 2013
Feb 9, 2030U-1287: Method of reducing tg levels in patient suffering from severe hypertriglyceridemia
Pat. No. 8546372 Methods of treating hypertriglyceridemia
Claim Types: Method of use
Pat. Sub. Date(s): 001: Oct 1, 2013
Feb 9, 2030U-1287: Method of reducing tg levels in patient suffering from severe hypertriglyceridemia
Pat. No. 8680144 Methods of treating mixed dyslipidemia
Claim Types: Method of use
Pat. Sub. Date(s): 001: Jan 6, 2020
Feb 9, 2030U-2695: Use of VASCEPA to treat mixed hypertriglyceridemia in an adult patient with elevated triglyceride (TG) levels (>= 150 mg/dl) and on statin therapy
Pat. No. 8298554 DP* Stable pharmaceutical composition and methods of using same
Claim Types: Formulation
Pat. Sub. Date(s): 001: None
Apr 29, 2030 
Pat. No. 8445003 Stable pharmaceutical composition and methods of using same
Claim Types: Method of administration
Pat. Sub. Date(s): 001: None
Apr 29, 2030U-1287: Method of reducing tg levels in patient suffering from severe hypertriglyceridemia
Pat. No. 8445013 Stable pharmaceutical composition and methods of using same
Claim Types: Method of administration
Pat. Sub. Date(s): 001: None
Apr 29, 2030U-1287: Method of reducing tg levels in patient suffering from severe hypertriglyceridemia
Pat. No. 8454994 Stable pharmaceutical composition and methods of using same
Claim Types: Method of use
Pat. Sub. Date(s): 001: Jan 6, 2020
Apr 29, 2030U-2689: Use of VASCEPA to treat mixed dyslipidemia in an adult patient with elevated triglyceride (TG) levels (>=150 mg/dl) and on statin therapy
Pat. No. 8501225 Stable pharmaceutical composition and methods of using same
Claim Types: Method of administration
Pat. Sub. Date(s): 001: None
Apr 29, 2030U-1287: Method of reducing tg levels in patient suffering from severe hypertriglyceridemia
Pat. No. 8551521 Stable pharmaceutical composition and methods of using same
Claim Types: Method of use
Pat. Sub. Date(s): 001: Oct 9, 2013
Apr 29, 2030U-1287: Method of reducing tg levels in patient suffering from severe hypertriglyceridemia
Pat. No. 8563608 Methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
Claim Types: Method of use
Pat. Sub. Date(s): 001: Oct 22, 2013
Apr 29, 2030U-1287: Method of reducing tg levels in patient suffering from severe hypertriglyceridemia
Pat. No. 8617593 Stable pharmaceutical composition and methods of using same
Claim Types: Method of use
Pat. Sub. Date(s): 001: Jan 14, 2014
Apr 29, 2030U-1478: Method of reducing TG levels in patient on statin therapy suffering from severe hypertriglyceridemia
U-2691: Use of VASCEPA to treat hypertriglyceridemia in an adult patient with elevated triglyceride (TG) levels (>= 150 mg/dl) and on statin therapy
Pat. No. 8617594 Stable pharmaceutical composition and methods of using same
Claim Types: Method of administration
Pat. Sub. Date(s): 001: None
Apr 29, 2030U-1287: Method of reducing tg levels in patient suffering from severe hypertriglyceridemia
Pat. No. 8618166 Methods of treating mixed dyslipidemia
Claim Types: Method of use
Pat. Sub. Date(s): 001: Jan 6, 2020
Apr 29, 2030U-2689: Use of VASCEPA to treat mixed dyslipidemia in an adult patient with elevated triglyceride (TG) levels (>=150 mg/dl) and on statin therapy
Pat. No. 8623406 Stable pharmaceutical composition and methods of using same
Claim Types: Method of use
Pat. Sub. Date(s): 001: Jan 14, 2014
Apr 29, 2030U-1478: Method of reducing TG levels in patient on statin therapy suffering from severe hypertriglyceridemia
U-2692: Use of VASCEPA to reduce triglycerides in an adult patient with elevated triglyceride (TG) levels (>= 150 mg/dl) and on statin therapy
Pat. No. 8642077 Stable pharmaceutical composition and methods of using same
Claim Types: Method of use
Pat. Sub. Date(s): 001: Jan 6, 2020
Apr 29, 2030U-2693: Use of VASCEPA to reduce triglycerides in a mixed dyslipidemia adult patient with elevated triglyceride (TG) levels (>= 150 mg/dl) and on statin therapy
Pat. No. 8691871 Methods of treating mixed dyslipidemia
Claim Types: Method of use
Pat. Sub. Date(s): 001: Jan 6, 2020
Apr 29, 2030U-2689: Use of VASCEPA to treat mixed dyslipidemia in an adult patient with elevated triglyceride (TG) levels (>=150 mg/dl) and on statin therapy
Pat. No. 8703185 Stable pharmaceutical composition and methods of using same
Claim Types: Method of use
Pat. Sub. Date(s): 001: Jan 6, 2020
Apr 29, 2030U-2691: Use of VASCEPA to treat hypertriglyceridemia in an adult patient with elevated triglyceride (TG) levels (>= 150 mg/dl) and on statin therapy
Pat. No. 8709475 Stable pharmaceutical composition and methods of using same
Claim Types: Method of use
Pat. Sub. Date(s): 001: Jan 6, 2020
Apr 29, 2030U-2689: Use of VASCEPA to treat mixed dyslipidemia in an adult patient with elevated triglyceride (TG) levels (>=150 mg/dl) and on statin therapy
Pat. No. 10010517 Stable pharmaceutical composition and methods of using same
Claim Types: Method of use
Pat. Sub. Date(s): 001: Jan 6, 2020
Apr 29, 2030U-2690: Use of VASCEPA to lower triglycerides in an adult patient with elevated triglyceride (TG) levels (about 200 mg/dl to less than about 500 mg/dl) and on statin therapy
Pat. No. 10265287 Methods of reducing triglycerides and LDL-C
Claim Types: Method of use
Pat. Sub. Date(s): 001: Jan 6, 2020
Apr 29, 2030U-2700: Use of VASCEPA to reduce triglycerides in an adult patient with elevated triglyceride (TG) levels (about 200 mg/dl to less than about 500 mg/dl) and on rosuvastatin therapy
Pat. No. 8410086 Compositions and methods for lowering triglycerides
Claim Types: Method of use
Pat. Sub. Date(s): 001: Jan 6, 2020
Jun 15, 2030U-2688: Use of VASCEPA to lower triglycerides and ldl-c in an adult patient with elevated triglyceride (TG) levels (about 200 mg/dl to less than about 500 mg/dl) and on statin therapy
Pat. No. 8455472 Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
Claim Types: Method of use
Pat. Sub. Date(s): 001: Jan 6, 2020
Jun 15, 2030U-2690: Use of VASCEPA to lower triglycerides in an adult patient with elevated triglyceride (TG) levels (about 200 mg/dl to less than about 500 mg/dl) and on statin therapy
Pat. No. 8669245 Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
Claim Types: Method of use
Pat. Sub. Date(s): 001: Jan 6, 2020
Jun 15, 2030U-2694: Use of VASCEPA to lower triglycerides in a mixed dyslipidemia adult patient with elevated triglyceride (TG) levels (about 200 mg/dl to less than about 500 mg/dl) and on statin therapy
Pat. No. 8710041 Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy
Claim Types: Method of use
Pat. Sub. Date(s): 001: Jan 6, 2020
Jun 15, 2030U-2690: Use of VASCEPA to lower triglycerides in an adult patient with elevated triglyceride (TG) levels (about 200 mg/dl to less than about 500 mg/dl) and on statin therapy
Pat. No. 9603826 Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
Claim Types: Method of use
Pat. Sub. Date(s): 001: Jan 6, 2020
Jun 28, 2033U-2696: Use of VASCEPA as an adjunct to statin therapy to reduce the risk of cardiovascular death, coronary revascularization, and unstable angina in an adult patient with elevated triglyceride levels (TG >= 150 mg/dl to about 500 mg/dl)
Pat. No. 9610272 Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
Claim Types: Method of use
Pat. Sub. Date(s): 001: Jan 6, 2020
Jun 28, 2033U-2697: Use of VASCEPA as an adjunct to statin therapy to reduce the risk of cardiovascular death and/or unstable angina in an adult patient with elevated triglyceride levels (TG >= 150 mg/dl to about 500 mg/dl)
Pat. No. 9623001 Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
Claim Types: Method of use
Pat. Sub. Date(s): 001: Jan 6, 2020
Jun 28, 2033U-2698: Use of VASCEPA as an adjunct to statin therapy to reduce the risk of cardiovascular death and/or coronary revascularization in an adult patient with elevated triglyceride levels (TG >= 150 mg/dl to about 500 mg/dl)
Pat. No. 9693984 Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
Claim Types: Method of use
Pat. Sub. Date(s): 001: Jan 6, 2020
Jun 28, 2033U-2697: Use of VASCEPA as an adjunct to statin therapy to reduce the risk of cardiovascular death and/or unstable angina in an adult patient with elevated triglyceride levels (TG >= 150 mg/dl to about 500 mg/dl)
Pat. No. 9693985 Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
Claim Types: Method of use
Pat. Sub. Date(s): 001: Jan 6, 2020
Jun 28, 2033U-2696: Use of VASCEPA as an adjunct to statin therapy to reduce the risk of cardiovascular death, coronary revascularization, and unstable angina in an adult patient with elevated triglyceride levels (TG >= 150 mg/dl to about 500 mg/dl)
Pat. No. 9693986 Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
Claim Types: Method of use
Pat. Sub. Date(s): 001: Jan 6, 2020
Jun 28, 2033U-2698: Use of VASCEPA as an adjunct to statin therapy to reduce the risk of cardiovascular death and/or coronary revascularization in an adult patient with elevated triglyceride levels (TG >= 150 mg/dl to about 500 mg/dl)
Pat. No. 9918954 Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
Claim Types: Method of use
Pat. Sub. Date(s): 001: Jan 6, 2020
Jun 28, 2033U-2699: Use of VASCEPA as an adjunct to statin therapy to reduce the risk of a cardiovascular event (coronary revascularization, unstable angina, stroke and/or myocardial infarction) in an adult patient with elevated triglyceride levels
Pat. No. 10278935 Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
Claim Types: Method of use
Pat. Sub. Date(s): 001: Jan 6, 2020
Jun 28, 2033U-2701: Use of VASCEPA as an adjunct to statin therapy to reduce the risk of coronary revascularization and/or unstable angina in an adult patient with elevated triglyceride levels (TG >= 150 mg/dl to about 500 mg/dl)
Pat. No. 10278936 Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
Claim Types: Method of use
Pat. Sub. Date(s): 001: Jan 6, 2020
Jun 28, 2033U-2702: Use of VASCEPA as an adjunct to statin therapy to reduce the risk of a cardiovascular event (cardiovascular death, coronary revascularization and/or unstable angina) in an adult patient with elevated triglyceride levels
Pat. No. 10278937 Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
Claim Types: Method of use
Pat. Sub. Date(s): 001: Jan 6, 2020
Jun 28, 2033U-2703: Use of VASCEPA as an adjunct to statin therapy to reduce the risk of a cv event (cv death, coronary revascularization, unstable angina, stroke and/or myocardial infarction) in an adult patient with elevated triglyceride levels and diabetes mellitus
Pat. No. 10383840 Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease
Claim Types: Method of use
Pat. Sub. Date(s): 001: Jan 6, 2020
Jun 28, 2033U-2704: Use of VASCEPA as an adjunct to statin therapy to reduce the risk of a cardiovascular event in an adult patient with elevated triglyceride levels and at least one risk factor for cardiovascular disease
Pat. No. 10555924 Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease
Claim Types: Method of use
Pat. Sub. Date(s): 001: Feb 26, 2020
Jun 28, 2033U-2743: Use of VASCEPA as an adjunct to statin therapy to reduce the risk of unstable angina in an adult patient with established cardiovascular disease
Pat. No. 10555925 Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease
Claim Types: Method of use
Pat. Sub. Date(s): 001: Feb 26, 2020
Jun 28, 2033U-2744: Use of VASCEPA as an adjunct to statin therapy to reduce the risk of stroke in an adult patient with established cardiovascular disease
Pat. No. 10568861 Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease
Claim Types: Method of use
Pat. Sub. Date(s): 001: Mar 20, 2020
Jun 28, 2033U-2756: Use of VASCEPA as an adjunct to statin therapy to reduce the risk of cardiovascular death in an adult patient with established cardiovascular disease
Pat. No. 10576054 Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease
Claim Types: Method of use
Pat. Sub. Date(s): 001: Mar 27, 2020
Jun 28, 2033U-2762: Use of VASCEPA as an adjunct to statin therapy to reduce the risk of a major cardiovascular event in an adult patient with diabetes mellitus and two or more additional risk factors for cardiovascular disease
Pat. No. 10668042 Methods of reducing the risk of cardiovascular events in a subject
Claim Types: Method of use
Pat. Sub. Date(s): 001: Jun 26, 2020
Jun 28, 2033U-2841: Use of VASCEPA with high intensity statin therapy to reduce the risk of a cv event in an adult patient with elevated triglyceride levels and (1) established CV disease, or (2) diabetes mellitus and two or more additional risk factors for CV disease
ExclusivityExpirationExclusivity Description
Exclusivity Code: I - New IndicationDec 13, 2022I-819: Adjunct to max tolerated statin tx to reduce risk of MI, stroke, coronary revascularization, & unstable angina requiring hospitalization in adults w/ elevated TG levels & established CV disease or diabetes mellitus & 2+ risk factors for CV disease

VASCEPA (CAPSULE) (ORAL) ICOSAPENT ETHYL
NDA Applicant: AMARIN PHARMS      NDA No.: 202057  Prod. No.: 002 RX (500MG)
PatentsExpirationPatented Use
Pat. No. 8188146 DS* DP* Highly purified ethyl EPA and other EPA derivatives
Claim Types: Formulation
Pat. Sub. Date(s): 002: Jun 26, 2017
Jan 27, 2020 
Pat. No. 9700537 Composition for preventing the occurrence of cardiovascular event in multiple risk patient
Claim Types: Method of use
Pat. Sub. Date(s): 002: Jan 10, 2020
May 31, 2027U-2707: Use of VASCEPA as an adjunct to statin therapy to reduce the occurrence of a cardiovascular event in an adult patient with hypercholesterolemia
Pat. No. 9198892 Composition and/or method for preventing onset and/or recurrence of cardiovascular events
Claim Types: Method of improving a treatment
Pat. Sub. Date(s): 002: Jan 10, 2020
Sep 25, 2027U-2706: Use of VASCEPA as an adjunct to statin therapy to reduce the risk of onset and/or recurrence of cardiovascular events in a patient who has escaped the unstable period after cardiovascular angioplasty
Pat. No. 8293727 Methods of treating hypertriglyceridemia
Claim Types: Method of use
Pat. Sub. Date(s): 002: Jun 26, 2017
Feb 9, 2030U-1287: Method of reducing tg levels in patient suffering from severe hypertriglyceridemia
Pat. No. 8293728 Methods of treating hypertriglyceridemia
Claim Types: Method of use
Pat. Sub. Date(s): 002: Jun 26, 2017
Feb 9, 2030U-1287: Method of reducing tg levels in patient suffering from severe hypertriglyceridemia
Pat. No. 8314086 Methods of treating hypertriglyceridemia
Claim Types: Method of use
Pat. Sub. Date(s): 002: Jun 26, 2017
Feb 9, 2030U-1287: Method of reducing tg levels in patient suffering from severe hypertriglyceridemia
Pat. No. 8318715 Methods of treating hypertriglyceridemia
Claim Types: Method of use
Pat. Sub. Date(s): 002: Jun 26, 2017
Feb 9, 2030U-1287: Method of reducing tg levels in patient suffering from severe hypertriglyceridemia
Pat. No. 8357677 Methods of treating hypertriglyceridemia
Claim Types: Method of use
Pat. Sub. Date(s): 002: Jun 26, 2017
Feb 9, 2030U-1287: Method of reducing tg levels in patient suffering from severe hypertriglyceridemia
Pat. No. 8367652 Methods of treating hypertriglyceridemia
Claim Types: Method of administration
Pat. Sub. Date(s): 002: Jun 26, 2017
Feb 9, 2030U-1287: Method of reducing tg levels in patient suffering from severe hypertriglyceridemia
Pat. No. 8377920 Methods of treating hypertriglyceridemia
Claim Types: Method of use
Pat. Sub. Date(s): 002: Jun 26, 2017
Feb 9, 2030U-1287: Method of reducing tg levels in patient suffering from severe hypertriglyceridemia
Pat. No. 8399446 Methods of treating hypertriglyceridemia
Claim Types: Method of use
Pat. Sub. Date(s): 002: Jun 26, 2017
Feb 9, 2030U-1287: Method of reducing tg levels in patient suffering from severe hypertriglyceridemia
Pat. No. 8415335 Methods of treating hypertriglyceridemia
Claim Types: Method of administration
Pat. Sub. Date(s): 002: Jun 26, 2017
Feb 9, 2030U-1287: Method of reducing tg levels in patient suffering from severe hypertriglyceridemia
Pat. No. 8426399 Methods of treating hypertriglyceridemia
Claim Types: Method of use
Pat. Sub. Date(s): 002: Jun 26, 2017
Feb 9, 2030U-1287: Method of reducing tg levels in patient suffering from severe hypertriglyceridemia
Pat. No. 8440650 Methods of treating hypertriglyceridemia
Claim Types: Method of use
Pat. Sub. Date(s): 002: Jun 26, 2017
Feb 9, 2030U-1287: Method of reducing tg levels in patient suffering from severe hypertriglyceridemia
Pat. No. 8518929 Methods of treating hypertriglyceridemia
Claim Types: Method of use
Pat. Sub. Date(s): 002: Jun 26, 2017
Feb 9, 2030U-1287: Method of reducing tg levels in patient suffering from severe hypertriglyceridemia
Pat. No. 8524698 Methods of treating hypertriglyceridemia
Claim Types: Method of administration
Pat. Sub. Date(s): 002: Jun 26, 2017
Feb 9, 2030U-1287: Method of reducing tg levels in patient suffering from severe hypertriglyceridemia
Pat. No. 8546372 Methods of treating hypertriglyceridemia
Claim Types: Method of use
Pat. Sub. Date(s): 002: Jun 26, 2017
Feb 9, 2030U-1287: Method of reducing tg levels in patient suffering from severe hypertriglyceridemia
Pat. No. 8680144 Methods of treating mixed dyslipidemia
Claim Types: Method of use
Pat. Sub. Date(s): 002: Jan 6, 2020
Feb 9, 2030U-2695: Use of VASCEPA to treat mixed hypertriglyceridemia in an adult patient with elevated triglyceride (TG) levels (>= 150 mg/dl) and on statin therapy
Pat. No. 8298554 DP* Stable pharmaceutical composition and methods of using same
Claim Types: Formulation
Pat. Sub. Date(s): 002: Jun 26, 2017
Apr 29, 2030 
Pat. No. 8445003 Stable pharmaceutical composition and methods of using same
Claim Types: Method of administration
Pat. Sub. Date(s): 002: Jun 26, 2017
Apr 29, 2030U-1287: Method of reducing tg levels in patient suffering from severe hypertriglyceridemia
Pat. No. 8445013 Stable pharmaceutical composition and methods of using same
Claim Types: Method of administration
Pat. Sub. Date(s): 002: Jun 26, 2017
Apr 29, 2030U-1287: Method of reducing tg levels in patient suffering from severe hypertriglyceridemia
Pat. No. 8454994 Stable pharmaceutical composition and methods of using same
Claim Types: Method of use
Pat. Sub. Date(s): 002: Jan 6, 2020
Apr 29, 2030U-2689: Use of VASCEPA to treat mixed dyslipidemia in an adult patient with elevated triglyceride (TG) levels (>=150 mg/dl) and on statin therapy
Pat. No. 8501225 Stable pharmaceutical composition and methods of using same
Claim Types: Method of administration
Pat. Sub. Date(s): 002: Jun 26, 2017
Apr 29, 2030U-1287: Method of reducing tg levels in patient suffering from severe hypertriglyceridemia
Pat. No. 8551521 Stable pharmaceutical composition and methods of using same
Claim Types: Method of use
Pat. Sub. Date(s): 002: Jun 26, 2017
Apr 29, 2030U-1287: Method of reducing tg levels in patient suffering from severe hypertriglyceridemia
Pat. No. 8563608 Methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
Claim Types: Method of use
Pat. Sub. Date(s): 002: Jun 26, 2017
Apr 29, 2030U-1287: Method of reducing tg levels in patient suffering from severe hypertriglyceridemia
Pat. No. 8617593 Stable pharmaceutical composition and methods of using same
Claim Types: Method of use
Pat. Sub. Date(s): 002: Jun 26, 2017
Apr 29, 2030U-1287: Method of reducing tg levels in patient suffering from severe hypertriglyceridemia
U-2691: Use of VASCEPA to treat hypertriglyceridemia in an adult patient with elevated triglyceride (TG) levels (>= 150 mg/dl) and on statin therapy
Pat. No. 8617594 Stable pharmaceutical composition and methods of using same
Claim Types: Method of administration
Pat. Sub. Date(s): 002: Jun 26, 2017
Apr 29, 2030U-1287: Method of reducing tg levels in patient suffering from severe hypertriglyceridemia
Pat. No. 8623406 Stable pharmaceutical composition and methods of using same
Claim Types: Method of use
Pat. Sub. Date(s): 002: Jun 26, 2017
Apr 29, 2030U-1287: Method of reducing tg levels in patient suffering from severe hypertriglyceridemia
U-2692: Use of VASCEPA to reduce triglycerides in an adult patient with elevated triglyceride (TG) levels (>= 150 mg/dl) and on statin therapy
Pat. No. 8642077 Stable pharmaceutical composition and methods of using same
Claim Types: Method of use
Pat. Sub. Date(s): 002: Jan 6, 2020
Apr 29, 2030U-2693: Use of VASCEPA to reduce triglycerides in a mixed dyslipidemia adult patient with elevated triglyceride (TG) levels (>= 150 mg/dl) and on statin therapy
Pat. No. 8691871 Methods of treating mixed dyslipidemia
Claim Types: Method of use
Pat. Sub. Date(s): 002: Jan 6, 2020
Apr 29, 2030U-2689: Use of VASCEPA to treat mixed dyslipidemia in an adult patient with elevated triglyceride (TG) levels (>=150 mg/dl) and on statin therapy
Pat. No. 8703185 Stable pharmaceutical composition and methods of using same
Claim Types: Method of use
Pat. Sub. Date(s): 002: Jan 6, 2020
Apr 29, 2030U-2691: Use of VASCEPA to treat hypertriglyceridemia in an adult patient with elevated triglyceride (TG) levels (>= 150 mg/dl) and on statin therapy
Pat. No. 8709475 Stable pharmaceutical composition and methods of using same
Claim Types: Method of use
Pat. Sub. Date(s): 002: Jan 6, 2020
Apr 29, 2030U-2689: Use of VASCEPA to treat mixed dyslipidemia in an adult patient with elevated triglyceride (TG) levels (>=150 mg/dl) and on statin therapy
Pat. No. 10010517 Stable pharmaceutical composition and methods of using same
Claim Types: Method of use
Pat. Sub. Date(s): 002: Jan 6, 2020
Apr 29, 2030U-2690: Use of VASCEPA to lower triglycerides in an adult patient with elevated triglyceride (TG) levels (about 200 mg/dl to less than about 500 mg/dl) and on statin therapy
Pat. No. 10265287 Methods of reducing triglycerides and LDL-C
Claim Types: Method of use
Pat. Sub. Date(s): 002: Jan 6, 2020
Apr 29, 2030U-2700: Use of VASCEPA to reduce triglycerides in an adult patient with elevated triglyceride (TG) levels (about 200 mg/dl to less than about 500 mg/dl) and on rosuvastatin therapy
Pat. No. 8410086 Compositions and methods for lowering triglycerides
Claim Types: Method of use
Pat. Sub. Date(s): 002: Jan 6, 2020
Jun 15, 2030U-2688: Use of VASCEPA to lower triglycerides and ldl-c in an adult patient with elevated triglyceride (TG) levels (about 200 mg/dl to less than about 500 mg/dl) and on statin therapy
Pat. No. 8669245 Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
Claim Types: Method of use
Pat. Sub. Date(s): 002: Jan 6, 2020
Jun 15, 2030U-2694: Use of VASCEPA to lower triglycerides in a mixed dyslipidemia adult patient with elevated triglyceride (TG) levels (about 200 mg/dl to less than about 500 mg/dl) and on statin therapy
Pat. No. 8710041 Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy
Claim Types: Method of use
Pat. Sub. Date(s): 002: Jan 6, 2020
Jun 15, 2030U-2690: Use of VASCEPA to lower triglycerides in an adult patient with elevated triglyceride (TG) levels (about 200 mg/dl to less than about 500 mg/dl) and on statin therapy
Pat. No. 9603826 Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
Claim Types: Method of use
Pat. Sub. Date(s): 002: Jan 6, 2020
Jun 28, 2033U-2696: Use of VASCEPA as an adjunct to statin therapy to reduce the risk of cardiovascular death, coronary revascularization, and unstable angina in an adult patient with elevated triglyceride levels (TG >= 150 mg/dl to about 500 mg/dl)
Pat. No. 9610272 Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
Claim Types: Method of use
Pat. Sub. Date(s): 002: Jan 6, 2020
Jun 28, 2033U-2697: Use of VASCEPA as an adjunct to statin therapy to reduce the risk of cardiovascular death and/or unstable angina in an adult patient with elevated triglyceride levels (TG >= 150 mg/dl to about 500 mg/dl)
Pat. No. 9623001 Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
Claim Types: Method of use
Pat. Sub. Date(s): 002: Jan 6, 2020
Jun 28, 2033U-2698: Use of VASCEPA as an adjunct to statin therapy to reduce the risk of cardiovascular death and/or coronary revascularization in an adult patient with elevated triglyceride levels (TG >= 150 mg/dl to about 500 mg/dl)
Pat. No. 9693984 Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
Claim Types: Method of use
Pat. Sub. Date(s): 002: Jan 6, 2020
Jun 28, 2033U-2697: Use of VASCEPA as an adjunct to statin therapy to reduce the risk of cardiovascular death and/or unstable angina in an adult patient with elevated triglyceride levels (TG >= 150 mg/dl to about 500 mg/dl)
Pat. No. 9693985 Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
Claim Types: Method of use
Pat. Sub. Date(s): 002: Jan 6, 2020
Jun 28, 2033U-2696: Use of VASCEPA as an adjunct to statin therapy to reduce the risk of cardiovascular death, coronary revascularization, and unstable angina in an adult patient with elevated triglyceride levels (TG >= 150 mg/dl to about 500 mg/dl)
Pat. No. 9693986 Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
Claim Types: Method of use
Pat. Sub. Date(s): 002: Jan 6, 2020
Jun 28, 2033U-2698: Use of VASCEPA as an adjunct to statin therapy to reduce the risk of cardiovascular death and/or coronary revascularization in an adult patient with elevated triglyceride levels (TG >= 150 mg/dl to about 500 mg/dl)
Pat. No. 9918954 Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
Claim Types: Method of use
Pat. Sub. Date(s): 002: Jan 6, 2020
Jun 28, 2033U-2699: Use of VASCEPA as an adjunct to statin therapy to reduce the risk of a cardiovascular event (coronary revascularization, unstable angina, stroke and/or myocardial infarction) in an adult patient with elevated triglyceride levels
Pat. No. 10278935 Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
Claim Types: Method of use
Pat. Sub. Date(s): 002: Jan 6, 2020
Jun 28, 2033U-2701: Use of VASCEPA as an adjunct to statin therapy to reduce the risk of coronary revascularization and/or unstable angina in an adult patient with elevated triglyceride levels (TG >= 150 mg/dl to about 500 mg/dl)
Pat. No. 10278936 Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
Claim Types: Method of use
Pat. Sub. Date(s): 002: Jan 6, 2020
Jun 28, 2033U-2702: Use of VASCEPA as an adjunct to statin therapy to reduce the risk of a cardiovascular event (cardiovascular death, coronary revascularization and/or unstable angina) in an adult patient with elevated triglyceride levels
Pat. No. 10278937 Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
Claim Types: Method of use
Pat. Sub. Date(s): 002: Jan 6, 2020
Jun 28, 2033U-2703: Use of VASCEPA as an adjunct to statin therapy to reduce the risk of a cv event (cv death, coronary revascularization, unstable angina, stroke and/or myocardial infarction) in an adult patient with elevated triglyceride levels and diabetes mellitus
Pat. No. 10383840 Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease
Claim Types: Method of use
Pat. Sub. Date(s): 002: Jan 6, 2020
Jun 28, 2033U-2704: Use of VASCEPA as an adjunct to statin therapy to reduce the risk of a cardiovascular event in an adult patient with elevated triglyceride levels and at least one risk factor for cardiovascular disease
Pat. No. 10555924 Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease
Claim Types: Method of use
Pat. Sub. Date(s): 002: Feb 26, 2020
Jun 28, 2033U-2743: Use of VASCEPA as an adjunct to statin therapy to reduce the risk of unstable angina in an adult patient with established cardiovascular disease
Pat. No. 10555925 Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease
Claim Types: Method of use
Pat. Sub. Date(s): 002: Feb 26, 2020
Jun 28, 2033U-2744: Use of VASCEPA as an adjunct to statin therapy to reduce the risk of stroke in an adult patient with established cardiovascular disease
Pat. No. 10568861 Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease
Claim Types: Method of use
Pat. Sub. Date(s): 002: Mar 20, 2020
Jun 28, 2033U-2756: Use of VASCEPA as an adjunct to statin therapy to reduce the risk of cardiovascular death in an adult patient with established cardiovascular disease
Pat. No. 10576054 Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease
Claim Types: Method of use
Pat. Sub. Date(s): 002: Mar 27, 2020
Jun 28, 2033U-2762: Use of VASCEPA as an adjunct to statin therapy to reduce the risk of a major cardiovascular event in an adult patient with diabetes mellitus and two or more additional risk factors for cardiovascular disease
Pat. No. 10668042 Methods of reducing the risk of cardiovascular events in a subject
Claim Types: Method of use
Pat. Sub. Date(s): 002: Jun 26, 2020
Jun 28, 2033U-2841: Use of VASCEPA with high intensity statin therapy to reduce the risk of a cv event in an adult patient with elevated triglyceride levels and (1) established CV disease, or (2) diabetes mellitus and two or more additional risk factors for CV disease
ExclusivityExpirationExclusivity Description
Exclusivity Code: I - New IndicationDec 13, 2022I-819: Adjunct to max tolerated statin tx to reduce risk of MI, stroke, coronary revascularization, & unstable angina requiring hospitalization in adults w/ elevated TG levels & established CV disease or diabetes mellitus & 2+ risk factors for CV disease

WAKIX (TABLET) (ORAL) PITOLISANT HYDROCHLORIDE
NDA Applicant: HARMONY      NDA No.: 211150  Prod. No.: 001 RX (EQ 4.45MG BASE); 002 RX (EQ 17.8MG BASE)
PatentsExpirationPatented Use
Pat. No. 7169928 DS* DP* Non-imidazole alkylamines as histamine H.sub.3-receptor ligands and their therapeutic applications
Claim Types: Compound; Composition
Pat. Sub. Date(s): All strengths: Sep 11, 2019
Feb 2, 2020 
Pat. No. 7910605 Non-imidazole alkylamines as histamine H.sub.3- receptor ligands and their therapeutic applications
Claim Types: Method of use
Pat. Sub. Date(s): All strengths: Sep 11, 2019
Sep 23, 2022U-1101: Method of treating excessive daytime sleepiness in patients with narcolepsy
Pat. No. 8354430 Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl) propoxy]propyl]-piperidine
Claim Types: Method of use
Pat. Sub. Date(s): All strengths: Sep 11, 2019
Feb 6, 2026U-1101: Method of treating excessive daytime sleepiness in patients with narcolepsy
Pat. No. 8207197 DS* DP* Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl) propoxy] propyl] -piperidine
Claim Types: New polymorph, salt or hydrate; Process; Composition
Pat. Sub. Date(s): All strengths: Sep 11, 2019
Feb 25, 2029 
Pat. No. 8486947 Treatment of Parkinson's disease, obstructive sleep apnea, dementia with Lewy bodies, vascular dementia with non-imidazole alkylamines histamine H.sub.3-receptor ligands
Claim Types: Method of use
Pat. Sub. Date(s): All strengths: Sep 11, 2019
Sep 26, 2029U-1101: Method of treating excessive daytime sleepiness in patients with narcolepsy
ExclusivityExpirationExclusivity Description
Exclusivity Code: NCE - New chemical entityAug 14, 2024 
Exclusivity Code: ODE - Orphan drug exclusivityAug 14, 2026ODE-255: Indicated for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy

CALCIJEX (INJECTABLE) (INJECTION) CALCITRIOL
Drug Classes: vitamin D3 analog
NDA Applicant: ABBVIE      NDA No.: 018874  Prod. No.: 001 DISC (0.001MG/ML**); 002 DISC (0.002MG/ML**)
PatentsExpirationPatented Use
Pat. No. 6051567 Low oxygen content compositions of 1.alpha., 25-dihydroxycholecalciferol
Claim Types: Formulation
Pat. Sub. Date(s): All strengths: None
Feb 2, 2020 *PED 
Pat. No. 6265392 Low oxygen content compositions of 1.alpha., 25-dihydroxycholeclciferol
Claim Types: Formulation
Pat. Sub. Date(s): All strengths: None
Feb 2, 2020 *PED 
Pat. No. 6274169 Low oxygen content compostions of 1.alpha., 25-dihydroxycholecalciferol
Claim Types: Product-by-process; Process
Pat. Sub. Date(s): All strengths: None
Feb 2, 2020 *PED 

NICODERM CQ (FILM, EXTENDED RELEASE) (TRANSDERMAL) NICOTINE [GENERIC OTC]
Drug Classes: nicotine agonist
NDA Applicant: SANOFI AVENTIS US      NDA No.: 020165  Prod. No.: 004 OTC (21MG/24HR); 005 OTC (14MG/24HR); 006 OTC (7MG/24HR)
PatentsExpirationPatented Use
Pat. No. 8663680 DP* Transparent transdermal nicotine delivery devices
Claim Types: Device
Pat. Sub. Date(s): All strengths: Mar 31, 2014
Feb 13, 2020 
Pat. No. 8999379 Transparent transdermal nicotine delivery devices
Claim Types: Method of administration
Pat. Sub. Date(s): All strengths: May 4, 2015
Feb 13, 2020U-1686: A method to reduce withdrawal symptoms, including nicotine craving, associated with smoking cessation
Pat. No. 8075911 DP* Transparent transdermal nicotine delivery devices
Claim Types: Device
Pat. Sub. Date(s): 004: Mar 9, 2012; 005: None; 006: None
May 22, 2021 

ERAXIS (POWDER) (INTRAVENOUS) ANIDULAFUNGIN
Drug Classes: echinocandin antifungal
NDA Applicant: VICURON      NDA No.: 021632  Prod. No.: 001 RX (50MG/VIAL); 002 RX (100MG/VIAL)
PatentsExpirationPatented Use
Pat. No. 5965525 DS* DP* [Extended 1223 days (3.4 years)]
Cyclic peptide antifungal agents
Claim Types: Compound; Method of use; Composition
Pat. Sub. Date(s): All strengths: None
Feb 17, 2020U-540: Treatment of fungal infections
Pat. No. 6960564 DP* Echinocandin pharmaceutical formulations containing micelle-forming surfactants
Claim Types: Formulation; Process; Method of use
Pat. Sub. Date(s): All strengths: None
Apr 12, 2021U-540: Treatment of fungal infections
Pat. No. 7709444 DP* Echinocandin pharmaceutical formulations containing micelle-forming surfactants
Claim Types: Formulation; Process; Method of use
Pat. Sub. Date(s): All strengths: None
Apr 12, 2021U-540: Treatment of fungal infections

SILENOR (TABLET) (ORAL) DOXEPIN HYDROCHLORIDE [GENERIC AB]
Drug Classes: tricyclic antidepressant (TCA)
NDA Applicant: CURRAX      NDA No.: 022036  Prod. No.: 001 RX (EQ 3MG BASE); 002 RX (EQ 6MG BASE)
PatentsExpirationPatented Use
Pat. No. 6211229 Treatment of transient and short term insomnia
Claim Types: Method of administration
Pat. Sub. Date(s): All strengths: None
Feb 17, 2020U-620: Treatment of insomnia
Pat. No. 9486437 Methods of using low-dose doxepin for the improvement of sleep
Claim Types: Method of administration
Pat. Sub. Date(s): All strengths: Dec 2, 2016
May 18, 2027U-620: Treatment of insomnia
Pat. No. 9861607 Methods of using low-dose doxepin for the improvement of sleep
Claim Types: Method of use
Pat. Sub. Date(s): All strengths: Jan 24, 2018
May 18, 2027U-620: Treatment of insomnia
Pat. No. 10238620 Methods of using low-dose doxepin for the improvement of sleep
Claim Types: Method of use
Pat. Sub. Date(s): All strengths: Apr 8, 2019
May 18, 2027U-620: Treatment of insomnia
Pat. No. 10653662 Methods of using low-dose doxepin for the improvement of sleep
Claim Types: Method of use
Pat. Sub. Date(s): All strengths: Jun 15, 2020
May 18, 2027U-620: Treatment of insomnia
Pat. No. 9572814 Methods of improving the pharmacokinetics of doxepin
Claim Types: Method of use
Pat. Sub. Date(s): All strengths: Mar 21, 2017
Jul 20, 2027U-620: Treatment of insomnia
Pat. No. 10653660 Methods of improving the pharmacokinetics of doxepin
Claim Types: Method of use
Pat. Sub. Date(s): All strengths: Jun 15, 2020
Jul 20, 2027U-620: Treatment of insomnia
Pat. No. 7915307 Methods of improving the pharmacokinetics of doxepin
Claim Types: Method of administration
Pat. Sub. Date(s): All strengths: None
Aug 24, 2027U-620: Treatment of insomnia
Pat. No. 9907780 DP* Low-dose doxepin formulations and methods of making and using the same
Claim Types: Formulation
Pat. Sub. Date(s): All strengths: Mar 26, 2018
Apr 11, 2028 
Pat. No. 10548871 Low-dose doxepin formulations and methods of making and using the same
Claim Types: Method of use
Pat. Sub. Date(s): All strengths: Feb 28, 2020
Apr 11, 2028U-620: Treatment of insomnia
Pat. No. 9107898 Methods of using low-dose doxepin for the improvement of sleep
Claim Types: Method of use
Pat. Sub. Date(s): All strengths: Sep 9, 2015
May 1, 2028U-620: Treatment of insomnia
Pat. No. 9532971 DP* Low-dose doxepin formulations and methods of making and using the same
Claim Types: Formulation
Pat. Sub. Date(s): All strengths: Jan 13, 2017
Jun 1, 2029 
Pat. No. 8513299 Methods of using low-dose doxepin for the improvement of sleep
Claim Types: Method of use
Pat. Sub. Date(s): 001: Sep 20, 2013; 002: None
Sep 7, 2030U-620: Treatment of insomnia

ZYMAR (SOLUTION/DROPS) (OPHTHALMIC) GATIFLOXACIN
Drug Classes: quinolone antimicrobial
NDA Applicant: ALLERGAN      NDA No.: 021493  Prod. No.: 001 RX (0.3%)
PatentsExpirationPatented Use
Pat. No. 6333045 DP* DLR* Aqueous liquid pharmaceutical composition comprised of gatifloxacin
Claim Types: Formulation; Process
Pat. Sub. Date(s): 001: None
Feb 20, 2020 *PED 

JUXTAPID (CAPSULE) (ORAL) LOMITAPIDE MESYLATE
Drug Classes: microsomal triglyceride transfer protein inhibitor
NDA Applicant: AMRYT      NDA No.: 203858  Prod. No.: 001 RX (EQ 5MG BASE); 002 RX (EQ 10MG BASE); 003 RX (EQ 20MG BASE); 004 RX (EQ 30MG BASE); 005 RX (EQ 40MG BASE); 006 RX (EQ 60MG BASE)
PatentsExpirationPatented Use
Pat. No. 5712279 DS* DP* [Extended 5 years]
Inhibitors of microsomal triglyceride transfer protein and method
Claim Types: Compound; Method of use
Pat. Sub. Date(s): 001: Jan 14, 2013; 002: Jan 14, 2013; 003: Jan 14, 2013; 004: May 29, 2015; 005: May 29, 2015; 006: May 29, 2015
Feb 21, 2020U-1317: Treatment of hypercholesterolemia, hyperlipidemia and hyperlipoproteinemia in patients with homozygous familial hypercholesterolemia
Pat. No. 8618135 Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
Claim Types: Method of administration
Pat. Sub. Date(s): 001: Jan 22, 2014; 002: Jan 22, 2014; 003: Jan 22, 2014; 004: May 29, 2015; 005: May 29, 2015; 006: May 29, 2015
Mar 7, 2025U-1316: A dosing regimen for the treatment of hypercholesterolemia and hyperlipidemia in patients with homozygous familial hypercholesterolemia using at least three step-wise increasing doses
Pat. No. 9265758 Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects
Claim Types: Method of administration
Pat. Sub. Date(s): All strengths: Feb 23, 2016
Mar 7, 2025U-1316: A dosing regimen for the treatment of hypercholesterolemia and hyperlipidemia in patients with homozygous familial hypercholesterolemia using at least three step-wise increasing doses
Pat. No. 9364470 Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects
Claim Types: Method of administration
Pat. Sub. Date(s): All strengths: Jun 20, 2016
Mar 7, 2025U-1851: A dosing regimen for the treatment of hypercholesterolemia and hyperlipidemia in patients with homozygous familial hypercholesterolemia using at least three step-wise increasing doses
Pat. No. 9433617 Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects
Claim Types: Method of administration
Pat. Sub. Date(s): All strengths: Sep 8, 2016
Mar 7, 2025U-1316: A dosing regimen for the treatment of hypercholesterolemia and hyperlipidemia in patients with homozygous familial hypercholesterolemia using at least three step-wise increasing doses
Pat. No. 9861622 Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects
Claim Types: Method of use; Method of administration
Pat. Sub. Date(s): All strengths: Feb 5, 2018
Mar 7, 2025U-1316: A dosing regimen for the treatment of hypercholesterolemia and hyperlipidemia in patients with homozygous familial hypercholesterolemia using at least three step-wise increasing doses
Pat. No. 10016404 Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
Claim Types: Dosaage regimen
Pat. Sub. Date(s): All strengths: Aug 2, 2018
Mar 7, 2025U-1316: A dosing regimen for the treatment of hypercholesterolemia and hyperlipidemia in patients with homozygous familial hypercholesterolemia using at least three step-wise increasing doses
Pat. No. 10555938 Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
Claim Types: Method of use
Pat. Sub. Date(s): All strengths: Apr 28, 2020
Mar 7, 2025U-1316: A dosing regimen for the treatment of hypercholesterolemia and hyperlipidemia in patients with homozygous familial hypercholesterolemia using at least three step-wise increasing doses
Pat. No. 7932268 Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
Claim Types: Method of use
Pat. Sub. Date(s): 001: Jan 14, 2013; 002: None; 003: None; 004: May 29, 2015; 005: May 29, 2015; 006: May 29, 2015
Aug 19, 2027U-1316: A dosing regimen for the treatment of hypercholesterolemia and hyperlipidemia in patients with homozygous familial hypercholesterolemia using at least three step-wise increasing doses

COMBIVENT RESPIMAT (SPRAY, METERED) (INHALATION) ALBUTEROL SULFATE; IPRATROPIUM BROMIDE
Drug Classes: beta-2 adrenergic agonist; anticholinergic
NDA Applicant: BOEHRINGER INGELHEIM      NDA No.: 021747  Prod. No.: 001 RX (EQ 0.1MG BASE/INH;0.02MG/INH)
PatentsExpirationPatented Use
Pat. No. 6988496 DP* Cartridge for a liquid
Claim Types: Method of administration; Drug in a container
Pat. Sub. Date(s): 001: Nov 2, 2011
Feb 23, 2020 
Pat. No. 7988001 DP* Container provided with a pressure equalization opening
Claim Types: Device
Pat. Sub. Date(s): 001: Nov 2, 2011
Aug 4, 2021 
Pat. No. 7284474 DP* Piston-pumping system having o-ring seal properties
Claim Types: Device
Pat. Sub. Date(s): 001: Nov 2, 2011
Aug 26, 2024 
Pat. No. 7896264 DP* Microstructured high pressure nozzle with built-in filter function
Claim Types: Device; Process
Pat. Sub. Date(s): 001: Nov 2, 2011
May 26, 2025 
Pat. No. 7396341 DP* Blocking device for a locking stressing mechanism having a spring-actuated output drive device
Claim Types: Device; Method of use; Method of administration
Pat. Sub. Date(s): 001: Nov 2, 2011
Oct 10, 2026 
Pat. No. 9027967 DP* Device for clamping a fluidic component
Claim Types: Device; Process
Pat. Sub. Date(s): 001: Sep 4, 2015
Mar 31, 2027 
Pat. No. 7837235 DP* Device for clamping a fluidic component
Claim Types: Device
Pat. Sub. Date(s): 001: Nov 2, 2011
Mar 13, 2028 
Pat. No. 8733341 DP* Atomizer and method of atomizing fluid with a nozzle rinsing mechanism
Claim Types: Device; Method of administration
Pat. Sub. Date(s): 001: Sep 4, 2015
Oct 16, 2030 

STRIVERDI RESPIMAT (SPRAY, METERED) (INHALATION) OLODATEROL HYDROCHLORIDE
Drug Classes: beta-2 adrenergic agonist
NDA Applicant: BOEHRINGER INGELHEIM      NDA No.: 203108  Prod. No.: 001 RX (EQ 0.0025MG BASE/INH)
PatentsExpirationPatented Use
Pat. No. 6988496 DP* Cartridge for a liquid
Claim Types: Method of administration; Drug in a container
Pat. Sub. Date(s): 001: Aug 15, 2014
Feb 23, 2020U-1547: Treatment of chronic obstructive pulmonary disease (COPD), chronic bronchitis or emphysema
Pat. No. 7988001 DP* Container provided with a pressure equalization opening
Claim Types: Device
Pat. Sub. Date(s): 001: Aug 15, 2014
Aug 4, 2021 
Pat. No. 7491719 DS* DP* Enantiomerically pure beta agonists, process for the manufacture thereof, and use thereof as medicaments
Claim Types: Compound; New polymorph, salt or hydrate; Composition
Pat. Sub. Date(s): 001: Aug 15, 2014
Nov 10, 2023 
Pat. No. 7786111 DP* Medicaments for the treatment of chronic obstructive pulmonary disease
Claim Types: Composition; Formulation
Pat. Sub. Date(s): 001: Aug 15, 2014
Nov 10, 2023 
Pat. No. 8044046 Medicaments for the treatment of chronic obstructive pulmonary disease
Claim Types: Method of use
Pat. Sub. Date(s): 001: Aug 15, 2014
Nov 10, 2023U-1547: Treatment of chronic obstructive pulmonary disease (COPD), chronic bronchitis or emphysema
Pat. No. 7056916 DS* DP* Medicaments for the treatment of chronic obstructive pulmonary disease
Claim Types: Compound; Composition; Formulation
Pat. Sub. Date(s): 001: Aug 15, 2014
Dec 7, 2023 
Pat. No. 7284474 DP* Piston-pumping system having o-ring seal properties
Claim Types: Device
Pat. Sub. Date(s): 001: Aug 15, 2014
Aug 26, 2024 
Pat. No. 7220742 DS* DP* Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
Claim Types: Compound; Composition; Method of use
Pat. Sub. Date(s): 001: Aug 15, 2014
May 12, 2025U-1547: Treatment of chronic obstructive pulmonary disease (COPD), chronic bronchitis or emphysema
Pat. No. 8034809 Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
Claim Types: Method of use
Pat. Sub. Date(s): 001: Aug 15, 2014
May 12, 2025U-1547: Treatment of chronic obstructive pulmonary disease (COPD), chronic bronchitis or emphysema
Pat. No. 7896264 DP* Microstructured high pressure nozzle with built-in filter function
Claim Types: Device; Process
Pat. Sub. Date(s): 001: Aug 15, 2014
May 26, 2025 
Pat. No. 7396341 DP* Blocking device for a locking stressing mechanism having a spring-actuated output drive device
Claim Types: Device; Method of use; Method of administration
Pat. Sub. Date(s): 001: Aug 15, 2014
Oct 10, 2026U-1547: Treatment of chronic obstructive pulmonary disease (COPD), chronic bronchitis or emphysema
Pat. No. 7727984 DS* Medicaments for the treatment of chronic obstructive pulmonary disease
Claim Types: Compound; New polymorph, salt or hydrate
Pat. Sub. Date(s): 001: Aug 15, 2014
Jan 19, 2027 
Pat. No. 9027967 DP* Device for clamping a fluidic component
Claim Types: Device; Process
Pat. Sub. Date(s): 001: Sep 3, 2015
Mar 31, 2027 
Pat. No. 7837235 DP* Device for clamping a fluidic component
Claim Types: Device
Pat. Sub. Date(s): 001: Aug 15, 2014
Mar 13, 2028 
Pat. No. 8733341 DP* Atomizer and method of atomizing fluid with a nozzle rinsing mechanism
Claim Types: Device; Method of administration
Pat. Sub. Date(s): 001: Sep 3, 2015
Oct 16, 2030 

DETROL LA (CAPSULE, EXTENDED RELEASE) (ORAL) TOLTERODINE TARTRATE [GENERIC AB]
Drug Classes: muscarinic antagonist
NDA Applicant: PHARMACIA AND UPJOHN      NDA No.: 021228  Prod. No.: 001 RX (2MG); 002 RX (4MG)
PatentsExpirationPatented Use
Pat. No. 6770295 DP* Therapeutic formulation for administering tolterodine with controlled release
Claim Types: Method of use; Formulation
Pat. Sub. Date(s): All strengths: None
Feb 26, 2020 *PEDU-544: Treatment of overactive bladder. Treatment of urinary incontinence.
Pat. No. 6630162 DP* Pharmaceutical formulation and its use
Claim Types: Formulation; Method of use; Method of administration
Pat. Sub. Date(s): All strengths: None
May 11, 2020 *PEDU-544: Treatment of overactive bladder. Treatment of urinary incontinence.
Pat. No. 6911217 DP* Controlled release bead, a method of producing the same and multiple unit formulationcomprising it
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): 001: Apr 30, 2013; 002: None
May 11, 2020 *PEDU-544: Treatment of overactive bladder. Treatment of urinary incontinence.

ONZETRA XSAIL (POWDER) (NASAL) SUMATRIPTAN SUCCINATE
Drug Classes: serotonin 5-HT1B/1D receptor agonist (triptan)
NDA Applicant: CURRAX      NDA No.: 206099  Prod. No.: 001 RX (EQ 11MG BASE)
PatentsExpirationPatented Use
Pat. No. 6715485 DP* Nasal delivery device
Claim Types: Device
Pat. Sub. Date(s): 001: Feb 23, 2016
Mar 3, 2020 
Pat. No. 8555877 DP* Nasal delivery device
Claim Types: Device
Pat. Sub. Date(s): 001: Feb 23, 2016
Mar 3, 2020 
Pat. No. 8047202 DP* Nasal devices
Claim Types: Device
Pat. Sub. Date(s): 001: Feb 23, 2016
Jul 2, 2023 
Pat. No. 8327844 Nasal delivery method
Claim Types: Method of use
Pat. Sub. Date(s): 001: Feb 23, 2016
Oct 3, 2023U-1809: Method of drug delivery via the nasal cavity
Pat. No. 9119932 DP* Nasal delivery device
Claim Types: Device; Drug in a container
Pat. Sub. Date(s): 001: Feb 23, 2016
Apr 23, 2024 
Pat. No. 7975690 DP* Nasal devices
Claim Types: Method of use
Pat. Sub. Date(s): 001: Feb 23, 2016
Aug 18, 2025U-1809: Method of drug delivery via the nasal cavity
Pat. No. 8590530 DP* Nasal delivery devices
Claim Types: Device; Drug in a container; Method of use
Pat. Sub. Date(s): 001: Feb 23, 2016
Sep 15, 2025U-1809: Method of drug delivery via the nasal cavity
Pat. No. 9108015 DP* Nasal delivery devices
Claim Types: Device
Pat. Sub. Date(s): 001: Feb 23, 2016
Sep 15, 2025 
Pat. No. 10124132 DP* Nasal delivery
Claim Types: Method of use; Device
Pat. Sub. Date(s): 001: Dec 10, 2018
Mar 6, 2027U-1719: Acute treatment of migraine
U-2010: Acute treatment of migraine by delivering a powdered substance comprising sumatriptan via a breath-powered delivery device
U-2011: Treatment of migraine via delivery of sumatriptan via the nasal cavity
Pat. No. 10398859 DP* Nasal delivery devices
Claim Types: Device
Pat. Sub. Date(s): 001: Sep 30, 2019
Dec 19, 2027 
Pat. No. 8875704 DP* Nasal administration
Claim Types: Device; Method of use; Drug in a container
Pat. Sub. Date(s): 001: Feb 23, 2016
Apr 7, 2028U-1809: Method of drug delivery via the nasal cavity
Pat. No. 10076615 Nasal delivery
Claim Types: Method of improving a treatment
Pat. Sub. Date(s): 001: Oct 12, 2018
Jul 30, 2029U-2010: Acute treatment of migraine by delivering a powdered substance comprising sumatriptan via a breath-powered delivery device
U-2011: Treatment of migraine via delivery of sumatriptan via the nasal cavity
U-2404: Method of delivering sumatriptan to a nasal cavity
Pat. No. 8550073 DP* Nasal delivery
Claim Types: Device
Pat. Sub. Date(s): 001: Feb 23, 2016
Oct 22, 2029 
Pat. No. 8899229 DP* Powder delivery devices
Claim Types: Device
Pat. Sub. Date(s): 001: Feb 23, 2016
Aug 18, 2030 
Pat. No. 9649456 DP* Nasal administration
Claim Types: Method of administration; Device
Pat. Sub. Date(s): 001: May 26, 2017
Oct 21, 2030U-1719: Acute treatment of migraine
U-2010: Acute treatment of migraine by delivering a powdered substance comprising sumatriptan via a breath-powered delivery device
U-2011: Treatment of migraine via delivery of sumatriptan via the nasal cavity
Pat. No. 8978647 DP* Nasal delivery
Claim Types: Device
Pat. Sub. Date(s): 001: Feb 23, 2016
Dec 6, 2030 
Pat. No. 10478574 Nasal administration
Claim Types: Method of use; Method of administration
Pat. Sub. Date(s): 001: Dec 9, 2019
Nov 4, 2033U-2404: Method of delivering sumatriptan to a nasal cavity
Pat. No. 10076614 DP* Nasal delivery devices
Claim Types: Device
Pat. Sub. Date(s): 001: Oct 12, 2018
Oct 20, 2034 

RENOVA (CREAM) (TOPICAL) TRETINOIN
Drug Classes: retinoid
NDA Applicant: VALEANT PHARMS NORTH      NDA No.: 021108  Prod. No.: 001 RX (0.02%)
PatentsExpirationPatented Use
Pat. No. 6531141 Oil-in-water emulsion containing tretinoin
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): 001: None
Mar 7, 2020 

FERAHEME (SOLUTION) (INTRAVENOUS) FERUMOXYTOL
Drug Classes: iron replacement product
NDA Applicant: AMAG PHARMS INC      NDA No.: 022180  Prod. No.: 001 RX (EQ 510MG IRON/17ML (EQ 30MG IRON/ML))
PatentsExpirationPatented Use
Pat. No. 7553479 DS* DP* Heat stable colloidal iron oxides coated with reduced carbohydrates and uses thereof
Claim Types: Formulation
Pat. Sub. Date(s): 001: None
Mar 8, 2020 
Pat. No. 7871597 DS* DP* Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): 001: Feb 15, 2011
Mar 8, 2020 
Pat. No. 8501158 Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents
Claim Types: Method of administration
Pat. Sub. Date(s): 001: Aug 6, 2013
Mar 8, 2020U-1422: Method of treating patients needing an iron supplement
Pat. No. 8591864 DP* Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents
Claim Types: Formulation
Pat. Sub. Date(s): 001: Dec 12, 2013
Mar 8, 2020 
Pat. No. 8926947 DS* DP* Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents
Claim Types: Product-by-process; Process
Pat. Sub. Date(s): 001: Jan 8, 2015
Mar 8, 2020 
Pat. No. 6599498 DS* DP* [Extended 1209 days (3.3 years)]
Heat stable colloidal iron oxides coated with reduced carbohydrates and carbohdrate derivatives
Claim Types: Method of administration; Process; Formulation
Pat. Sub. Date(s): 001: None
Jun 30, 2023 
ExclusivityExpirationExclusivity Description
Exclusivity Code: I - New IndicationFeb 2, 2021I-767: Treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron

SOMATULINE DEPOT (SOLUTION) (SUBCUTANEOUS) LANREOTIDE ACETATE
Drug Classes: somatostatin analog
NDA Applicant: IPSEN PHARMA      NDA No.: 022074  Prod. No.: 001 RX (EQ 60MG BASE/0.2ML (EQ 60MG BASE/0.2ML)); 002 RX (EQ 90MG BASE/0.3ML (EQ 90MG BASE/0.3ML)); 003 RX (EQ 120MG BASE/0.5ML (EQ 120MG BASE/0.5ML))
PatentsExpirationPatented Use
Pat. No. 5595760 DP* [Extended 5 years]
Sustained release of peptides from pharmaceutical compositions
Claim Types: Method of use; Formulation
Pat. Sub. Date(s): All strengths: None
Mar 8, 2020U-831: Method of administering lanreotide acetate
ExclusivityExpirationExclusivity Description
Exclusivity Code: I - New IndicationSep 15, 2020I-754: To reduce the frequency of short-acting somatostatin analog rescue therapy when used for the treatment of adults with carcinoid syndrome
Exclusivity Code: ODE - Orphan drug exclusivitySep 15, 2024ODE-156: Treatment of adults with carcinoid syndrome; when used, it reduces the frequency of short-acting somatostatin analog rescue therapy
Exclusivity Code: ODE - Orphan drug exclusivityDec 16, 2021ODE-82: Treatment of patients with unresectable,well- or moderately-differentiated locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors to improve progression-free survival

AFINITOR (TABLET) (ORAL) EVEROLIMUS [GENERIC AB]
Drug Classes: kinase inhibitor; mTor inhibitor immunosuppressant
NDA Applicant: NOVARTIS      NDA No.: 022334  Prod. No.: 001 RX (5MG); 002 RX (10MG); 003 RX (2.5MG); 004 RX (7.5MG)
PatentsExpirationPatented Use
Pat. No. 5665772 DS* DP* [Extended 5 years]
O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants
Claim Types: Compound; Composition; Method of use
Pat. Sub. Date(s): 001: None; 002: None; 003: None; 004: May 11, 2012
Mar 9, 2020 *PED 
Pat. No. 7297703 DP* Macrolides
Claim Types: Formulation; Process
Pat. Sub. Date(s): 001: None; 002: None; 003: May 11, 2012; 004: May 11, 2012
Jun 6, 2020 *PED 
Pat. No. 8778962 Treatment of solid tumors with rapamycin derivatives
Claim Types: Method of use
Pat. Sub. Date(s): All strengths: Jul 28, 2014
Aug 18, 2022 *PEDU-1541: Treatment of patients with tuberous sclerosis complex (TSC) who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected.
Pat. No. 8436010 Treatment of solid tumors with rapamycin derivatives
Claim Types: Method of use; Method of administration
Pat. Sub. Date(s): All strengths: Jun 3, 2013
Aug 22, 2022 *PEDU-1396: Treatment of advanced hormone receptor positive, her2-negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole
Pat. No. 8410131 Cancer treatment
Claim Types: Method of use
Pat. Sub. Date(s): All strengths: Apr 2, 2013
May 1, 2026 *PEDU-1368: Treatment of solid excretory system tumors; advanced renal cell carcinoma (RCC), after failure of treatment with sunitinib or sorafenib
Pat. No. 9006224 Neuroendocrine tumor treatment
Claim Types: Method of use
Pat. Sub. Date(s): All strengths: Apr 20, 2015
Jul 1, 2028U-1681: Treatment of patients with progessive neuroendocrine tumors of pancreatic origin (PNET) that are unresectable, locally advanced or metastatic
ExclusivityExpirationExclusivity Description
Exclusivity Code: ODE - Orphan drug exclusivityFeb 26, 2023ODE-108: Treatment of adult patients with progressive, well-differentiated, non-functional, neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin, (excluding pancreatic) with unresectable, locally advanced or metastatic disease

AFINITOR DISPERZ (TABLET, FOR SUSPENSION) (ORAL) EVEROLIMUS
Drug Classes: kinase inhibitor; mTor inhibitor immunosuppressant
NDA Applicant: NOVARTIS PHARM      NDA No.: 203985  Prod. No.: 001 RX (2MG); 002 RX (3MG); 003 RX (5MG)
PatentsExpirationPatented Use
Pat. No. 5665772 DS* DP* [Extended 5 years]
O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants
Claim Types: Compound; Composition; Method of use
Pat. Sub. Date(s): 001: Sep 26, 2012; 002: None; 003: None
Mar 9, 2020 *PED 
Pat. No. 7297703 DP* Macrolides
Claim Types: Formulation; Process
Pat. Sub. Date(s): 001: Sep 26, 2012; 002: None; 003: None
Jun 6, 2020 *PED 
Pat. No. 8778962 Treatment of solid tumors with rapamycin derivatives
Claim Types: Method of use
Pat. Sub. Date(s): All strengths: Jul 28, 2014
Aug 18, 2022 *PEDU-1541: Treatment of patients with tuberous sclerosis complex (TSC) who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected.
U-2280: Adjunctive treatment of patients with TSC-associated partial-onset seizures
Pat. No. 8617598 DP* Pharmaceutical compositions comprising colloidal silicon dioxide
Claim Types: Formulation; Method of use; Process
Pat. Sub. Date(s): All strengths: Mar 27, 2014
Mar 27, 2023 *PED 
ExclusivityExpirationExclusivity Description
Exclusivity Code: I - New IndicationApr 10, 2021I-773: For the adjunctive treatment of adult and pediatric patients age 2 years and older with tuberous sclerosis complex (TSC)-associated partial-onset seizures
Exclusivity Code: ODE - Orphan drug exclusivityApr 10, 2025ODE-169: For the adjunctive treatment of adult and pediatric patients aged 2 years and older with tuberous sclerosis complex (TSC)-associated partial-onset seizures

ZORTRESS (TABLET) (ORAL) EVEROLIMUS [GENERIC AB]
Drug Classes: kinase inhibitor; mTor inhibitor immunosuppressant
NDA Applicant: NOVARTIS      NDA No.: 021560  Prod. No.: 001 RX (0.25MG); 002 RX (0.5MG); 003 RX (0.75MG)
PatentsExpirationPatented Use
Pat. No. 5665772 DS* DP* [Extended 5 years]
O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants
Claim Types: Compound; Composition; Method of use
Pat. Sub. Date(s): All strengths: None
Mar 9, 2020 *PEDU-1049: Prophylaxis of organ rejection in adult patients at low-moderate immunologic risk receiving a renal transplant
U-1365: Prophylaxis of allograft rejection in adult patients receiving a liver transplant

CYMBALTA (CAPSULE, DELAYED REL PELLETS) (ORAL) DULOXETINE HYDROCHLORIDE [GENERIC AB]
Drug Classes: serotonin and norepinephrine reuptake inhibitor (SNRI)
NDA Applicant: LILLY      NDA No.: 021427  Prod. No.: 001 RX (EQ 20MG BASE); 002 RX (EQ 30MG BASE); 004 RX (EQ 60MG BASE)
PatentsExpirationPatented Use
Pat. No. 6596756 Treatment of fibromyalgia
Claim Types: Method of use
Pat. Sub. Date(s): All strengths: None
Mar 10, 2020 *PEDU-882: Management of fibromyalgia (FM)
ExclusivityExpirationExclusivity Description
Exclusivity Code: NPP - New patient populationApr 20, 2023 

TOTECT (INJECTABLE) (INJECTION) DEXRAZOXANE HYDROCHLORIDE [Has competitive generic]
Drug Classes: cytoprotective agent
NDA Applicant: CLINIGEN      NDA No.: 022025  Prod. No.: 001 RX (EQ 500MG BASE/VIAL)
PatentsExpirationPatented Use
Pat. No. 6727253 Treatment of accidental extravasation of anthracyclines
Claim Types: Method of use
Pat. Sub. Date(s): 001: None
Mar 13, 2020U-829: Treatment of extravasation resulting from IV anthracycline chemotherapy

RAYOS (TABLET, DELAYED RELEASE) (ORAL) PREDNISONE
Drug Classes: corticosteroid
NDA Applicant: HORIZON PHARMA USA      NDA No.: 202020  Prod. No.: 001 RX (1MG)
PatentsExpirationPatented Use
Pat. No. 6488960 DP* Corticosteroid formulation
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): 001: Aug 22, 2012
Mar 14, 2020U-1267: Treatment of rheumatoid arthritis by delayed release formulation of 1mg or 2mg of prednisone
Pat. No. 6677326 DP* Corticosteroid formulation comprising less than 2.5 mg prednisolone for once daily administration
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): 001: Aug 22, 2012
Mar 14, 2020U-1268: Treatment of pulmonary, gastrointestinal and/or rheumatological diseases or conditions by use of delayed release formulations of 1mg or 2mg prednisone
Pat. No. 8309124 Delayed release tablet with defined core geometry
Claim Types: Method of administration
Pat. Sub. Date(s): 001: Nov 13, 2012
Apr 23, 2024U-1292: Treatment of diseases or conditions by the use of a delayed release 1, 2, or 5 mg prednisone tablet
Pat. No. 8394407 DP* Delayed release tablet with defined core geometry
Claim Types: Formulation; Method of use; Process
Pat. Sub. Date(s): 001: Mar 12, 2013
Apr 23, 2024U-1362: Treatment of diseases or conditions by the use of a delayed-release 1,2, or 5mg prednisone tablet
Pat. No. 9040085 Delayed release tablet with defined core geometry
Claim Types: Method of use
Pat. Sub. Date(s): 001: Jun 25, 2015
Apr 23, 2024U-1362: Treatment of diseases or conditions by the use of a delayed-release 1,2, or 5mg prednisone tablet
Pat. No. 9186332 Delayed release tablet with defined core geometry
Claim Types: Method of use
Pat. Sub. Date(s): 001: Dec 4, 2015
Apr 23, 2024U-1362: Treatment of diseases or conditions by the use of a delayed-release 1,2, or 5mg prednisone tablet
Pat. No. 9504699 Delayed-release glucocorticoid treatment of rheumatoid disease
Claim Types: Method of use
Pat. Sub. Date(s): 001: Dec 7, 2016
Aug 3, 2027U-1362: Treatment of diseases or conditions by the use of a delayed-release 1,2, or 5mg prednisone tablet

RAYOS (TABLET, DELAYED RELEASE) (ORAL) PREDNISONE
Drug Classes: corticosteroid
NDA Applicant: HORIZON PHARMA USA      NDA No.: 202020  Prod. No.: 002 RX (2MG)
PatentsExpirationPatented Use
Pat. No. 6488960 DP* Corticosteroid formulation
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): 002: None
Mar 14, 2020U-1267: Treatment of rheumatoid arthritis by delayed release formulation of 1mg or 2mg of prednisone
Pat. No. 6677326 DP* Corticosteroid formulation comprising less than 2.5 mg prednisolone for once daily administration
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): 002: None
Mar 14, 2020U-1268: Treatment of pulmonary, gastrointestinal and/or rheumatological diseases or conditions by use of delayed release formulations of 1mg or 2mg prednisone
Pat. No. 8309124 Delayed release tablet with defined core geometry
Claim Types: Method of administration
Pat. Sub. Date(s): 002: None
Apr 23, 2024 
Pat. No. 8394407 DP* Delayed release tablet with defined core geometry
Claim Types: Formulation; Method of use; Process
Pat. Sub. Date(s): 002: None
Apr 23, 2024U-1362: Treatment of diseases or conditions by the use of a delayed-release 1,2, or 5mg prednisone tablet
Pat. No. 9040085 Delayed release tablet with defined core geometry
Claim Types: Method of use
Pat. Sub. Date(s): 002: Jun 25, 2015
Apr 23, 2024U-1362: Treatment of diseases or conditions by the use of a delayed-release 1,2, or 5mg prednisone tablet
Pat. No. 9186332 Delayed release tablet with defined core geometry
Claim Types: Method of use
Pat. Sub. Date(s): 002: Dec 4, 2015
Apr 23, 2024U-1362: Treatment of diseases or conditions by the use of a delayed-release 1,2, or 5mg prednisone tablet
Pat. No. 9504699 Delayed-release glucocorticoid treatment of rheumatoid disease
Claim Types: Method of use
Pat. Sub. Date(s): 002: Dec 7, 2016
Aug 3, 2027U-1362: Treatment of diseases or conditions by the use of a delayed-release 1,2, or 5mg prednisone tablet

LONSURF (TABLET) (ORAL) TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE
Drug Classes: thymidine phosphorylase inhibitor; nucleoside analog antiviral; nucleoside metabolic inhibitor
NDA Applicant: TAIHO ONCOLOGY      NDA No.: 207981  Prod. No.: 001 RX (EQ 6.14MG BASE;15MG); 002 RX (EQ 8.19MG BASE;20MG)
PatentsExpirationPatented Use
Pat. No. 6479500 Agents for alleviating side effects
Claim Types: Method of use
Pat. Sub. Date(s): All strengths: Oct 21, 2015
Mar 16, 2020U-1751: Treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-vegf biological therapy, and if RAS wild-type, an anti-EGFR therapy
Pat. No. RE46284 Method of administrating an anticancer drug containing .alpha., .alpha., .alpha.-trifluorothymidine and thymidine phosphorylase inhibitor
Claim Types: Method of use; Method of administration
Pat. Sub. Date(s): All strengths: Feb 7, 2017
Dec 16, 2026U-1751: Treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-vegf biological therapy, and if RAS wild-type, an anti-EGFR therapy
U-2503: Treatment of adults with metastatic gastric or GJA previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropiate, HER2/NEU-targeted therapy
Pat. No. 9527833 DS* DP* Stable crystal form of tipiracil hydrochloride and crystallization method for the same
Claim Types: New polymorph, salt or hydrate; Composition; Process
Pat. Sub. Date(s): All strengths: Jan 27, 2017
Jun 17, 2034 
Pat. No. 10457666 DS* DP* Stable crystal form of tipiracil hydrochloride and crystallization method for the same
Claim Types: New polymorph, salt or hydrate; Process
Pat. Sub. Date(s): All strengths: Nov 8, 2019
Jun 17, 2034 
Pat. No. 10456399 Method for treating cancer patients with severe renal impairment
Claim Types: Method of use
Pat. Sub. Date(s): All strengths: Nov 8, 2019
Feb 3, 2037U-2642: Method of treating cancer by detecting a creatinine clearance of a patient and administering LONSURF
ExclusivityExpirationExclusivity Description
Exclusivity Code: I - New IndicationFeb 22, 2022I-794: Treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy, and if appropriate, HER2/NEU-targeted therapy
Exclusivity Code: NCE - New chemical entitySep 22, 2020 
Exclusivity Code: ODE - Orphan drug exclusivityFeb 22, 2026ODE-229: Treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy, and if appropriate, HER2/NEU-targeted therapy

KOVANAZE (SPRAY, METERED) (NASAL) OXYMETAZOLINE HYDROCHLORIDE; TETRACAINE HYDROCHLORIDE
Drug Classes: vasoconstrictor; ester local anesthetic
NDA Applicant: ST RENATUS      NDA No.: 208032  Prod. No.: 001 RX (0.1MG/SPRAY;6MG/SPRAY)
PatentsExpirationPatented Use
Pat. No. 6413499 Methods and kits for maxillary dental anesthesia by means of a nasal deliverable anesthetic
Claim Types: Method of use
Pat. Sub. Date(s): 001: Jul 20, 2016
Mar 20, 2020U-1876: Method of anesthetizing at least a portion of the maxillary dental arch
Pat. No. 8580282 DP* Dental anesthetic comprising tetracaine and a vasoconstrictor for intranasal administration
Claim Types: Formulation; Method of use; Device; Method of administration
Pat. Sub. Date(s): 001: Jul 20, 2016
Apr 2, 2030U-1876: Method of anesthetizing at least a portion of the maxillary dental arch
Pat. No. 9308191 DP* Dental anesthetic comprising tetracaine and a vasoconstrictor for intranasal administration
Claim Types: Formulation; Method of use; Method of administration
Pat. Sub. Date(s): 001: Jul 20, 2016
Apr 2, 2030U-1876: Method of anesthetizing at least a portion of the maxillary dental arch

PREFEST (TABLET) (ORAL) ESTRADIOL; NORGESTIMATE
Drug Classes: estrogen; progestin
NDA Applicant: TEVA WOMENS      NDA No.: 021040  Prod. No.: 001 DISC (1MG,1MG;N/A,0.09MG**)
PatentsExpirationPatented Use
Pat. No. 6747019 Low dose estrogen interrupted hormone replacement therapy
Claim Types: Kit; Method of use
Pat. Sub. Date(s): 001: None
Mar 20, 2020U-311: Hormone replacement
Pat. No. 7320970 DP* Low dose estrogen interrupted hormone replacement therapy
Claim Types: Method of use; Kit
Pat. Sub. Date(s): 001: None
Mar 30, 2020U-844: PREFEST is indicated in women who have a uterus for the treatment of moderate to severe vasomotor symptoms associated with menopause; treatment of vulvar and vaginal atrophy; prevention of osteoporosis

XHANCE (SPRAY, METERED) (NASAL) FLUTICASONE PROPIONATE
Drug Classes: corticosteroid
NDA Applicant: OPTINOSE US INC      NDA No.: 209022  Prod. No.: 001 RX (0.093MG)
PatentsExpirationPatented Use
Pat. No. 8555878 DP* Nasal delivery device
Claim Types: Device
Pat. Sub. Date(s): 001: Oct 17, 2017
Mar 20, 2020 
Pat. No. 9468727 DP* Nasal delivery
Claim Types: Device
Pat. Sub. Date(s): 001: Oct 17, 2017
Jul 30, 2020 
Pat. No. 6715485 DP* Nasal delivery device
Claim Types: Device
Pat. Sub. Date(s): 001: Oct 17, 2017
Sep 3, 2020 
Pat. No. 9072857 DP* Nasal delivery device
Claim Types: Device
Pat. Sub. Date(s): 001: Oct 17, 2017
Apr 10, 2021 
Pat. No. 8522778 DP* Nasal devices
Claim Types: Device
Pat. Sub. Date(s): 001: Oct 17, 2017
May 11, 2022 
Pat. No. 8327844 Nasal delivery method
Claim Types: Method of use
Pat. Sub. Date(s): 001: Oct 17, 2017
Oct 8, 2023U-2133: Method of delivering fluticasone propionate to a nasal airway
Pat. No. 7975690 Nasal devices
Claim Types: Method of use
Pat. Sub. Date(s): 001: Oct 17, 2017
Dec 29, 2025U-2133: Method of delivering fluticasone propionate to a nasal airway
Pat. No. 10124132 DP* Nasal delivery
Claim Types: Method of use; Device
Pat. Sub. Date(s): 001: Dec 6, 2018
Mar 6, 2027U-2133: Method of delivering fluticasone propionate to a nasal airway
Pat. No. 10076615 Nasal delivery
Claim Types: Method of improving a treatment
Pat. Sub. Date(s): 001: Oct 12, 2018
Jul 30, 2029U-2133: Method of delivering fluticasone propionate to a nasal airway
Pat. No. 8550073 DP* Nasal delivery
Claim Types: Device
Pat. Sub. Date(s): 001: Oct 17, 2017
Oct 22, 2029 
Pat. No. 8978647 DP* Nasal delivery
Claim Types: Device
Pat. Sub. Date(s): 001: Oct 17, 2017
Aug 6, 2030 
Pat. No. 10252010 DP* Nasal delivery devices
Claim Types: Device
Pat. Sub. Date(s): 001: May 8, 2019
Feb 7, 2031 
Pat. No. 10179216 DP* Nasal delivery devices
Claim Types: Device; Method of administration
Pat. Sub. Date(s): 001: Feb 8, 2019
Jul 8, 2033U-2133: Method of delivering fluticasone propionate to a nasal airway
Pat. No. 10478574 Nasal administration
Claim Types: Method of use; Method of administration
Pat. Sub. Date(s): 001: Dec 10, 2019
Nov 4, 2033U-2133: Method of delivering fluticasone propionate to a nasal airway
Pat. No. 10076614 DP* Nasal delivery devices
Claim Types: Device
Pat. Sub. Date(s): 001: Oct 12, 2018
Oct 20, 2034 
Pat. No. 10300229 DP* Nasal delivery devices
Claim Types: Device; Method of administration
Pat. Sub. Date(s): 001: Jun 18, 2019
Jul 7, 2035U-2133: Method of delivering fluticasone propionate to a nasal airway
ExclusivityExpirationExclusivity Description
Exclusivity Code: NP - New productSep 18, 2020 

ELIGARD KIT (POWDER) (SUBCUTANEOUS) LEUPROLIDE ACETATE
Drug Classes: gonadotropin releasing hormone (GnRH) agonist
NDA Applicant: TOLMAR THERAP      NDA No.: 021343  Prod. No.: 001 RX (7.5MG)
PatentsExpirationPatented Use
Pat. No. 6626870 DP* Stoppering method to maintain sterility
Claim Types: Device; Process
Pat. Sub. Date(s): 001: None
Mar 27, 2020 

ELIGARD KIT (POWDER) (SUBCUTANEOUS) LEUPROLIDE ACETATE
Drug Classes: gonadotropin releasing hormone (GnRH) agonist
NDA Applicant: TOLMAR THERAP      NDA No.: 021379  Prod. No.: 001 RX (22.5MG)
PatentsExpirationPatented Use
Pat. No. 6626870 DP* Stoppering method to maintain sterility
Claim Types: Device; Process
Pat. Sub. Date(s): 001: None
Mar 27, 2020 
Pat. No. 8840916 DP* Sustained release polymer
Claim Types: Compound
Pat. Sub. Date(s): 001: Jan 31, 2017
Nov 13, 2020 
Pat. No. 9539333 DS* DP* Sustained release polymer
Claim Types: Intermediate; Formulation; Method of use
Pat. Sub. Date(s): 001: Jan 31, 2017
Nov 13, 2020U-621: Method of treating cancer
Pat. No. 8470359 DS* DP* Sustained release polymer
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): 001: Jan 31, 2017
Oct 15, 2023U-621: Method of treating cancer

ELIGARD KIT (POWDER) (SUBCUTANEOUS) LEUPROLIDE ACETATE
Drug Classes: gonadotropin releasing hormone (GnRH) agonist
NDA Applicant: TOLMAR THERAP      NDA No.: 021488  Prod. No.: 001 RX (30MG)
PatentsExpirationPatented Use
Pat. No. 6626870 DP* Stoppering method to maintain sterility
Claim Types: Device; Process
Pat. Sub. Date(s): 001: None
Mar 27, 2020 
Pat. No. 8840916 DP* Sustained release polymer
Claim Types: Compound
Pat. Sub. Date(s): 001: Jan 31, 2017
Nov 13, 2020 
Pat. No. 9539333 DS* DP* Sustained release polymer
Claim Types: Intermediate; Formulation; Method of use
Pat. Sub. Date(s): 001: Jan 30, 2017
Nov 13, 2020U-621: Method of treating cancer
Pat. No. 8470359 DS* DP* Sustained release polymer
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): 001: Jan 31, 2017
Oct 15, 2023U-621: Method of treating cancer

ELIGARD KIT (POWDER) (SUBCUTANEOUS) LEUPROLIDE ACETATE
Drug Classes: gonadotropin releasing hormone (GnRH) agonist
NDA Applicant: TOLMAR THERAP      NDA No.: 021731  Prod. No.: 001 RX (45MG)
PatentsExpirationPatented Use
Pat. No. 6626870 DP* Stoppering method to maintain sterility
Claim Types: Device; Process
Pat. Sub. Date(s): 001: None
Mar 27, 2020 
Pat. No. 8840916 DP* Sustained release polymer
Claim Types: Compound
Pat. Sub. Date(s): 001: Jan 31, 2017
Nov 13, 2020 
Pat. No. 9539333 DS* DP* Sustained release polymer
Claim Types: Intermediate; Formulation; Method of use
Pat. Sub. Date(s): 001: Jan 31, 2017
Nov 13, 2020U-621: Method of treating cancer
Pat. No. 9914802 DS* DP* Sustained release polymer
Claim Types: Method of use; Process; Formulation
Pat. Sub. Date(s): 001: Mar 14, 2018
Nov 13, 2020U-1666: Palliative treatment of prostate cancer
Pat. No. 8470359 DS* DP* Sustained release polymer
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): 001: Jan 31, 2017
Oct 15, 2023U-621: Method of treating cancer

TAYTULLA (CAPSULE) (ORAL) ETHINYL ESTRADIOL; NORETHINDRONE ACETATE
Drug Classes: estrogen; progestin
NDA Applicant: APIL      NDA No.: 204426  Prod. No.: 001 RX (0.02MG;1MG)
PatentsExpirationPatented Use
Pat. No. 6652880 DP* Oral pharmaceutical compositions containing long-chain triglycerides and liphophilic surfactants
Claim Types: Formulation
Pat. Sub. Date(s): 001: None
Mar 29, 2020 

MOXEZA (SOLUTION/DROPS) (OPHTHALMIC) MOXIFLOXACIN HYDROCHLORIDE [GENERIC AT2]
Drug Classes: quinolone antimicrobial
NDA Applicant: NOVARTIS      NDA No.: 022428  Prod. No.: 001 RX (EQ 0.5% BASE)
PatentsExpirationPatented Use
Pat. No. 6716830 DP* Ophthalmic antibiotic compositions containing moxifloxacin
Claim Types: Composition
Pat. Sub. Date(s): 001: None
Mar 29, 2020 *PED 
Pat. No. 7671070 DP* Method of treating ophthalmic infections with moxifloxacin compositions
Claim Types: Method of use
Pat. Sub. Date(s): 001: None
Mar 29, 2020 *PEDU-709: Method of combating bacteria in a patient
Pat. No. 8450311 DP* Pharmaceutical compositions containing a fluoroquinolone antibiotic drug
Claim Types: Formulation
Pat. Sub. Date(s): 001: Jun 10, 2013
May 29, 2029 
Pat. No. 9114168 DP* Pharmaceutical compositions containing a fluoroquinolone antibiotic drug
Claim Types: Formulation
Pat. Sub. Date(s): 001: Sep 8, 2015
May 29, 2029 

VIGAMOX (SOLUTION/DROPS) (OPHTHALMIC) MOXIFLOXACIN HYDROCHLORIDE [GENERIC AT1]
Drug Classes: quinolone antimicrobial
NDA Applicant: NOVARTIS      NDA No.: 021598  Prod. No.: 001 RX (EQ 0.5% BASE)
PatentsExpirationPatented Use
Pat. No. 6716830 DP* Ophthalmic antibiotic compositions containing moxifloxacin
Claim Types: Composition
Pat. Sub. Date(s): 001: None
Mar 29, 2020 *PED 
Pat. No. 7671070 Method of treating ophthalmic infections with moxifloxacin compositions
Claim Types: Method of use
Pat. Sub. Date(s): 001: None
Mar 29, 2020 *PEDU-709: Method of combating bacteria in a patient

LEVO-T (TABLET) (ORAL) LEVOTHYROXINE SODIUM [GENERIC AB1,AB2,AB3]
Drug Classes: L-thyroxine (T4)
NDA Applicant: CEDIPROF INC      NDA No.: 021342  Prod. No.: 001 RX (0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium); 002 RX (0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium); 003 RX (0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium); 004 RX (0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium); 005 RX (0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium); 006 RX (0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium); 007 RX (0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium); 008 RX (0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium); 009 RX (0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium); 010 RX (0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium); 011 RX (0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium)
PatentsExpirationPatented Use
Pat. No. 6399101 Stable thyroid hormone preparations and method of making same
Claim Types: Formulation; Process
Pat. Sub. Date(s): All strengths: None
Mar 30, 2020 

MARQIBO KIT (INJECTABLE, LIPOSOMAL) (INTRAVENOUS) VINCRISTINE SULFATE
Drug Classes: vinca alkaloid
NDA Applicant: ACROTECH      NDA No.: 202497  Prod. No.: 001 RX (5MG/5ML (1MG/ML))
PatentsExpirationPatented Use
Pat. No. 6723338 Compositions and methods for treating lymphoma
Claim Types: Method of use
Pat. Sub. Date(s): 001: Sep 6, 2012
Mar 31, 2020U-1271: Treatment of adult patients with Philadelphia chromosome-negative(ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies
Pat. No. 7887836 Compositions and methods for treating lymphoma
Claim Types: Method of use
Pat. Sub. Date(s): 001: Sep 6, 2012
Mar 31, 2020U-1271: Treatment of adult patients with Philadelphia chromosome-negative(ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies
Pat. No. 7247316 DP* Compositions and methods for treating lymphoma
Claim Types: Kit
Pat. Sub. Date(s): 001: Sep 6, 2012
Sep 25, 2020 

AUGMENTIN XR (TABLET, EXTENDED RELEASE) (ORAL) AMOXICILLIN; CLAVULANATE POTASSIUM [GENERIC AB]
Drug Classes: penicillin class antibacterial
NDA Applicant: NEOPHARMA      NDA No.: 050785  Prod. No.: 001 RX (1GM;EQ 62.5MG BASE)
PatentsExpirationPatented Use
Pat. No. 6746692 DP* Modified release pharmaceutical formulation comprising amoxycillin
Claim Types: Formulation
Pat. Sub. Date(s): 001: None
Apr 4, 2020 
Pat. No. 6783773 DP* Composition comprising amoxicillin and potassium clavulanate
Claim Types: Formulation
Pat. Sub. Date(s): 001: None
Apr 4, 2020 
Pat. No. 6878386 Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
Claim Types: Method of use
Pat. Sub. Date(s): 001: None
Apr 4, 2020U-926: Mgt specific bacterial infections. treatment pts w/ community acquired pneumonia or bacterial sinusitis due to confirmed, or suspected b-lactamase producing pathogens & S. pneumoniae with reduced susceptibility to penicillin (mic=2mc/ml)
Pat. No. 7217430 DP* Compositions and methods of treatment comprising amoxicillin and potassium clavulanate with xanthan
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): 001: None
Apr 4, 2020U-926: Mgt specific bacterial infections. treatment pts w/ community acquired pneumonia or bacterial sinusitis due to confirmed, or suspected b-lactamase producing pathogens & S. pneumoniae with reduced susceptibility to penicillin (mic=2mc/ml)
Pat. No. 7250176 Method of treating a bacterial infection
Claim Types: Method of use
Pat. Sub. Date(s): 001: None
Apr 4, 2020U-926: Mgt specific bacterial infections. treatment pts w/ community acquired pneumonia or bacterial sinusitis due to confirmed, or suspected b-lactamase producing pathogens & S. pneumoniae with reduced susceptibility to penicillin (mic=2mc/ml)

QBREXZA (CLOTH) (TOPICAL) GLYCOPYRRONIUM TOSYLATE
Drug Classes: anticholinergic
NDA Applicant: DERMIRA INC      NDA No.: 210361  Prod. No.: 001 RX (EQ 2.4% BASE)
PatentsExpirationPatented Use
Pat. No. 6433003 Method for treating hyperhidrosis in mammals
Claim Types: Method of use
Pat. Sub. Date(s): 001: Sep 20, 2018
Apr 10, 2020U-2398: Topical treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older
Pat. No. 10052267 DP* Topical glycopyrrolate formulations
Claim Types: Formulation; Device; Method of use
Pat. Sub. Date(s): 001: Sep 20, 2018
Oct 17, 2028U-2398: Topical treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older
Pat. No. 8618160 DP* Topical glycopyrrolate formulations
Claim Types: Device; Method of use
Pat. Sub. Date(s): 001: Sep 20, 2018
Dec 10, 2029U-2398: Topical treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older
Pat. No. 9744105 DP* Topical glycopyrrolate formulations
Claim Types: Formulation; Device; Method of use
Pat. Sub. Date(s): 001: Sep 20, 2018
Jul 18, 2030U-2398: Topical treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older
Pat. No. 8859610 DP* Crystalline glycopyrrolate tosylate
Claim Types: Device; Method of use
Pat. Sub. Date(s): 001: Sep 20, 2018
Feb 28, 2033U-2398: Topical treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older
Pat. No. 9259414 Glycopyrrolate salts
Claim Types: Method of use
Pat. Sub. Date(s): 001: Sep 20, 2018
Feb 28, 2033U-2398: Topical treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older
Pat. No. 10004717 DP* Glycopyrrolate salts
Claim Types: Formulation; Method of use; Device
Pat. Sub. Date(s): 001: Sep 20, 2018
Feb 28, 2033U-2398: Topical treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older
Pat. No. 10543192 DP* Glycopyrrolate salts
Claim Types: Formulation
Pat. Sub. Date(s): 001: Feb 27, 2020
Feb 28, 2033 
Pat. No. 10548875 DS* DP* Glycopyrrolate salts
Claim Types: Composition
Pat. Sub. Date(s): 001: Mar 3, 2020
Feb 28, 2033U-2398: Topical treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older

ZOLOFT (CONCENTRATE) (ORAL) SERTRALINE HYDROCHLORIDE [GENERIC AA]
Drug Classes: selective serotonin reuptake inhibitor (SSRI)
NDA Applicant: UPJOHN      NDA No.: 020990  Prod. No.: 001 RX (EQ 20MG BASE/ML)
PatentsExpirationPatented Use
Pat. No. 6727283 DP* Sertraline oral concentrate
Claim Types: Formulation; Process; Method of use
Pat. Sub. Date(s): 001: None
Apr 11, 2020 *PEDU-580: Treatment of disorders of the serotonergic system such as depression and anxiety-related disorders
Pat. No. 7067555 DP* Sertraline oral concentrate
Claim Types: Formulation; Process
Pat. Sub. Date(s): 001: None
Apr 11, 2020 *PED 

ABILIFY (TABLET, ORALLY DISINTEGRATING) (ORAL) ARIPIPRAZOLE
Drug Classes: atypical antipsychotic
NDA Applicant: OTSUKA      NDA No.: 021729  Prod. No.: 002 DISC (10MG**); 003 DISC (15MG**)
PatentsExpirationPatented Use
Pat. No. 9358207 DP* Flashmelt oral dosage formulation
Claim Types: Formulation
Pat. Sub. Date(s): All strengths: Jun 30, 2016
Apr 12, 2020 
Pat. No. 8518421 DP* Flashmelt oral dosage formulation
Claim Types: Formulation
Pat. Sub. Date(s): All strengths: Sep 26, 2013
Jul 24, 2021 *PED 
Pat. No. 7053092 5-HT1a receptor subtype agonist
Claim Types: Method of use
Pat. Sub. Date(s): All strengths: None
Jan 28, 2022U-839: Treatment of major depressive disorder (MDD)
Pat. No. 9089567 Method of treating cognitive impairments and schizophrenias
Claim Types: Method of use
Pat. Sub. Date(s): All strengths: Aug 26, 2015
Jan 28, 2022U-543: Treatment of schizophrenia
Pat. No. 8642600 Method of treating autism
Claim Types: Method of use
Pat. Sub. Date(s): All strengths: Mar 5, 2014
Jul 28, 2022 *PEDU-1492: Treatment of irritability associated with autistic disorder
Pat. No. 9359302 DS* DP* Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Claim Types: New polymorph, salt or hydrate; Process; Product-by-process; Composition; Method of use; Kit; Formulation
Pat. Sub. Date(s): All strengths: Jun 30, 2016
Sep 25, 2022U-1859: Treatment of schizophrenia, acute treatment of manic and mixed episodes associated with bipolar I disorder, adjunctive treatment of major depressive disorder, and treatment of irritability associated with autistic disorder
Pat. No. 8580796 DS* Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Claim Types: New polymorph, salt or hydrate
Pat. Sub. Date(s): All strengths: None
Mar 25, 2023 *PED 
Pat. No. 8642760 DS* Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Claim Types: Compound
Pat. Sub. Date(s): All strengths: Mar 5, 2014
Mar 25, 2023 *PED 
Pat. No. 9387182 Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): All strengths: Aug 2, 2016
Dec 25, 2023U-1529: Adjunctive treatment of major depressive disorder (MDD)
Pat. No. 8017615 DP* Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Claim Types: Composition; Product-by-process; Process
Pat. Sub. Date(s): All strengths: None
Dec 16, 2024 *PED 
Pat. No. 9125939 Carbostyril derivatives and mood stabilizers for treating mood disorders
Claim Types: Method of use
Pat. Sub. Date(s): All strengths: Oct 7, 2015
Jul 28, 2026U-1749: Acute treatment of manic and mixed episodes associated with bipolar I disorder
Pat. No. 8759350 Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): All strengths: Jul 22, 2014
Mar 2, 2027U-1529: Adjunctive treatment of major depressive disorder (MDD)
ExclusivityExpirationExclusivity Description
Exclusivity Code: ODE - Orphan drug exclusivityDec 12, 2021ODE-80: Treatment of pediatric patients with Tourette's

ABILIFY (TABLET, ORALLY DISINTEGRATING) (ORAL) ARIPIPRAZOLE
Drug Classes: atypical antipsychotic
NDA Applicant: OTSUKA      NDA No.: 021729  Prod. No.: 004 DISC (20MG**); 005 DISC (30MG**)
PatentsExpirationPatented Use
Pat. No. 9358207 DP* Flashmelt oral dosage formulation
Claim Types: Formulation
Pat. Sub. Date(s): All strengths: Jun 30, 2016
Apr 12, 2020 
Pat. No. 8518421 DP* Flashmelt oral dosage formulation
Claim Types: Formulation
Pat. Sub. Date(s): All strengths: Sep 26, 2013
Jul 24, 2021 *PED 
Pat. No. 7053092 5-HT1a receptor subtype agonist
Claim Types: Method of use
Pat. Sub. Date(s): All strengths: None
Jan 28, 2022U-839: Treatment of major depressive disorder (MDD)
Pat. No. 8642600 Method of treating autism
Claim Types: Method of use
Pat. Sub. Date(s): All strengths: Mar 5, 2014
Jul 28, 2022 *PEDU-1492: Treatment of irritability associated with autistic disorder
Pat. No. 9359302 DS* DP* Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Claim Types: New polymorph, salt or hydrate; Process; Product-by-process; Composition; Method of use; Kit; Formulation
Pat. Sub. Date(s): All strengths: Jun 30, 2016
Sep 25, 2022U-1859: Treatment of schizophrenia, acute treatment of manic and mixed episodes associated with bipolar I disorder, adjunctive treatment of major depressive disorder, and treatment of irritability associated with autistic disorder
Pat. No. 8580796 DS* Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Claim Types: New polymorph, salt or hydrate
Pat. Sub. Date(s): All strengths: None
Mar 25, 2023 *PED 
Pat. No. 8642760 DS* Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Claim Types: Compound
Pat. Sub. Date(s): All strengths: Mar 5, 2014
Mar 25, 2023 *PED 
Pat. No. 9387182 Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): All strengths: Aug 2, 2016
Dec 25, 2023U-1529: Adjunctive treatment of major depressive disorder (MDD)
Pat. No. 8017615 DP* Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Claim Types: Composition; Product-by-process; Process
Pat. Sub. Date(s): All strengths: None
Dec 16, 2024 *PED 
ExclusivityExpirationExclusivity Description
Exclusivity Code: ODE - Orphan drug exclusivityDec 12, 2021ODE-80: Treatment of pediatric patients with Tourette's

OTREXUP (SOLUTION) (SUBCUTANEOUS) METHOTREXATE
Drug Classes: folate analog metabolic inhibitor
NDA Applicant: ANTARES PHARMA INC      NDA No.: 204824  Prod. No.: 001 RX (10MG/0.4ML (10MG/0.4ML)); 002 RX (15MG/0.4ML (15MG/0.4ML)); 003 RX (20MG/0.4ML (20MG/0.4ML)); 004 RX (25MG/0.4ML (25MG/0.4ML)); 006 RX (12.5MG/0.4ML (12.5MG/0.4ML)); 007 RX (17.5MG/0.4ML (17.5MG/0.4ML)); 008 RX (22.5MG/0.4ML (22.5MG/0.4ML)) NDA No.: 204824  Prod. No.: 005 DISC (7.5MG/0.4ML (7.5MG/0.4ML))
PatentsExpirationPatented Use
Pat. No. 6746429 DP* Needle assisted jet injector
Claim Types: Device
Pat. Sub. Date(s): 001: Nov 4, 2013; 002: Nov 4, 2013; 003: Nov 4, 2013; 004: Nov 4, 2013; 005: Dec 2, 2014; 006: Jun 1, 2016; 007: Jun 1, 2016; 008: Jun 1, 2016
Apr 12, 2020 
Pat. No. 8562564 DP* Prefilled syringe jet injector
Claim Types: Device
Pat. Sub. Date(s): 001: Nov 4, 2013; 002: Nov 4, 2013; 003: Nov 4, 2013; 004: Nov 4, 2013; 005: Dec 2, 2014; 006: Jun 1, 2016; 007: Jun 1, 2016; 008: Jun 1, 2016
Jan 24, 2026 
Pat. No. 9533102 DP* Prefilled syringe jet injector
Claim Types: Device
Pat. Sub. Date(s): All strengths: Feb 2, 2017
Jan 24, 2026 
Pat. No. 9629959 DP* Prefilled syringe jet injector
Claim Types: Device
Pat. Sub. Date(s): All strengths: May 25, 2017
Jan 24, 2026 
Pat. No. 8021335 DP* Prefilled syringe jet injector
Claim Types: Device
Pat. Sub. Date(s): 001: Nov 4, 2013; 002: Nov 4, 2013; 003: Nov 4, 2013; 004: Nov 4, 2013; 005: Dec 2, 2014; 006: Jun 1, 2016; 007: Jun 1, 2016; 008: Jun 1, 2016
Oct 4, 2026 
Pat. No. 8480631 DP* Hazardous agent injection system
Claim Types: Device; Method of administration
Pat. Sub. Date(s): 001: Nov 4, 2013; 002: None; 003: None; 004: None; 005: Dec 2, 2014; 006: Jun 1, 2016; 007: Jun 1, 2016; 008: Jun 1, 2016
Mar 19, 2030U-1442: Subcutaneous injection of methotrexate
Pat. No. 8579865 DP* Hazardous agent injection system
Claim Types: Device; Method of use
Pat. Sub. Date(s): 001: Nov 21, 2013; 002: Nov 21, 2013; 003: Nov 21, 2013; 004: Nov 21, 2013; 005: Dec 2, 2014; 006: Jun 1, 2016; 007: Jun 1, 2016; 008: Jun 1, 2016
Mar 19, 2030U-1442: Subcutaneous injection of methotrexate
Pat. No. 8945063 DP* Hazardous agent injection system
Claim Types: Device; Method of administration
Pat. Sub. Date(s): 001: Mar 2, 2015; 002: Mar 2, 2015; 003: Mar 2, 2015; 004: Mar 2, 2015; 005: Mar 2, 2015; 006: Jun 1, 2016; 007: Jun 1, 2016; 008: Jun 1, 2016
Mar 19, 2030U-1442: Subcutaneous injection of methotrexate
Pat. No. 9421333 DP* Hazardous agent injection system
Claim Types: Device; Method of use; Method of administration
Pat. Sub. Date(s): All strengths: Sep 21, 2016
Mar 19, 2030U-1442: Subcutaneous injection of methotrexate

ULTRAM (TABLET) (ORAL) TRAMADOL HYDROCHLORIDE [Has competitive generic]
Drug Classes: opioid agonist
NDA Applicant: JANSSEN PHARMS      NDA No.: 020281  Prod. No.: 002 RX (50MG) NDA No.: 020281  Prod. No.: 001 DISC (100MG)
PatentsExpirationPatented Use
Pat. No. 6339105 Analgesic regimen
Claim Types: Method of administration
Pat. Sub. Date(s): All strengths: None
Apr 12, 2020 *PEDU-435: A titration dosing regimen for the treatment of pain using an initial dose of about 25mg

DELZICOL (CAPSULE, DELAYED RELEASE) (ORAL) MESALAMINE [GENERIC AB]
Drug Classes: aminosalicylate
NDA Applicant: APIL      NDA No.: 204412  Prod. No.: 001 RX (400MG)
PatentsExpirationPatented Use
Pat. No. 6649180 DP* Hard capsule formed of cellulose ether film with a specific content of methoxyl and hydroxypropoxyl groups
Claim Types: Formulation
Pat. Sub. Date(s): 001: Jul 12, 2013
Apr 13, 2020 

SAFYRAL (TABLET) (ORAL) DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM [GENERIC AB]
Drug Classes: progestin; estrogen
NDA Applicant: BAYER HLTHCARE      NDA No.: 022574  Prod. No.: 001 RX (3MG,N/A;0.03MG,N/A;0.451MG,0.451MG)
PatentsExpirationPatented Use
Pat. No. 6441168 DS* [Extended 834 days (2.3 years)]
Stable crystalline salts of 5-methyltetrahydrofolic acid
Claim Types: New polymorph, salt or hydrate; Process
Pat. Sub. Date(s): 001: None
Apr 17, 2020 
Pat. No. 6958326 DP* Cyclodextrin-drospirenone inclusion complexes
Claim Types: Formulation; Process
Pat. Sub. Date(s): 001: None
Dec 20, 2021 
Pat. No. 7163931 Compositions of estrogen-cyclodextrin complexes
Claim Types: Method of use
Pat. Sub. Date(s): 001: None
Mar 3, 2022U-1: Prevention of pregnancy
Pat. No. 8617597 DP* Pharmaceutical composition containing a tetrahydrofolic acid
Claim Types: Formulation
Pat. Sub. Date(s): 001: Jan 29, 2014
Feb 8, 2030 

VIAGRA (TABLET) (ORAL) SILDENAFIL CITRATE [GENERIC AB]
Drug Classes: phosphodiesterase-5 (PDE-5) inhibitor
NDA Applicant: UPJOHN      NDA No.: 020895  Prod. No.: 001 RX (EQ 25MG BASE); 002 RX (EQ 50MG BASE); 003 RX (EQ 100MG BASE)
PatentsExpirationPatented Use
Pat. No. 6469012 Pyrazolopyrimidinones for the treatment of impotence
Claim Types: Method of use
Pat. Sub. Date(s): All strengths: None
Apr 22, 2020 *PEDU-155: Treatment of erectile dysfunction

GELNIQUE (GEL) (TRANSDERMAL) OXYBUTYNIN CHLORIDE
Drug Classes: muscarinic antagonist
NDA Applicant: ALLERGAN      NDA No.: 022204  Prod. No.: 001 RX (10% (100MG/PACKET))
PatentsExpirationPatented Use
Pat. No. 7029694 DP* Compositions and methods for transdermal oxybutynin therapy
Claim Types: Method of use; Formulation
Pat. Sub. Date(s): 001: None
Apr 26, 2020U-318: Treatment of patients with an overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence
Pat. No. 7179483 Compositions and methods for transdermal oxybutynin therapy
Claim Types: Method of use
Pat. Sub. Date(s): 001: None
Apr 26, 2020U-318: Treatment of patients with an overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence
Pat. No. 8241662 Unoccluded topical oxybutynin gel composition and methods for transdermal oxybutynin therapy
Claim Types: Method of use
Pat. Sub. Date(s): 001: Aug 22, 2012
Apr 26, 2020U-318: Treatment of patients with an overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence
Pat. No. 10272061 Compositions and methods for unoccluded transdermal oxybutynin therapy
Claim Types: Method of use
Pat. Sub. Date(s): 001: May 30, 2019
Apr 26, 2020U-2525: Treatment of patients with an overactive bladder with symptoms of urinary frequency, urgency or urge incontinence
Pat. No. 9259388 Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions
Claim Types: Method of administration
Pat. Sub. Date(s): 001: Mar 16, 2016
Nov 6, 2029U-1644: Treatment of overactive bladder by application of oxybutynin chloride gel to skin
Pat. No. 10449173 DP* Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions
Claim Types: Device; Method of use
Pat. Sub. Date(s): 001: Oct 30, 2019
Nov 6, 2029U-2637: Treatment of patients with an overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence with a single unit dose of 10% oxybutynin chloride gel
Pat. No. 8920392 Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions
Claim Types: Drug in a container; Method of use; Method of administration
Pat. Sub. Date(s): 001: Jan 27, 2015
Mar 26, 2031U-1644: Treatment of overactive bladder by application of oxybutynin chloride gel to skin

GELNIQUE 3% (GEL, METERED) (TRANSDERMAL) OXYBUTYNIN
Drug Classes: muscarinic antagonist
NDA Applicant: ALLERGAN      NDA No.: 202513  Prod. No.: 001 DISC (3%)
PatentsExpirationPatented Use
Pat. No. 7029694 DP* Compositions and methods for transdermal oxybutynin therapy
Claim Types: Method of use; Formulation
Pat. Sub. Date(s): 001: Apr 27, 2012
Apr 26, 2020U-318: Treatment of patients with an overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence
Pat. No. 7179483 Compositions and methods for transdermal oxybutynin therapy
Claim Types: Method of use
Pat. Sub. Date(s): 001: Apr 27, 2012
Apr 26, 2020U-318: Treatment of patients with an overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence
Pat. No. 8241662 Unoccluded topical oxybutynin gel composition and methods for transdermal oxybutynin therapy
Claim Types: Method of use
Pat. Sub. Date(s): 001: Aug 23, 2012
Apr 26, 2020U-318: Treatment of patients with an overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence
Pat. No. 7198801 DP* Formulations for transdermal or transmucosal application
Claim Types: Formulation
Pat. Sub. Date(s): 001: Apr 27, 2012
Jun 25, 2022 

ILUVIEN (IMPLANT) (INTRAVITREAL) FLUOCINOLONE ACETONIDE
Drug Classes: corticosteroid
NDA Applicant: ALIMERA SCIENCES INC      NDA No.: 201923  Prod. No.: 001 RX (0.19MG)
PatentsExpirationPatented Use
Pat. No. 6375972 DP* Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
Claim Types: Device; Method of administration
Pat. Sub. Date(s): 001: Oct 23, 2014
Apr 26, 2020U-1597: Treatment of diabetic macular edema
Pat. No. 8871241 DP* Injectable sustained release delivery devices
Claim Types: Device
Pat. Sub. Date(s): 001: Nov 12, 2014
Aug 12, 2027 

OXYTROL (FILM, EXTENDED RELEASE) (TRANSDERMAL) OXYBUTYNIN
Drug Classes: muscarinic antagonist
NDA Applicant: ALLERGAN      NDA No.: 021351  Prod. No.: 002 RX (3.9MG/24HR)
PatentsExpirationPatented Use
Pat. No. 6743441 DP* Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy
Claim Types: Method of use; Device
Pat. Sub. Date(s): 002: None
Apr 26, 2020U-318: Treatment of patients with an overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence
Pat. No. 7081249 DP* Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy
Claim Types: Method of use; Formulation
Pat. Sub. Date(s): 002: None
Apr 26, 2020U-318: Treatment of patients with an overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence
Pat. No. 7081250 DP* Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy
Claim Types: Method of use; Formulation
Pat. Sub. Date(s): 002: None
Apr 26, 2020U-318: Treatment of patients with an overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence
Pat. No. 7081251 DP* Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy
Claim Types: Method of use; Formulation
Pat. Sub. Date(s): 002: None
Apr 26, 2020U-318: Treatment of patients with an overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence
Pat. No. 7081252 DP* Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy
Claim Types: Method of use; Formulation
Pat. Sub. Date(s): 002: None
Apr 26, 2020U-318: Treatment of patients with an overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence
Pat. No. 7179483 DS* DP* Compositions and methods for transdermal oxybutynin therapy
Claim Types: Method of use
Pat. Sub. Date(s): 002: None
Apr 26, 2020U-318: Treatment of patients with an overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence

OXYTROL FOR WOMEN (FILM, EXTENDED RELEASE) (TRANSDERMAL) OXYBUTYNIN
Drug Classes: muscarinic antagonist
NDA Applicant: ALLERGAN      NDA No.: 202211  Prod. No.: 001 OTC (3.9MG/24HR)
PatentsExpirationPatented Use
Pat. No. 6743441 DP* Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy
Claim Types: Method of use; Device
Pat. Sub. Date(s): 001: None
Apr 26, 2020U-1329: Treatment of patients with an overactive bladder
Pat. No. 7081249 DP* Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy
Claim Types: Method of use; Formulation
Pat. Sub. Date(s): 001: None
Apr 26, 2020U-1329: Treatment of patients with an overactive bladder
Pat. No. 7081250 DP* Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy
Claim Types: Method of use; Formulation
Pat. Sub. Date(s): 001: None
Apr 26, 2020U-1329: Treatment of patients with an overactive bladder
Pat. No. 7081251 DP* Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy
Claim Types: Method of use; Formulation
Pat. Sub. Date(s): 001: None
Apr 26, 2020U-1329: Treatment of patients with an overactive bladder
Pat. No. 7081252 DP* Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy
Claim Types: Method of use; Formulation
Pat. Sub. Date(s): 001: None
Apr 26, 2020U-1329: Treatment of patients with an overactive bladder
Pat. No. 7179483 Compositions and methods for transdermal oxybutynin therapy
Claim Types: Method of use
Pat. Sub. Date(s): 001: None
Apr 26, 2020U-1329: Treatment of patients with an overactive bladder

YUTIQ (IMPLANT) (INTRAVITREAL) FLUOCINOLONE ACETONIDE
Drug Classes: corticosteroid
NDA Applicant: EYEPOINT PHARMS      NDA No.: 210331  Prod. No.: 001 RX (0.18MG)
PatentsExpirationPatented Use
Pat. No. 6375972 DP* Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
Claim Types: Device; Method of administration
Pat. Sub. Date(s): 001: Nov 1, 2018
Apr 26, 2020U-708: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye
Pat. No. 8574613 DP* Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
Claim Types: Device
Pat. Sub. Date(s): 001: Nov 1, 2018
Apr 26, 2020 
Pat. No. 8574659 DP* Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
Claim Types: Process
Pat. Sub. Date(s): 001: Nov 1, 2018
Apr 26, 2020 
Pat. No. 9192579 DP* Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
Claim Types: Device; Process
Pat. Sub. Date(s): 001: Nov 1, 2018
Apr 26, 2020 
Pat. No. 9849085 Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
Claim Types: Method of use
Pat. Sub. Date(s): 001: Nov 1, 2018
Apr 26, 2020U-708: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye
Pat. No. 8871241 DP* Injectable sustained release delivery devices
Claim Types: Device
Pat. Sub. Date(s): 001: Nov 1, 2018
Aug 12, 2027 
ExclusivityExpirationExclusivity Description
Exclusivity Code: NP - New productNov 12, 2021 

MINIVELLE (FILM, EXTENDED RELEASE) (TRANSDERMAL) ESTRADIOL [GENERIC AB3]
Drug Classes: estrogen
NDA Applicant: NOVEN      NDA No.: 203752  Prod. No.: 001 RX (0.0375MG/24HR); 002 RX (0.075MG/24HR); 003 RX (0.05MG/24HR); 004 RX (0.1MG/24HR)
PatentsExpirationPatented Use
Pat. No. 6841716 DP* Patch
Claim Types: Formulation
Pat. Sub. Date(s): 001: Nov 27, 2012; 002: None; 003: None; 004: None
Apr 27, 2020 
Pat. No. 9730900 Transdermal estrogen device and delivery
Claim Types: Method of administration; Process
Pat. Sub. Date(s): All strengths: Aug 18, 2017
Jul 10, 2028U-2086: A method for administering estradiol comprising a monolithic transdermal drug delivery system consisting of (i) a backing layer and (ii) a single adhesive polymer matrix layer as claimed in US Patent No. 9730900
Pat. No. 9833419 DP* Transdermal estrogen device and delivery
Claim Types: Formulation
Pat. Sub. Date(s): All strengths: Dec 14, 2017
Jul 10, 2028 
Pat. No. 8231906 DS* DP* Transdermal estrogen device and delivery
Claim Types: Formulation; Method of administration; Process
Pat. Sub. Date(s): 001: Mar 22, 2013; 002: None; 003: None; 004: None
Jul 4, 2030 

MINIVELLE (FILM, EXTENDED RELEASE) (TRANSDERMAL) ESTRADIOL [GENERIC AB3]
Drug Classes: estrogen
NDA Applicant: NOVEN      NDA No.: 203752  Prod. No.: 005 RX (0.025MG/24HR)
PatentsExpirationPatented Use
Pat. No. 6841716 DP* Patch
Claim Types: Formulation
Pat. Sub. Date(s): 005: May 8, 2015
Apr 27, 2020 
Pat. No. 9724310 DS* DP* Transdermal estrogen device and delivery
Claim Types: Formulation
Pat. Sub. Date(s): 005: Aug 18, 2017
Jul 10, 2028 
Pat. No. 9730900 DP* Transdermal estrogen device and delivery
Claim Types: Method of administration; Process
Pat. Sub. Date(s): 005: Aug 18, 2017
Jul 10, 2028U-2086: A method for administering estradiol comprising a monolithic transdermal drug delivery system consisting of (i) a backing layer and (ii) a single adhesive polymer matrix layer as claimed in US Patent No. 9730900
Pat. No. 9833419 DP* Transdermal estrogen device and delivery
Claim Types: Formulation
Pat. Sub. Date(s): 005: Dec 14, 2017
Jul 10, 2028 
Pat. No. 8231906 DS* DP* Transdermal estrogen device and delivery
Claim Types: Formulation; Method of administration; Process
Pat. Sub. Date(s): 005: May 8, 2015
Jul 4, 2030 

MUCINEX (TABLET, EXTENDED RELEASE) (ORAL) GUAIFENESIN [GENERIC OTC]
NDA Applicant: RB HLTH      NDA No.: 021282  Prod. No.: 001 OTC (600MG); 002 OTC (1.2GM)
PatentsExpirationPatented Use
Pat. No. 6372252 Guaifenesin sustained release formulation and tablets
Claim Types: Formulation
Pat. Sub. Date(s): All strengths: None
Apr 28, 2020U-489: Expectorant
Pat. No. 6955821 DP* Sustained release formulations of guaifenesin and additional drug ingredients
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): All strengths: None
Apr 28, 2020U-489: Expectorant
Pat. No. 7838032 DP* Sustained release of guaifenesin
Claim Types: Formulation
Pat. Sub. Date(s): 001: Dec 21, 2010; 002: None
Apr 28, 2020 

MUCINEX D (TABLET, EXTENDED RELEASE) (ORAL) GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE [GENERIC OTC]
Drug Classes: alpha adrenergic agonist
NDA Applicant: RB HLTH      NDA No.: 021585  Prod. No.: 001 OTC (600MG;60MG); 002 OTC (1.2GM;120MG)
PatentsExpirationPatented Use
Pat. No. 6372252 DP* Guaifenesin sustained release formulation and tablets
Claim Types: Formulation
Pat. Sub. Date(s): All strengths: None
Apr 28, 2020 
Pat. No. 6955821 DP* Sustained release formulations of guaifenesin and additional drug ingredients
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): All strengths: None
Apr 28, 2020U-686: Expectorant and nasal decongestant
Pat. No. 7838032 DP* Sustained release of guaifenesin
Claim Types: Formulation
Pat. Sub. Date(s): 001: Dec 21, 2010; 002: None
Apr 28, 2020 

MUCINEX DM (TABLET, EXTENDED RELEASE) (ORAL) DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN [GENERIC OTC]
Drug Classes: sigma-1 agonist; uncompetitive NMDA receptor antagonist
NDA Applicant: RB HLTH      NDA No.: 021620  Prod. No.: 001 OTC (60MG;1.2GM); 002 OTC (30MG;600MG)
PatentsExpirationPatented Use
Pat. No. 6372252 DP* Guaifenesin sustained release formulation and tablets
Claim Types: Formulation
Pat. Sub. Date(s): All strengths: None
Apr 28, 2020 
Pat. No. 6955821 DP* Sustained release formulations of guaifenesin and additional drug ingredients
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): All strengths: None
Apr 28, 2020U-685: Expectorant and cough suppressant
Pat. No. 7838032 DP* Sustained release of guaifenesin
Claim Types: Formulation
Pat. Sub. Date(s): 001: Dec 21, 2010; 002: None
Apr 28, 2020 

APTIVUS (CAPSULE) (ORAL) TIPRANAVIR
Drug Classes: HIV protease inhibitor
NDA Applicant: BOEHRINGER INGELHEIM      NDA No.: 021814  Prod. No.: 001 RX (250MG)
PatentsExpirationPatented Use
Pat. No. 6147095 Method for improving the pharmacokinetics of tipranavir
Claim Types: Method of use
Pat. Sub. Date(s): 001: None
Apr 29, 2020 *PEDU-670: Treatment of HIV-1 infection by the co-administration of tipranavir and ritonavir.

APTIVUS (SOLUTION) (ORAL) TIPRANAVIR
Drug Classes: HIV protease inhibitor
NDA Applicant: BOEHRINGER INGELHEIM      NDA No.: 022292  Prod. No.: 001 RX (100MG/ML)
PatentsExpirationPatented Use
Pat. No. 6147095 Method for improving the pharmacokinetics of tipranavir
Claim Types: Method of use
Pat. Sub. Date(s): 001: None
Apr 29, 2020 *PEDU-670: Treatment of HIV-1 infection by the co-administration of tipranavir and ritonavir.

INTELENCE (TABLET) (ORAL) ETRAVIRINE
Drug Classes: HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI)
NDA Applicant: JANSSEN R AND D      NDA No.: 022187  Prod. No.: 001 RX (100MG); 002 RX (200MG)
PatentsExpirationPatented Use
Pat. No. 8003789 DS* DP* HIV replication inhibiting pyrimidines
Claim Types: Compound; Composition; Process; Method of use
Pat. Sub. Date(s): All strengths: Sep 21, 2011
May 1, 2020 *PED 
Pat. No. 6878717 HIV replication inhibiting pyrimidines
Claim Types: Method of use
Pat. Sub. Date(s): 001: None; 002: Jan 20, 2011
May 5, 2020 *PEDU-1016: In combination with other antiretroviral agents for the treatment of HIV-1 infection in treatment-experienced adult patients, who have evidence of viral replication and HIV-1 strains resistant to an NNRTI and other antiretroviral agents
U-1237: Combo w/ other antiretrovirals for tx of HIV-1 in antiretroviral tx-experienced pt 6 years up, who have evidence of viral replication and HIV-1 strains resistant to non-nucleoside reverse transcriptase inhibitor and other antiretrovirals
U-2354: Combination with other antiretrovirals (ATV) for treatment of HIV-1 in atv treatment-experienced patients 2 years and older with evidence of viral replication and HIV-1 strains resistant to non-nucleoside reverse transcriptase inhibitor and other ATV
U-256: Treatment of HIV infection in combination with one or more additional HIV antiviral agents
Pat. No. 7037917 DS* DP* [Extended 404 days (1.1 years)]
HIV replication inhibiting pyrimidines
Claim Types: Compound; Composition; Formulation; Process; Method of use
Pat. Sub. Date(s): 001: None; 002: Jan 20, 2011
Jun 13, 2021 *PEDU-1016: In combination with other antiretroviral agents for the treatment of HIV-1 infection in treatment-experienced adult patients, who have evidence of viral replication and HIV-1 strains resistant to an NNRTI and other antiretroviral agents
U-1237: Combo w/ other antiretrovirals for tx of HIV-1 in antiretroviral tx-experienced pt 6 years up, who have evidence of viral replication and HIV-1 strains resistant to non-nucleoside reverse transcriptase inhibitor and other antiretrovirals
U-2354: Combination with other antiretrovirals (ATV) for treatment of HIV-1 in atv treatment-experienced patients 2 years and older with evidence of viral replication and HIV-1 strains resistant to non-nucleoside reverse transcriptase inhibitor and other ATV
U-256: Treatment of HIV infection in combination with one or more additional HIV antiviral agents
ExclusivityExpirationExclusivity Description
Exclusivity Code: NPP - New patient populationJan 16, 2022 PED 

INTELENCE (TABLET) (ORAL) ETRAVIRINE
Drug Classes: HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI)
NDA Applicant: JANSSEN R AND D      NDA No.: 022187  Prod. No.: 003 RX (25MG)
PatentsExpirationPatented Use
Pat. No. 8003789 DS* DP* HIV replication inhibiting pyrimidines
Claim Types: Compound; Composition; Process; Method of use
Pat. Sub. Date(s): 003: Apr 20, 2012
May 1, 2020 *PED 
Pat. No. 6878717 HIV replication inhibiting pyrimidines
Claim Types: Method of use
Pat. Sub. Date(s): 003: Apr 20, 2012
May 5, 2020 *PEDU-1016: In combination with other antiretroviral agents for the treatment of HIV-1 infection in treatment-experienced adult patients, who have evidence of viral replication and HIV-1 strains resistant to an NNRTI and other antiretroviral agents
U-1237: Combo w/ other antiretrovirals for tx of HIV-1 in antiretroviral tx-experienced pt 6 years up, who have evidence of viral replication and HIV-1 strains resistant to non-nucleoside reverse transcriptase inhibitor and other antiretrovirals
U-2354: Combination with other antiretrovirals (ATV) for treatment of HIV-1 in atv treatment-experienced patients 2 years and older with evidence of viral replication and HIV-1 strains resistant to non-nucleoside reverse transcriptase inhibitor and other ATV
U-256: Treatment of HIV infection in combination with one or more additional HIV antiviral agents
Pat. No. 7037917 DS* DP* [Extended 404 days (1.1 years)]
HIV replication inhibiting pyrimidines
Claim Types: Compound; Composition; Formulation; Process; Method of use
Pat. Sub. Date(s): 003: Apr 20, 2012
Jun 13, 2021 *PEDU-1237: Combo w/ other antiretrovirals for tx of HIV-1 in antiretroviral tx-experienced pt 6 years up, who have evidence of viral replication and HIV-1 strains resistant to non-nucleoside reverse transcriptase inhibitor and other antiretrovirals
U-2354: Combination with other antiretrovirals (ATV) for treatment of HIV-1 in atv treatment-experienced patients 2 years and older with evidence of viral replication and HIV-1 strains resistant to non-nucleoside reverse transcriptase inhibitor and other ATV
ExclusivityExpirationExclusivity Description
Exclusivity Code: NPP - New patient populationJan 16, 2022 PED 

NEXIUM (CAPSULE, DELAYED REL PELLETS) (ORAL) ESOMEPRAZOLE MAGNESIUM [GENERIC AB]
Drug Classes: proton pump inhibitor
NDA Applicant: ASTRAZENECA PHARMS      NDA No.: 021153  Prod. No.: 001 RX (EQ 20MG BASE); 002 RX (EQ 40MG BASE)
PatentsExpirationPatented Use
Pat. No. 6428810 DP* Pharmaceutical formulation comprising omeprazole
Claim Types: Formulation; Method of use; Process
Pat. Sub. Date(s): All strengths: None
May 3, 2020 *PEDU-469: Treatment of gastroesophageal reflex disease (GERD) and eradication of H.pylori to reduce risk of duodenal ulcer recurrence
U-729: Treatment of gastroesophageal reflux disease (GERD), risk-reduction of NSAID-associated gastric ulcer, H. pylori eradication to reduce the risk of duodenal ulcer recurrence
U-770: Long-term treatment of pathological hypersecretory conditions

NEXIUM (FOR SUSPENSION, DELAYED RELEASE) (ORAL) ESOMEPRAZOLE MAGNESIUM [GENERIC AB]
Drug Classes: proton pump inhibitor
NDA Applicant: ASTRAZENECA PHARMS      NDA No.: 021957  Prod. No.: 001 RX (EQ 20MG BASE/PACKET); 002 RX (EQ 40MG BASE/PACKET)
PatentsExpirationPatented Use
Pat. No. 6428810 DP* Pharmaceutical formulation comprising omeprazole
Claim Types: Formulation; Method of use; Process
Pat. Sub. Date(s): All strengths: None
May 3, 2020 *PEDU-1207: Infant use aged 1 month to less than one year, GERD and erosive esophagitis
U-729: Treatment of gastroesophageal reflux disease (GERD), risk-reduction of NSAID-associated gastric ulcer, H. pylori eradication to reduce the risk of duodenal ulcer recurrence
U-773: Pathological hypersecretory conditions

NEXIUM (FOR SUSPENSION, DELAYED RELEASE) (ORAL) ESOMEPRAZOLE MAGNESIUM
Drug Classes: proton pump inhibitor
NDA Applicant: ASTRAZENECA PHARMS      NDA No.: 021957  Prod. No.: 003 RX (EQ 2.5MG BASE/PACKET); 004 RX (EQ 5MG BASE/PACKET)
PatentsExpirationPatented Use
Pat. No. 6428810 DP* Pharmaceutical formulation comprising omeprazole
Claim Types: Formulation; Method of use; Process
Pat. Sub. Date(s): 003: Jan 12, 2012; 004: None
May 3, 2020 *PEDU-1207: Infant use aged 1 month to less than one year, GERD and erosive esophagitis

NEXIUM (FOR SUSPENSION, DELAYED RELEASE) (ORAL) ESOMEPRAZOLE MAGNESIUM [GENERIC AB]
Drug Classes: proton pump inhibitor
NDA Applicant: ASTRAZENECA PHARMS      NDA No.: 022101  Prod. No.: 001 RX (EQ 10MG BASE/PACKET)
PatentsExpirationPatented Use
Pat. No. 6428810 DP* Pharmaceutical formulation comprising omeprazole
Claim Types: Formulation; Method of use; Process
Pat. Sub. Date(s): 001: None
May 3, 2020 *PEDU-858: Pediatric use aged 1-11 years, GERD and erosive esophagitis

NEXIUM 24HR (CAPSULE, DELAYED RELEASE) (ORAL) ESOMEPRAZOLE MAGNESIUM [GENERIC OTC]
Drug Classes: proton pump inhibitor
NDA Applicant: ASTRAZENECA LP      NDA No.: 204655  Prod. No.: 001 OTC (EQ 20MG BASE)
PatentsExpirationPatented Use
Pat. No. 6428810 DP* Pharmaceutical formulation comprising omeprazole
Claim Types: Formulation; Method of use; Process
Pat. Sub. Date(s): 001: Apr 24, 2014
May 3, 2020 *PEDU-1509: Treatment of frequent heartburn by administering a gastric acid reducer
U-1874: Treatment of frequent heartburn by administering omeprazole according to claims 1-8

NEXIUM 24HR (TABLET, DELAYED RELEASE) (ORAL) ESOMEPRAZOLE MAGNESIUM [GENERIC OTC]
Drug Classes: proton pump inhibitor
NDA Applicant: ASTRAZENECA LP      NDA No.: 207920  Prod. No.: 001 OTC (EQ 20MG BASE)
PatentsExpirationPatented Use
Pat. No. 6428810 DP* Pharmaceutical formulation comprising omeprazole
Claim Types: Formulation; Method of use; Process
Pat. Sub. Date(s): 001: Dec 18, 2015
May 3, 2020 *PEDU-1785: Method of treating frequent heartburn by administering an esomeprazole magnesium formulation as claimed

ABLAVAR (SOLUTION) (INTRAVENOUS) GADOFOSVESET TRISODIUM
Drug Classes: paramagnetic contrast agent
NDA Applicant: LANTHEUS MEDCL      NDA No.: 021711  Prod. No.: 001 DISC (2440MG/10ML (244MG/ML)); 002 DISC (3660MG/15ML (244MG/ML))
PatentsExpirationPatented Use
Pat. No. 6676929 DP* [Extended 1805 days (4.9 years)]
Diagnostic imaging contrast agents with extended blood retention
Claim Types: Compound; Composition
Pat. Sub. Date(s): All strengths: None
May 4, 2020 

INSPRA (TABLET) (ORAL) EPLERENONE [GENERIC AB]
Drug Classes: aldosterone antagonist
NDA Applicant: SEARLE, GD LLC      NDA No.: 021437  Prod. No.: 001 RX (25MG); 002 RX (50MG) NDA No.: 021437  Prod. No.: 003 DISC (100MG)
PatentsExpirationPatented Use
Pat. No. 6410524 Combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease
Claim Types: Composition; Method of use
Pat. Sub. Date(s): All strengths: None
May 5, 2020 *PEDU-467: Use of eplerenone in combination with an angiotensin converting enzyme (ACE) inhibitor for treating hypertension
Pat. No. 6747020 Methods of treating heart failure and hypertension using combinations of eplerenone and an angiotensin converting enzyme inhibitor
Claim Types: Method of use
Pat. Sub. Date(s): All strengths: None
May 5, 2020 *PEDU-587: Use of eplerenone in combination with an angiotensin converting enzyme (ACE) inhibitor (and optionally a diuretic) for treating congestive heart failure and hypertension
Pat. No. 6410054 Immediate release eplerenone compositions
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): All strengths: None
Jun 8, 2020 *PEDU-3: Treatment of hypertension
U-537: Treatment of conditions related to hyperaldosteronism such as hypertension and cardiac insufficiency, with eplerenone
Pat. No. 6495165 Eplerenone compositions having improved bioavailability
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): All strengths: None
Jun 8, 2020 *PEDU-3: Treatment of hypertension
U-537: Treatment of conditions related to hyperaldosteronism such as hypertension and cardiac insufficiency, with eplerenone
Pat. No. 6534093 Immediate release eplerenone compositions
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): All strengths: None
Jun 8, 2020 *PEDU-3: Treatment of hypertension
U-537: Treatment of conditions related to hyperaldosteronism such as hypertension and cardiac insufficiency, with eplerenone
Pat. No. 6558707 DP* Immediate release eplerenone compositions
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): All strengths: None
Jun 8, 2020 *PEDU-537: Treatment of conditions related to hyperaldosteronism such as hypertension and cardiac insufficiency, with eplerenone
Pat. No. 7157101 DP* Micronized eplerenone compositions
Claim Types: Formulation
Pat. Sub. Date(s): All strengths: None
Jun 8, 2020 *PEDU-664: Treatment of conditions for which an aldosterone receptor blocker is indicated, such as hypertension, heart failure, and post-myocardial infarction

LUVOX CR (CAPSULE, EXTENDED RELEASE) (ORAL) FLUVOXAMINE MALEATE
Drug Classes: selective serotonin reuptake inhibitor (SSRI)
NDA Applicant: JAZZ PHARMS      NDA No.: 022033  Prod. No.: 001 DISC (100MG**); 002 DISC (150MG**)
PatentsExpirationPatented Use
Pat. No. 7465462 DP* Multiparticulate controlled release selective serotonin reuptake inhibitor formulations
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): All strengths: None
May 10, 2020U-929: Treatment of obsessive compulsive disorder treatable with an ssri

TOBI PODHALER (POWDER) (INHALATION) TOBRAMYCIN
Drug Classes: aminoglycoside antibacterial
NDA Applicant: MYLAN SPECIALITY LP      NDA No.: 201688  Prod. No.: 001 RX (28MG)
PatentsExpirationPatented Use
Pat. No. 7442388 DP* Phospholipid-based powders for drug delivery
Claim Types: Formulation; Method of administration; Process
Pat. Sub. Date(s): 001: Apr 19, 2013
May 10, 2020 
Pat. No. 8349294 DP* Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
Claim Types: Formulation
Pat. Sub. Date(s): 001: Apr 19, 2013
May 10, 2020 
Pat. No. 7368102 DP* Pulmonary delivery of aminoglycosides
Claim Types: Formulation; Method of administration
Pat. Sub. Date(s): 001: Apr 19, 2013
Dec 19, 2022U-909: Treatment of cystic fibrosis patients with pseudomonas aeruginosa
Pat. No. 8715623 DP* Pulmonary delivery of aminoglycoside
Claim Types: Formulation; Method of use; Method of administration
Pat. Sub. Date(s): 001: Oct 20, 2014
Dec 19, 2022U-909: Treatment of cystic fibrosis patients with pseudomonas aeruginosa
Pat. No. 9421166 DP* Pulmonary delivery of aminoglycoside
Claim Types: Formulation; Method of administration
Pat. Sub. Date(s): 001: Jun 17, 2019
Dec 19, 2022U-909: Treatment of cystic fibrosis patients with pseudomonas aeruginosa
Pat. No. 7516741 DP* Aerosolization apparatus with feedback mechanism
Claim Types: Device; Method of administration
Pat. Sub. Date(s): 001: Apr 19, 2013
Jan 11, 2024 
Pat. No. RE47526 DP* Aerosolization apparatus with air inlet shield
Claim Types: Device
Pat. Sub. Date(s): 001: Jun 1, 2020
Apr 9, 2024 
Pat. No. 8069851 DP* Aeorosolization apparatus with air inlet shield
Claim Types: Device
Pat. Sub. Date(s): 001: Apr 19, 2013
Sep 24, 2024 
Pat. No. 8664187 Methods of treatment of endobronchial infections
Claim Types: Method of improving a treatment; Method of use
Pat. Sub. Date(s): 001: Jun 17, 2019
Jun 20, 2025U-909: Treatment of cystic fibrosis patients with pseudomonas aeruginosa
Pat. No. 7559325 DP* Aerosolization apparatus with air inlet shield
Claim Types: Device
Pat. Sub. Date(s): 001: Apr 19, 2013
Oct 27, 2025 
Pat. No. 8869794 DP* Aerosolization apparatus with capsule puncturing member
Claim Types: Device; Process; Part of a dosage form
Pat. Sub. Date(s): 001: Jun 17, 2019
Sep 12, 2028U-909: Treatment of cystic fibrosis patients with pseudomonas aeruginosa
Pat. No. 10207066 DP* Aerosolization apparatus with capsule puncture alignment guide
Claim Types: Device; Method of administration
Pat. Sub. Date(s): 001: Jun 17, 2019
Nov 4, 2030U-909: Treatment of cystic fibrosis patients with pseudomonas aeruginosa

EPANOVA (CAPSULE) (ORAL) OMEGA-3-CARBOXYLIC ACIDS
Drug Classes: omega-3 fatty acid
NDA Applicant: ASTRAZENECA PHARMS      NDA No.: 205060  Prod. No.: 001 DISC (1GM CONTAINS AT LEAST 850MG OF POLYUNSATURATED FATTY ACIDS)
PatentsExpirationPatented Use
Pat. No. 5792795 DP* Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): 001: Jun 3, 2014
May 13, 2020 
Pat. No. 5948818 DP* Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): 001: Jun 3, 2014
May 13, 2020 
Pat. No. 8383678 DP* Type a gelatin capsule containing PUFA in free acid form
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): 001: Jun 3, 2014
Feb 7, 2025U-1511: Treatment of hypertriglyceridemia
Pat. No. 9012501 DP* Type A gelatin capsule containing PUFA in free acid form
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): 001: May 20, 2015
Feb 7, 2025U-1511: Treatment of hypertriglyceridemia
Pat. No. 9132112 DP* Type A gelatin capsule containing PUFA in free acid form
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): 001: Sep 30, 2015
Feb 7, 2025U-1511: Treatment of hypertriglyceridemia
Pat. No. 7960370 DP* Type A gelatin capsule containing PUFA in free acid form
Claim Types: Formulation
Pat. Sub. Date(s): 001: Jun 3, 2014
Dec 20, 2026 
Pat. No. 9050308 DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
Claim Types: Method of treatment
Pat. Sub. Date(s): 001: Jul 7, 2015
Jan 4, 2033U-1511: Treatment of hypertriglyceridemia
Pat. No. 9050309 DS* DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
Claim Types: Formulation
Pat. Sub. Date(s): 001: Jul 7, 2015
Jan 4, 2033 
Pat. No. 10117844 DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
Claim Types: Method of use
Pat. Sub. Date(s): 001: Dec 4, 2018
Jan 4, 2033U-2447: Treatment of severe hypertriglyceridemia (500 mg/dl) in adult patients as an adjunct to diet

DEPO-SUBQ PROVERA 104 (INJECTABLE) (SUBCUTANEOUS) MEDROXYPROGESTERONE ACETATE
Drug Classes: progestin
NDA Applicant: PHARMACIA AND UPJOHN      NDA No.: 021583  Prod. No.: 001 RX (104MG/0.65ML)
PatentsExpirationPatented Use
Pat. No. 6495534 DP* Stabilized aqueous suspensions for parenteral use
Claim Types: Composition; Process; Formulation
Pat. Sub. Date(s): 001: None
May 15, 2020 

FORTOVASE (CAPSULE) (ORAL) SAQUINAVIR
Drug Classes: HIV protease inhibitor
NDA Applicant: HOFFMANN LA ROCHE      NDA No.: 020828  Prod. No.: 001 DISC (200MG**)
PatentsExpirationPatented Use
Pat. No. 6352717 Process for encapsulating shear sensitive fill masses into capsules and capsules containing shear sensitive fill masses
Claim Types: Formulation; Process; Product-by-process
Pat. Sub. Date(s): 001: None
May 16, 2020 *PED 

GEODON (SUSPENSION) (ORAL) ZIPRASIDONE HYDROCHLORIDE
Drug Classes: atypical antipsychotic
NDA Applicant: PFIZER INC      NDA No.: 021483  Prod. No.: 001 DISC (EQ 10MG BASE/ML)
PatentsExpirationPatented Use
Pat. No. 7175855 DP* Ziprasidone suspension
Claim Types: Formulation
Pat. Sub. Date(s): 001: None
May 18, 2020 

JYNARQUE (TABLET) (ORAL) TOLVAPTAN [Has competitive generic]
Drug Classes: vasopressin V2-receptor antagonist
NDA Applicant: OTSUKA PHARM CO LTD      NDA No.: 204441  Prod. No.: 001 RX (15MG); 002 RX (30MG); 003 RX (45MG); 004 RX (60MG); 005 RX (90MG)
PatentsExpirationPatented Use
Pat. No. 5753677 [Extended 5 years]
Benzoheterocyclic compounds
Claim Types: Method of use
Pat. Sub. Date(s): All strengths: May 21, 2018
May 19, 2020U-2307: Treatment of autosomal dominant polycystic kidney disease
Pat. No. 8501730 DS* Process for preparing benzazepine compounds or salts thereof
Claim Types: Product-by-process
Pat. Sub. Date(s): All strengths: May 21, 2018
Sep 1, 2026 
ExclusivityExpirationExclusivity Description
Exclusivity Code: I - New IndicationApr 23, 2021I-779: Use of tolvaptan to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD)
Exclusivity Code: ODE - Orphan drug exclusivityApr 23, 2025ODE-178: Indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD)

SAMSCA (TABLET) (ORAL) TOLVAPTAN [GENERIC AB]
Drug Classes: vasopressin V2-receptor antagonist
NDA Applicant: OTSUKA AMERICA PHARM      NDA No.: 022275  Prod. No.: 001 RX (15MG); 002 RX (30MG) NDA No.: 022275  Prod. No.: 003 DISC (60MG**)
PatentsExpirationPatented Use
Pat. No. 5753677 [Extended 5 years]
Benzoheterocyclic compounds
Claim Types: Method of use
Pat. Sub. Date(s): All strengths: None
May 19, 2020U-978: Method of treating hyponatremia
Pat. No. 8501730 DS* Process for preparing benzazepine compounds or salts thereof
Claim Types: Product-by-process
Pat. Sub. Date(s): All strengths: Sep 27, 2013
Sep 1, 2026 

VIVITROL (FOR SUSPENSION, EXTENDED RELEASE) (INTRAMUSCULAR) NALTREXONE
Drug Classes: opioid antagonist
NDA Applicant: ALKERMES      NDA No.: 021897  Prod. No.: 001 RX (380MG/VIAL)
PatentsExpirationPatented Use
Pat. No. 6264987 DP* Method for preparing microparticles having a selected polymer molecular weight
Claim Types: Product-by-process; Process
Pat. Sub. Date(s): 001: None
May 19, 2020 
Pat. No. 6379704 DP* Method for preparing microparticles having a selected polymer molecular weight
Claim Types: Product-by-process; Process
Pat. Sub. Date(s): 001: None
May 19, 2020 
Pat. No. 6534092 DP* Method for preparing microparticles having a selected polymer molecular weight
Claim Types: Product-by-process; Process
Pat. Sub. Date(s): 001: None
May 19, 2020 
Pat. No. 6495164 DP* Preparation of injectable suspensions having improved injectability
Claim Types: Formulation; Process; Method of use; Product-by-process
Pat. Sub. Date(s): 001: None
May 25, 2020 
Pat. No. 6667061 DP* Preparation of injectable suspensions having improved injectability
Claim Types: Formulation
Pat. Sub. Date(s): 001: None
May 25, 2020 
Pat. No. 7799345 DP* Preparation of injectable suspensions having improved injectability
Claim Types: Composition
Pat. Sub. Date(s): 001: Oct 28, 2010
May 25, 2020 
Pat. No. 7919499 Naltrexone long acting formulations and methods of use
Claim Types: Method of use
Pat. Sub. Date(s): 001: May 16, 2011
Oct 15, 2029U-1123: Treatment of alcohol dependence
U-1124: Prevention of relapse to opioid dependence, following opioid detoxification

ATROVENT HFA (AEROSOL, METERED) (INHALATION) IPRATROPIUM BROMIDE
Drug Classes: anticholinergic
NDA Applicant: BOEHRINGER INGELHEIM      NDA No.: 021527  Prod. No.: 001 RX (0.021MG/INH)
PatentsExpirationPatented Use
Pat. No. 6739333 DP* Stainless steel canister for propellant-driven metering aerosols
Claim Types: Device
Pat. Sub. Date(s): 001: None
May 26, 2020 
Pat. No. 6983743 DP* Stainless steel canister for propellant-driven metering aerosols
Claim Types: Device
Pat. Sub. Date(s): 001: None
May 26, 2020 
Pat. No. 8474447 DP* Inhaler device
Claim Types: Device
Pat. Sub. Date(s): 001: May 28, 2015
Jan 17, 2030 

VARITHENA (SOLUTION) (INTRAVENOUS) POLIDOCANOL
Drug Classes: sclerosing agent
NDA Applicant: PROVENSIS      NDA No.: 205098  Prod. No.: 001 RX (180MG/18ML (10MG/ML))
PatentsExpirationPatented Use
Pat. No. 6572873 Generation of therapeutic microfoam
Claim Types: Process
Pat. Sub. Date(s): 001: None
May 26, 2020U-1461: A method of generating an injectable foam of controlled density and bubble size
Pat. No. 6942165 DP* Generation of therapeutic microfoam
Claim Types: Device
Pat. Sub. Date(s): 001: None
May 26, 2020 
Pat. No. 7025290 DP* Generation of therapeutic microfoam
Claim Types: Device; Process
Pat. Sub. Date(s): 001: None
May 26, 2020U-1461: A method of generating an injectable foam of controlled density and bubble size
Pat. No. 7357336 Generation of therapeutic microfoam
Claim Types: Process
Pat. Sub. Date(s): 001: None
May 26, 2020U-1461: A method of generating an injectable foam of controlled density and bubble size
Pat. No. 7604185 DS* DP* Generation of therapeutic microfoam
Claim Types: Composition; Method of use
Pat. Sub. Date(s): 001: None
May 26, 2020U-1462: A method of using a sclerosing agent for the treatment of incompetent great saphenous veins, accessory saphenous veins and visible varicosities of the great saphenous (GSV) system above and below the knee
Pat. No. 7842282 Generation of therapeutic microfoam
Claim Types: Method of use
Pat. Sub. Date(s): 001: None
May 26, 2020U-1461: A method of generating an injectable foam of controlled density and bubble size
Pat. No. 7842283 DP* Generation of therapeutic microfoam
Claim Types: Device
Pat. Sub. Date(s): 001: None
May 26, 2020 
Pat. No. 8323677 DS* Therapeutic foam
Claim Types: Formulation
Pat. Sub. Date(s): 001: None
May 26, 2020 
Pat. No. 8734833 DS* DP* Therapeutic foam
Claim Types: Formulation
Pat. Sub. Date(s): 001: Jun 19, 2014
May 26, 2020 
Pat. No. 6846412 DP* Combination filter assembly
Claim Types: Device; Process
Pat. Sub. Date(s): 001: None
Jul 19, 2022 
Pat. No. 8122917 DP* Apparatus and method for dispensing foam
Claim Types: Device; Kit
Pat. Sub. Date(s): 001: None
Sep 9, 2024 
Pat. No. 7731986 DS* DP* Therapeutic foam
Claim Types: Formulation; Drug in a container; Device; Process; Method of use
Pat. Sub. Date(s): 001: None
Nov 17, 2024U-1463: A method of intravenous injection using ultrasound guidance, administered via a single cannula into the lumen of the target incompetent trunk veins or by direct injection into varicosities
Pat. No. 7814943 DP* Apparatus and method for dispensing foam
Claim Types: Device; Kit; Method of use
Pat. Sub. Date(s): 001: None
Nov 19, 2027U-1461: A method of generating an injectable foam of controlled density and bubble size
Pat. No. 9480652 DP* Aerosol valve
Claim Types: Device; Process
Pat. Sub. Date(s): 001: Nov 30, 2016
May 12, 2032 

AMBIEN CR (TABLET, EXTENDED RELEASE) (ORAL) ZOLPIDEM TARTRATE [GENERIC AB]
Drug Classes: gamma-aminobutyric acid (GABA)-ergic agonist
NDA Applicant: SANOFI AVENTIS US      NDA No.: 021774  Prod. No.: 001 RX (12.5MG); 002 RX (6.25MG)
PatentsExpirationPatented Use
Pat. No. 6514531 DP* Controlled-release dosage forms comprising zolpidem or a salt thereof
Claim Types: Formulation
Pat. Sub. Date(s): All strengths: None
Jun 1, 2020 *PED 

ARCAPTA NEOHALER (POWDER) (INHALATION) INDACATEROL MALEATE
Drug Classes: beta-2 adrenergic agonist
NDA Applicant: NOVARTIS      NDA No.: 022383  Prod. No.: 001 DISC (EQ 75MCG BASE)
PatentsExpirationPatented Use
Pat. No. 8067437 Beta-2-adrenoreceptor agonists
Claim Types: Method of use
Pat. Sub. Date(s): 001: Apr 26, 2013
Jun 2, 2020U-1168: The long term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema
Pat. No. 8658673 DS* DP* BETA2-adrenoreceptor agonists
Claim Types: Composition; Method of use; Formulation
Pat. Sub. Date(s): 001: Jul 28, 2015
Jun 2, 2020U-1168: The long term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema
Pat. No. 8796307 DS* DP* Beta2-adrenoreceptor agonists
Claim Types: Composition
Pat. Sub. Date(s): 001: Dec 9, 2015
Jun 2, 2020 
Pat. No. 6878721 DS* DP* [Extended 1599 days (4.4 years)]
Beta2-adrenoceptor agonists
Claim Types: Compound; Composition; Method of use; Process
Pat. Sub. Date(s): 001: None
Feb 25, 2025U-1168: The long term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema
Pat. No. 8479730 DP* Inhaler device
Claim Types: Device
Pat. Sub. Date(s): 001: Aug 6, 2013
Oct 11, 2028 

UTIBRON (POWDER) (INHALATION) GLYCOPYRROLATE; INDACATEROL MALEATE
Drug Classes: anticholinergic; beta-2 adrenergic agonist
NDA Applicant: NOVARTIS      NDA No.: 207930  Prod. No.: 001 DISC (15.6MCG/INH;27.5MCG/INH)
PatentsExpirationPatented Use
Pat. No. 7820694 DP* Beta-2-adrenoreceptor agonists
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): 001: Dec 4, 2015
Jun 2, 2020U-1773: Long - term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD)
Pat. No. 8067437 Beta-2-adrenoreceptor agonists
Claim Types: Method of use
Pat. Sub. Date(s): 001: Dec 4, 2015
Jun 2, 2020U-1773: Long - term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD)
Pat. No. 8283362 DP* Beta-2-adrenoreceptor agonists
Claim Types: Method of use; Formulation
Pat. Sub. Date(s): 001: Dec 4, 2015
Jun 2, 2020U-1773: Long - term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD)
Pat. No. 8658673 DP* BETA2-adrenoreceptor agonists
Claim Types: Composition; Method of use; Formulation
Pat. Sub. Date(s): 001: Dec 4, 2015
Jun 2, 2020U-1773: Long - term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD)
Pat. No. 8796307 DP* Beta2-adrenoreceptor agonists
Claim Types: Composition
Pat. Sub. Date(s): 001: Dec 4, 2015
Jun 2, 2020 
Pat. No. 7229607 Treatment of respiratory disease
Claim Types: Method of use
Pat. Sub. Date(s): 001: Dec 4, 2015
Apr 9, 2021U-1773: Long - term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD)
Pat. No. 8029768 Treatment of respiratory diseases
Claim Types: Method of use
Pat. Sub. Date(s): 001: Dec 4, 2015
Apr 9, 2021U-1773: Long - term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD)
Pat. No. 7736670 DP* Method of making particles for use in a pharmaceutical composition
Claim Types: Formulation; Process
Pat. Sub. Date(s): 001: Dec 4, 2015
Jun 27, 2021 
Pat. No. 8048451 DP* Pharmaceutical compositions for inhalation
Claim Types: Method of use; Product-by-process; Method of improving a treatment; Process
Pat. Sub. Date(s): 001: Dec 4, 2015
Jun 27, 2021 
Pat. No. 8303991 DP* Method of making particles for use in a pharmaceutical composition
Claim Types: Formulation
Pat. Sub. Date(s): 001: Dec 4, 2015
Jun 27, 2021 
Pat. No. 8435567 DP* Pharmaceutical compositions of hydrophobic surface-modified active substance microparticles for inhalation
Claim Types: Formulation
Pat. Sub. Date(s): 001: Dec 4, 2015
Jun 27, 2021 
Pat. No. 8580306 DP* Particles for use in a pharmaceutical composition
Claim Types: Formulation; ; Method of use; Process
Pat. Sub. Date(s): 001: Dec 4, 2015
Jun 27, 2021 
Pat. No. 8956661 DP* Method of making composite particles for use in pharmaceutical compositions and composite particles and compositions thereof
Claim Types: Product-by-process; Process
Pat. Sub. Date(s): 001: Dec 4, 2015
Jun 27, 2021 
Pat. No. 9931304 DP* Method of making particles for use in a pharmaceutical composition
Claim Types: Formulation
Pat. Sub. Date(s): 001: May 2, 2018
Jun 27, 2021 
Pat. No. 9962338 DP* Method of making particles for use in a pharmaceutical composition
Claim Types: Formulation
Pat. Sub. Date(s): 001: May 29, 2018
Jun 27, 2021 
Pat. No. 6878721 DS* DP* [Extended 1599 days (4.4 years)]
Beta2-adrenoceptor agonists
Claim Types: Compound; Composition; Method of use; Process
Pat. Sub. Date(s): 001: Dec 4, 2015
Feb 25, 2025U-1773: Long - term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD)
Pat. No. 8479730 DP* Inhaler device
Claim Types: Device
Pat. Sub. Date(s): 001: Dec 4, 2015
Oct 11, 2028 
Pat. No. 8182838 DP* Dry powder composition comprising co-jet milled particles for pulmonary inhalation
Claim Types: Product-by-process; Drug in a container; Process
Pat. Sub. Date(s): 001: Dec 4, 2015
Oct 20, 2028 

LIALDA (TABLET, DELAYED RELEASE) (ORAL) MESALAMINE [GENERIC AB]
Drug Classes: aminosalicylate
NDA Applicant: SHIRE      NDA No.: 022000  Prod. No.: 001 RX (1.2GM)
PatentsExpirationPatented Use
Pat. No. 6773720 DP* Mesalazine controlled release oral pharmaceutical compositions
Claim Types: Formulation; Process
Pat. Sub. Date(s): 001: None
Jun 8, 2020 

UCERIS (TABLET, EXTENDED RELEASE) (ORAL) BUDESONIDE [GENERIC AB]
Drug Classes: corticosteroid
NDA Applicant: SALIX      NDA No.: 203634  Prod. No.: 001 RX (9MG)
PatentsExpirationPatented Use
Pat. No. RE43799 DP* Controlled release and taste masking oral pharmaceutical composition
Claim Types: Composition; Method of use
Pat. Sub. Date(s): 001: Jan 18, 2013
Jun 9, 2020U-1325: Induction of remission in patients with active, mild to moderate ulcerative colitis
Pat. No. 7410651 DP* Controlled release and taste masking oral pharmaceutical composition
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): 001: Jan 18, 2013
Jun 9, 2020U-1325: Induction of remission in patients with active, mild to moderate ulcerative colitis
Pat. No. 7431943 DP* Controlled release and taste masking oral pharmaceutical compositions
Claim Types: Formulation
Pat. Sub. Date(s): 001: Jan 18, 2013
Jun 9, 2020 
Pat. No. 8293273 DP* Controlled release and taste masking oral pharmaceutical composition
Claim Types: Formulation
Pat. Sub. Date(s): 001: Jan 18, 2013
Jun 9, 2020 
Pat. No. 8784888 DP* Controlled release and taste masking oral pharmaceutical composition
Claim Types: Formulation
Pat. Sub. Date(s): 001: Jul 28, 2014
Jun 9, 2020 
Pat. No. 9320716 DP* Controlled release and taste masking oral pharmaceutical compositions
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): 001: May 5, 2016
Jun 9, 2020U-1325: Induction of remission in patients with active, mild to moderate ulcerative colitis
Pat. No. 9532954 DP* Controlled release and taste masking oral pharmaceutical compositions
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): 001: Jan 20, 2017
Jun 9, 2020U-1325: Induction of remission in patients with active, mild to moderate ulcerative colitis
Pat. No. 10064878 DP* Controlled release and taste masking oral pharmaceutical compositions
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): 001: Sep 24, 2018
Jun 9, 2020U-1325: Induction of remission in patients with active, mild to moderate ulcerative colitis
Pat. No. 10105374 DP* Controlled release and taste masking oral pharmaceutical compositions
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): 001: Nov 9, 2018
Jun 9, 2020U-1325: Induction of remission in patients with active, mild to moderate ulcerative colitis
Pat. No. 10143698 DP* Controlled release and taste masking oral pharmaceutical compositions
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): 001: Dec 10, 2018
Jun 9, 2020U-1325: Induction of remission in patients with active, mild to moderate ulcerative colitis
Pat. No. 8895064 DP* Controlled release and taste masking oral pharmaceutical composition
Claim Types: Formulation
Pat. Sub. Date(s): 001: Nov 25, 2014
Sep 7, 2031 
Pat. No. 9132093 DP* Controlled release and taste making oral pharmaceutical composition
Claim Types: Formulation
Pat. Sub. Date(s): 001: Sep 16, 2015
Sep 7, 2031 
Pat. No. 9192581 DP* Controlled release and taste masking oral pharmaceutical composition
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): 001: Dec 3, 2015
Sep 7, 2031U-1325: Induction of remission in patients with active, mild to moderate ulcerative colitis
Pat. No. 10307375 DP* Controlled release and taste masking oral pharmaceutical composition
Claim Types: Formulation
Pat. Sub. Date(s): 001: Jun 14, 2019
Sep 7, 2031 

VELPHORO (TABLET, CHEWABLE) (ORAL) SUCROFERRIC OXYHYDROXIDE
NDA Applicant: VIFOR FRESENIUS      NDA No.: 205109  Prod. No.: 001 RX (500MG)
PatentsExpirationPatented Use
Pat. No. 6174442 DS* Adsorbent for phosphate from an aqueous medium, production and use of said adsorbent
Claim Types: Formulation; Process
Pat. Sub. Date(s): 001: None
Jun 12, 2020U-1468: Control of phosphorous levels in patients
Pat. No. 10682376 DP* Pharmaceutical compositions
Claim Types: Formulation
Pat. Sub. Date(s): 001: Jun 17, 2020
Nov 13, 2028 
Pat. No. 10695367 DP* Pharmaceutical compositions
Claim Types: Formulation
Pat. Sub. Date(s): 001: Jul 1, 2020
Nov 13, 2028 
Pat. No. 9561251 DP* Pharmaceutical compositions
Claim Types: Formulation; Process; Product-by-process; Method of use
Pat. Sub. Date(s): 001: Mar 2, 2017
Jan 23, 2030U-1468: Control of phosphorous levels in patients
Pat. No. 10624855 DP* Pharmaceutical composition, comprising phosphate binder particles
Claim Types: Formulation
Pat. Sub. Date(s): 001: Apr 27, 2020
Nov 26, 2034 

QSYMIA (CAPSULE, EXTENDED RELEASE) (ORAL) PHENTERMINE HYDROCHLORIDE; TOPIRAMATE
Drug Classes: sympathomimetic amine anorectic
NDA Applicant: VIVUS      NDA No.: 022580  Prod. No.: 001 RX (EQ 3.75MG BASE;23MG); 002 RX (EQ 7.5MG BASE;46MG); 003 RX (EQ 11.25MG BASE;69MG); 004 RX (EQ 15MG BASE;92MG)
PatentsExpirationPatented Use
Pat. No. 7056890 DP* Combination therapy for effecting weight loss and treating obesity
Claim Types: Formulation; Method of use; Kit
Pat. Sub. Date(s): 001: Aug 16, 2012; 002: None; 003: None; 004: None
Jun 14, 2020U-1262: Use of QSYMIA (phentermine and topiramate) for weight management, including, but not limited to effecting weight loss, treating obesity, and/or treating overweight
Pat. No. 7553818 Combination therapy for effecting weight loss and treating obesity
Claim Types: Method of use
Pat. Sub. Date(s): 001: Aug 16, 2012; 002: None; 003: None; 004: None
Jun 14, 2020U-1262: Use of QSYMIA (phentermine and topiramate) for weight management, including, but not limited to effecting weight loss, treating obesity, and/or treating overweight
Pat. No. 7659256 DP* Combination therapy for effecting weight loss and treating obesity
Claim Types: Method of use; Formulation
Pat. Sub. Date(s): 001: Aug 16, 2012; 002: None; 003: None; 004: None
Jun 14, 2020U-1262: Use of QSYMIA (phentermine and topiramate) for weight management, including, but not limited to effecting weight loss, treating obesity, and/or treating overweight
Pat. No. 7674776 DP* Combination therapy for effecting weight loss and treating obesity
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): 001: Aug 16, 2012; 002: None; 003: None; 004: None
Jun 14, 2020U-1262: Use of QSYMIA (phentermine and topiramate) for weight management, including, but not limited to effecting weight loss, treating obesity, and/or treating overweight
Pat. No. 8895057 Escalating dosing regimen for effecting weight loss and treating obesity
Claim Types: Method of administration
Pat. Sub. Date(s): All strengths: Dec 18, 2014
Jun 9, 2028U-1262: Use of QSYMIA (phentermine and topiramate) for weight management, including, but not limited to effecting weight loss, treating obesity, and/or treating overweight
Pat. No. 8895058 DP* Low dose topiramate/phentermine composition and methods of use thereof
Claim Types: Formulation; Drug in a container
Pat. Sub. Date(s): All strengths: Dec 18, 2014
Jun 9, 2028 
Pat. No. 9011905 DP* Low dose topiramate/phentermine composition and methods of use thereof
Claim Types: Formulation
Pat. Sub. Date(s): All strengths: May 13, 2015
Jun 9, 2028 
Pat. No. 9011906 Escalating dosing regimen for effecting weight loss and treating obesity
Claim Types: Method of use; Formulation
Pat. Sub. Date(s): All strengths: May 13, 2015
Jun 9, 2028U-1262: Use of QSYMIA (phentermine and topiramate) for weight management, including, but not limited to effecting weight loss, treating obesity, and/or treating overweight
Pat. No. 8580298 DP* Low dose topiramate/phentermine composition and methods of use thereof
Claim Types: Formulation; Drug in a container
Pat. Sub. Date(s): 001: Nov 14, 2013; 002: None; 003: None; 004: None
May 15, 2029 
Pat. No. 8580299 Escalating dosing regimen for effecting weight loss and treating obesity
Claim Types: Method of administration
Pat. Sub. Date(s): 001: Nov 14, 2013; 002: None; 003: None; 004: None
Jun 14, 2029U-1262: Use of QSYMIA (phentermine and topiramate) for weight management, including, but not limited to effecting weight loss, treating obesity, and/or treating overweight

CAPLYTA (CAPSULE) (ORAL) LUMATEPERONE TOSYLATE
NDA Applicant: INTRA-CELLULAR      NDA No.: 209500  Prod. No.: 001 RX (EQ 42MG BASE)
PatentsExpirationPatented Use
Pat. No. RE39680 DS* DP* Substituted heterocycle fused gamma-carbolines
Claim Types: Compound; Composition; Method of use
Pat. Sub. Date(s): 001: Jan 17, 2020
Jun 15, 2020U-543: Treatment of schizophrenia
Pat. No. 7183282 DS* DP* Substituted heterocycle fused .gamma.-carbolines
Claim Types: Compound; Composition
Pat. Sub. Date(s): 001: Jan 17, 2020
Jun 15, 2020 
Pat. No. 10464938 DP* Pharmaceutical compositions comprising ((6bR,10aS)-1-(4-fluorophenyl)-4-(3-methyl-2,3,6b,9,10,10a-hexahydro-1H-p- yrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)butan-1-one or pharmaceutically acceptable salts thereof
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): 001: Jan 17, 2020
Mar 12, 2028 
Pat. No. 9199995 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrro- lo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid addition salt and salt crystals
Claim Types: Method of use
Pat. Sub. Date(s): 001: Jan 17, 2020
Mar 12, 2029U-2713: Modulation of 5-hydroxytryptamine 2 receptor activity in schizophrenia
Pat. No. 9586960 DS* DP* 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrro- lo[1,2,3-de] quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid salt crystal forms
Claim Types: New polymorph, salt or hydrate; Composition
Pat. Sub. Date(s): 001: Jan 17, 2020
Mar 12, 2029 
Pat. No. 9616061 DP* Methods and compositions for sleep disorders and other disorders
Claim Types: Formulation
Pat. Sub. Date(s): 001: Jan 17, 2020
May 27, 2029 
Pat. No. 8648077 DS* DP* 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrro- lo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid addition salt and salt crystals
Claim Types: New polymorph, salt or hydrate; Composition; Process
Pat. Sub. Date(s): 001: Jan 17, 2020
Dec 1, 2029 
Pat. No. 8598119 Methods and compositions for sleep disorders and other disorders
Claim Types: Method of use
Pat. Sub. Date(s): 001: Jan 17, 2020
Dec 28, 2029U-543: Treatment of schizophrenia
Pat. No. 9956227 Method for the treatment of residual symptoms of schizophrenia
Claim Types: Method of use
Pat. Sub. Date(s): 001: Jan 17, 2020
Dec 3, 2034U-2714: Treatment of schizophrenia with improvement in residual symptoms of schizophrenia
ExclusivityExpirationExclusivity Description
Exclusivity Code: NCE - New chemical entityDec 20, 2024 

DEXILANT (CAPSULE, DELAYED RELEASE) (ORAL) DEXLANSOPRAZOLE [GENERIC AB]
Drug Classes: proton pump inhibitor
NDA Applicant: TAKEDA PHARMS USA      NDA No.: 022287  Prod. No.: 001 RX (30MG); 002 RX (60MG)
PatentsExpirationPatented Use
Pat. No. 9145389 DS* DP* Benzimidazole compound crystal
Claim Types: New polymorph, salt or hydrate; Product-by-process; Composition
Pat. Sub. Date(s): All strengths: Oct 27, 2015
Jun 15, 2020 
Pat. No. 6462058 DS* DP* Benzimidazole compound crystal
Claim Types: New polymorph, salt or hydrate; Composition; Process; Method of use
Pat. Sub. Date(s): All strengths: None
Dec 15, 2020 *PEDU-949: Healing of all grades of erosive esophagitis (EE) for up to 8 weeks
U-950: Maintain healing of erosive esophagitis (EE) for up to 6 months
U-951: Treatment of heartburn associated with non-erosive gastroesophageal reflux disease (GERD) for 4 weeks
Pat. No. 6939971 Benzimidazole compound crystal
Claim Types: Method of use
Pat. Sub. Date(s): All strengths: None
Dec 15, 2020 *PEDU-949: Healing of all grades of erosive esophagitis (EE) for up to 8 weeks
U-950: Maintain healing of erosive esophagitis (EE) for up to 6 months
U-951: Treatment of heartburn associated with non-erosive gastroesophageal reflux disease (GERD) for 4 weeks
Pat. No. 7285668 DS* Process for the crystallization of (R)- or (S)-lansoprazole
Claim Types: New polymorph, salt or hydrate; Process
Pat. Sub. Date(s): All strengths: None
Dec 15, 2020 *PED 
Pat. No. 6664276 DS* DP* [Extended 959 days (2.6 years)]
Benzimidazole compound crystal
Claim Types: New polymorph, salt or hydrate; Composition; Method of use; Process
Pat. Sub. Date(s): All strengths: None
Jul 30, 2023 *PEDU-1507: To maintain healing of EE and relief of heartburn
U-949: Healing of all grades of erosive esophagitis (EE) for up to 8 weeks
U-950: Maintain healing of erosive esophagitis (EE) for up to 6 months
U-951: Treatment of heartburn associated with non-erosive gastroesophageal reflux disease (GERD) for 4 weeks
Pat. No. 8722084 DP* Controlled release preparation
Claim Types: Formulation
Pat. Sub. Date(s): All strengths: Jun 9, 2014
Apr 15, 2024 *PED 
Pat. No. 8784885 DP* Controlled release preparation
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): All strengths: Aug 19, 2014
Apr 15, 2024 *PEDU-1552: For healing of all grades of erosive esophagitis (EE)
U-1553: To maintain healing of EE and relief of heartburn
U-1554: For the treatment of heartburn associated with symptomatic non-erosive gastroesophageal disease (GERD)
Pat. No. 9238029 DP* Multiple PPI dosage form
Claim Types: Formulation
Pat. Sub. Date(s): All strengths: Feb 11, 2016
Jan 17, 2026 
Pat. No. 9011926 DP* Method for producing granules
Claim Types: Product-by-process; Process
Pat. Sub. Date(s): All strengths: May 1, 2015
Feb 24, 2026 
Pat. No. 8461187 DP* Multiple PPI dosage form
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): All strengths: None
Jul 17, 2026 *PED 
Pat. No. 7790755 DP* Controlled release preparation
Claim Types: Formulation
Pat. Sub. Date(s): 001: Sep 29, 2010; 002: None
Feb 2, 2027 *PED 
Pat. No. 8105626 DP* Granules containing acid-unstable chemical in large amount
Claim Types: Formulation
Pat. Sub. Date(s): 001: Feb 28, 2012; 002: None
Mar 27, 2027 *PED 
Pat. No. 8871273 DP* Method for producing granules
Claim Types: Formulation
Pat. Sub. Date(s): All strengths: Dec 1, 2014
Jan 11, 2028 
Pat. No. 8173158 Methods of treating gastrointestinal disorders independent of the intake of food
Claim Types: Method of use
Pat. Sub. Date(s): 001: Jun 1, 2012; 002: None
Sep 17, 2030 *PEDU-949: Healing of all grades of erosive esophagitis (EE) for up to 8 weeks
U-950: Maintain healing of erosive esophagitis (EE) for up to 6 months
U-951: Treatment of heartburn associated with non-erosive gastroesophageal reflux disease (GERD) for 4 weeks
Pat. No. 9233103 Methods for treating heartburn, gastric bleeding or hemorrhage in patients receiving clopidogrel therapy
Claim Types: Method of use
Pat. Sub. Date(s): All strengths: Feb 11, 2016
Mar 5, 2032U-1805: Use of dexlansoprazole in patients taking clopidogrel without meaningful cyp2c19 interactions

DEXILANT SOLUTAB (TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE) (ORAL) DEXLANSOPRAZOLE
Drug Classes: proton pump inhibitor
NDA Applicant: TAKEDA PHARMS USA      NDA No.: 208056  Prod. No.: 001 DISC (30MG)
PatentsExpirationPatented Use
Pat. No. 9145389 DS* DP* Benzimidazole compound crystal
Claim Types: New polymorph, salt or hydrate; Product-by-process; Composition
Pat. Sub. Date(s): 001: Feb 25, 2016
Jun 15, 2020 
Pat. No. 6462058 DS* DP* Benzimidazole compound crystal
Claim Types: New polymorph, salt or hydrate; Composition; Process; Method of use
Pat. Sub. Date(s): 001: Feb 25, 2016
Dec 15, 2020 *PEDU-950: Maintain healing of erosive esophagitis (EE) for up to 6 months
U-951: Treatment of heartburn associated with non-erosive gastroesophageal reflux disease (GERD) for 4 weeks
Pat. No. 6939971 Benzimidazole compound crystal
Claim Types: Method of use
Pat. Sub. Date(s): 001: Feb 25, 2016
Dec 15, 2020 *PEDU-950: Maintain healing of erosive esophagitis (EE) for up to 6 months
U-951: Treatment of heartburn associated with non-erosive gastroesophageal reflux disease (GERD) for 4 weeks
Pat. No. 7285668 DS* Process for the crystallization of (R)- or (S)-lansoprazole
Claim Types: New polymorph, salt or hydrate; Process
Pat. Sub. Date(s): 001: Feb 25, 2016
Dec 15, 2020 *PED 
Pat. No. 6664276 DS* DP* [Extended 959 days (2.6 years)]
Benzimidazole compound crystal
Claim Types: New polymorph, salt or hydrate; Composition; Method of use; Process
Pat. Sub. Date(s): 001: Feb 25, 2016
Jul 30, 2023 *PEDU-950: Maintain healing of erosive esophagitis (EE) for up to 6 months
U-951: Treatment of heartburn associated with non-erosive gastroesophageal reflux disease (GERD) for 4 weeks
Pat. No. 8784885 DP* Controlled release preparation
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): 001: Feb 25, 2016
Apr 15, 2024 *PED 
Pat. No. 9238029 DP* Multiple PPI dosage form
Claim Types: Formulation
Pat. Sub. Date(s): 001: Feb 25, 2016
Jan 17, 2026 
Pat. No. 9011926 DP* Method for producing granules
Claim Types: Product-by-process; Process
Pat. Sub. Date(s): 001: Feb 25, 2016
Feb 24, 2026 
Pat. No. 8461187 DP* Multiple PPI dosage form
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): 001: Feb 25, 2016
Jul 17, 2026 *PED 
Pat. No. 8871273 DP* Method for producing granules
Claim Types: Formulation
Pat. Sub. Date(s): 001: Feb 25, 2016
Jul 11, 2028 *PED 
Pat. No. 9241910 DP* Orally-disintegrating solid preparation
Claim Types: Formulation
Pat. Sub. Date(s): 001: None
Mar 10, 2029 

APTENSIO XR (CAPSULE, EXTENDED RELEASE) (ORAL) METHYLPHENIDATE HYDROCHLORIDE [GENERIC AB3]
Drug Classes: central nervous system stimulant
NDA Applicant: RHODES PHARMS      NDA No.: 205831  Prod. No.: 001 RX (10MG); 002 RX (15MG); 003 RX (20MG); 004 RX (30MG); 005 RX (40MG); 006 RX (50MG); 007 RX (60MG)
PatentsExpirationPatented Use
Pat. No. 6419960 DP* Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
Claim Types: Formulation; Process
Pat. Sub. Date(s): All strengths: May 18, 2015
Jun 16, 2020 *PED 
Pat. No. 7083808 DP* Controlled/modified release oral methylphenidate formulations
Claim Types: Formulation
Pat. Sub. Date(s): All strengths: May 18, 2015
Jun 16, 2020 *PED 
Pat. No. 7247318 DP* Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
Claim Types: Formulation
Pat. Sub. Date(s): All strengths: May 18, 2015
Jun 16, 2020 *PED 
Pat. No. 7438930 DP* DLR* Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
Claim Types: Formulation
Pat. Sub. Date(s): All strengths: May 18, 2015
Jun 16, 2020 *PED 
Pat. No. 8580310 DP* Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
Claim Types: Formulation
Pat. Sub. Date(s): All strengths: May 18, 2015
Jun 16, 2020 *PED 
Pat. No. 9066869 DP* Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): All strengths: Jul 27, 2015
Jun 16, 2020 *PED 
Pat. No. 9801823 DP* Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
Claim Types: Formulation
Pat. Sub. Date(s): All strengths: Nov 29, 2017
Jun 16, 2020 *PED 
Pat. No. 10039719 Methods of treating attention deficit hyperactivity disorder
Claim Types: Method of use
Pat. Sub. Date(s): All strengths: Aug 15, 2018
Jun 16, 2020 *PEDU-2357: Method of treating attention deficit hyperactivity disorder (ADHD)

DENAVIR (CREAM) (TOPICAL) PENCICLOVIR
Drug Classes: nucleoside analog HSV DNA polymerase inhibitor / VZV DNA polymerase inhibitor
NDA Applicant: MYLAN      NDA No.: 020629  Prod. No.: 001 RX (1%)
PatentsExpirationPatented Use
Pat. No. 6579981 Antiviral guanine derivatives
Claim Types: Composition; Method of use; Formulation
Pat. Sub. Date(s): 001: None
Jun 17, 2020U-501: Treatment of recurrent Herpes Labialis (cold sores) in adults

INBRIJA (POWDER) (INHALATION) LEVODOPA
Drug Classes: aromatic amino acid
NDA Applicant: ACORDA      NDA No.: 209184  Prod. No.: 001 RX (42MG)
PatentsExpirationPatented Use
Pat. No. 6921528 Highly efficient delivery of a large therapeutic mass aerosol
Claim Types: Method of administration
Pat. Sub. Date(s): 001: Jan 18, 2019
Jun 19, 2020U-2485: Intermittent treatment of off episodes in patients with Parkinson's Disease treated with carbidopa/levodopa by inhalation of levodopa powder particles through a single breath activated step
Pat. No. 8628754 Highly efficient delivery of a large therapeutic mass aerosol
Claim Types: Method of administration
Pat. Sub. Date(s): 001: Jan 18, 2019
Jun 19, 2020U-2485: Intermittent treatment of off episodes in patients with Parkinson's Disease treated with carbidopa/levodopa by inhalation of levodopa powder particles through a single breath activated step
Pat. No. 6514482 DP* Pulmonary delivery in treating disorders of the central nervous system
Claim Types: Method of use; Formulation
Pat. Sub. Date(s): 001: Jan 18, 2019
Sep 19, 2020U-2484: Intermittent treatment of off episodes in patients with Parkinson's Disease treated with carbidopa/levodopa by inhalation of levodopa powder particles
Pat. No. 6613308 Pulmonary delivery in treating disorders of the central nervous system
Claim Types: Method of use
Pat. Sub. Date(s): 001: Jan 18, 2019
Sep 19, 2020U-2484: Intermittent treatment of off episodes in patients with Parkinson's Disease treated with carbidopa/levodopa by inhalation of levodopa powder particles
Pat. No. 6979437 Pulmonary delivery in treating disorders of the central nervous system
Claim Types: Method of use
Pat. Sub. Date(s): 001: Jan 18, 2019
Sep 19, 2020U-2484: Intermittent treatment of off episodes in patients with Parkinson's Disease treated with carbidopa/levodopa by inhalation of levodopa powder particles
Pat. No. 7146978 Inhalation device and method
Claim Types: Method of administration
Pat. Sub. Date(s): 001: Jan 18, 2019
Apr 16, 2021U-2486: Intermittent treatment of off episodes in patients with Parkinson's Disease with a powder inhaler
Pat. No. 6858199 High efficient delivery of a large therapeutic mass aerosol
Claim Types: Method of administration
Pat. Sub. Date(s): 001: Jan 18, 2019
Nov 4, 2021U-2485: Intermittent treatment of off episodes in patients with Parkinson's Disease treated with carbidopa/levodopa by inhalation of levodopa powder particles through a single breath activated step
Pat. No. 7556798 Highly efficient delivery of a large therapeutic mass aerosol
Claim Types: Method of administration
Pat. Sub. Date(s): 001: Jan 18, 2019
Nov 4, 2021U-2485: Intermittent treatment of off episodes in patients with Parkinson's Disease treated with carbidopa/levodopa by inhalation of levodopa powder particles through a single breath activated step
Pat. No. 7384649 DP* Particulate compositions for pulmonary delivery
Claim Types: Formulation; Process
Pat. Sub. Date(s): 001: Jan 18, 2019
Nov 20, 2022 
Pat. No. 8404276 Pulmonary delivery for levodopa
Claim Types: Method of use; Method of administration
Pat. Sub. Date(s): 001: Jan 18, 2019
Mar 19, 2023U-2484: Intermittent treatment of off episodes in patients with Parkinson's Disease treated with carbidopa/levodopa by inhalation of levodopa powder particles
Pat. No. 8586093 Pulmonary delivery for levodopa
Claim Types: Method of use; Method of administration
Pat. Sub. Date(s): 001: Jan 18, 2019
Mar 19, 2023U-2484: Intermittent treatment of off episodes in patients with Parkinson's Disease treated with carbidopa/levodopa by inhalation of levodopa powder particles
Pat. No. 9155699 DP* Pulmonary delivery for levodopa
Claim Types: Formulation
Pat. Sub. Date(s): 001: Jan 18, 2019
Mar 19, 2023 
Pat. No. 7182961 DP* Particulate compositions for pulmonary delivery
Claim Types: Formulation
Pat. Sub. Date(s): 001: Jan 18, 2019
Feb 22, 2024 
Pat. No. RE43711 Pulmonary delivery for levodopa
Claim Types: Method of use; Method of administration
Pat. Sub. Date(s): 001: Jan 18, 2019
Feb 3, 2029U-2484: Intermittent treatment of off episodes in patients with Parkinson's Disease treated with carbidopa/levodopa by inhalation of levodopa powder particles
Pat. No. 8545878 DP* Capsules containing high doses of levodopa for pulmonary use
Claim Types: Formulation
Pat. Sub. Date(s): 001: Jan 18, 2019
Nov 16, 2032 
Pat. No. 8685442 DP* Capsules containing high doses of levodopa for pulmonary use
Claim Types: Formulation
Pat. Sub. Date(s): 001: Jan 18, 2019
Nov 16, 2032 
Pat. No. 8945612 DP* Capsules containing high doses of levodopa for pulmonary use
Claim Types: Formulation
Pat. Sub. Date(s): 001: Jan 18, 2019
Nov 16, 2032 
Pat. No. 9393210 DP* Capsules containing high doses of levodopa for pulmonary use
Claim Types: Formulation
Pat. Sub. Date(s): 001: Jan 18, 2019
Nov 16, 2032 
ExclusivityExpirationExclusivity Description
Exclusivity Code: NP - New productDec 21, 2021 

GLUMETZA (TABLET, EXTENDED RELEASE) (ORAL) METFORMIN HYDROCHLORIDE [GENERIC AB3]
Drug Classes: biguanide
NDA Applicant: SANTARUS INC      NDA No.: 021748  Prod. No.: 001 RX (500MG)
PatentsExpirationPatented Use
Pat. No. 6488962 DS* DP* Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
Claim Types: Composition
Pat. Sub. Date(s): 001: None
Jun 20, 2020 
Pat. No. 6723340 DS* DP* Optimal polymer mixtures for gastric retentive tablets
Claim Types: Formulation
Pat. Sub. Date(s): 001: None
Oct 25, 2021 

GRALISE (TABLET) (ORAL) GABAPENTIN [Has competitive generic]
Drug Classes: antiepileptic drug (AED)
NDA Applicant: ALMATICA      NDA No.: 022544  Prod. No.: 001 RX (300MG); 002 RX (600MG)
PatentsExpirationPatented Use
Pat. No. 6488962 DP* Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
Claim Types: Composition
Pat. Sub. Date(s): 001: Mar 28, 2011; 002: None
Jun 20, 2020 
Pat. No. 6723340 DP* Optimal polymer mixtures for gastric retentive tablets
Claim Types: Formulation
Pat. Sub. Date(s): 001: Mar 28, 2011; 002: None
Oct 25, 2021 
Pat. No. 7731989 DP* Gastric retained gabapentin dosage form
Claim Types: Formulation
Pat. Sub. Date(s): 001: Mar 28, 2011; 002: None
Oct 25, 2022 
Pat. No. 8192756 DP* Gastric retained gabapentin dosage form
Claim Types: Formulation; Method of administration
Pat. Sub. Date(s): All strengths: Jun 8, 2012
Oct 25, 2022U-1114: Treatment with gabapentin, including treatment of neuropathic pain, including neuropathic pain associated with postherpetic neuralgia
Pat. No. 8252332 DP* Gastric retained gabapentin dosage form
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): 001: Sep 17, 2012; 002: None
Oct 25, 2022U-1114: Treatment with gabapentin, including treatment of neuropathic pain, including neuropathic pain associated with postherpetic neuralgia
Pat. No. 8333992 DP* Gastric retained gabapentin dosage form
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): 001: Jan 17, 2013; 002: None
Oct 25, 2022U-1114: Treatment with gabapentin, including treatment of neuropathic pain, including neuropathic pain associated with postherpetic neuralgia
Pat. No. 7438927 Methods of treatment using a gastric retained gabapentin dosage
Claim Types: Method of use
Pat. Sub. Date(s): 001: Mar 28, 2011; 002: None
Feb 26, 2024U-1114: Treatment with gabapentin, including treatment of neuropathic pain, including neuropathic pain associated with postherpetic neuralgia

JENTADUETO XR (TABLET, EXTENDED RELEASE) (ORAL) LINAGLIPTIN; METFORMIN HYDROCHLORIDE
Drug Classes: dipeptidyl peptidase-4 (DPP-4) inhibitor; biguanide
NDA Applicant: BOEHRINGER INGELHEIM      NDA No.: 208026  Prod. No.: 001 RX (2.5MG;1GM); 002 RX (5MG;1GM)
PatentsExpirationPatented Use
Pat. No. 6488962 DP* Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
Claim Types: Composition
Pat. Sub. Date(s): All strengths: Jun 22, 2016
Jun 20, 2020 
Pat. No. 8119648 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Claim Types: Method of use
Pat. Sub. Date(s): All strengths: Jun 22, 2016
Aug 12, 2023U-802: Method of treating Type 2 diabetes mellitus by administering a dipeptidyl peptidase-IV inhibitor
Pat. No. 8178541 DP* 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): All strengths: Jun 22, 2016
Aug 12, 2023U-1853: Method of treating Type 2 diabetes mellitus by administering a dipeptidyl peptidase-IV inhibitor in combination with metformin and, optionally, a sulfonylurea
Pat. No. 7407955 DS* DP* [Extended 629 days (1.7 years)]
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Claim Types: Compound; Composition
Pat. Sub. Date(s): All strengths: Jun 22, 2016
May 2, 2025 
Pat. No. 8883805 DP* Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
Claim Types: Compound; Process; Product-by-process
Pat. Sub. Date(s): All strengths: Jun 22, 2016
Nov 26, 2025 
Pat. No. 8673927 DLR* Uses of DPP-IV inhibitors
Claim Types: Method of use
Pat. Sub. Date(s): All strengths: Jun 22, 2016
May 4, 2027U-1503: Method of treating Type 2 diabetes mellitus by administering linagliptin in combination with metformin
Pat. No. 9173859 DP* DLR* Uses of DPP IV inhibitors
Claim Types: Method of use; Method of administration; Formulation
Pat. Sub. Date(s): All strengths: Jun 22, 2016
May 4, 2027U-1503: Method of treating Type 2 diabetes mellitus by administering linagliptin in combination with metformin
Pat. No. 9415016 DP* DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Claim Types: Formulation
Pat. Sub. Date(s): All strengths: Aug 30, 2016
Apr 2, 2029 
Pat. No. 10022379 DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Claim Types: Method of use
Pat. Sub. Date(s): All strengths: Aug 6, 2018
Apr 2, 2029U-2339: Use of a pharmaceutical composition comprising linagliptin, metformin and a basic amino acid to treat Type 2 diabetes mellitus
Pat. No. 9155705 DP* DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Claim Types: Composition; Formulation
Pat. Sub. Date(s): All strengths: Jun 22, 2016
May 21, 2030 
Pat. No. 9555001 DP* Pharmaceutical composition and uses thereof
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): All strengths: Feb 22, 2017
Mar 6, 2033U-1967: Method of treating Type 2 diabetes in patients with insufficient glycemic control despite therapy with one or more conventional antihyperglycemic agents by administering linagliptin in combination with metformin
U-1968: Method of treating Type 2 diabetes in patients who have not been previously treated with an antihyperglycemic agent by administering linagliptin in combination with metformin
ExclusivityExpirationExclusivity Description
Exclusivity Code: M - MiscellaneousMar 30, 2023M-252: Addition of information to clinical studies section regarding cardiovascular outcome
Exclusivity Code: M - MiscellaneousJul 3, 2022M-258: Information added to the labeling to describe carmelina trial to fulfill postmarketing commitment 1766-4

PROQUIN XR (TABLET, EXTENDED RELEASE) (ORAL) CIPROFLOXACIN HYDROCHLORIDE
Drug Classes: quinolone antimicrobial
NDA Applicant: DEPOMED INC      NDA No.: 021744  Prod. No.: 001 DISC (EQ 500MG BASE)
PatentsExpirationPatented Use
Pat. No. 6488962 DP* Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
Claim Types: Composition
Pat. Sub. Date(s): 001: None
Jun 20, 2020 

SYNJARDY XR (TABLET, EXTENDED RELEASE) (ORAL) EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE
Drug Classes: sodium-glucose co-transporter 2 (SGLT2) inhibitor; biguanide
NDA Applicant: BOEHRINGER INGELHEIM      NDA No.: 208658  Prod. No.: 001 RX (5MG;1GM); 002 RX (10MG;1GM); 003 RX (12.5MG;1GM); 004 RX (25MG;1GM)
PatentsExpirationPatented Use
Pat. No. 6488962 DP* Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
Claim Types: Composition
Pat. Sub. Date(s): All strengths: Jan 4, 2017
Jun 20, 2020 
Pat. No. 7579449 DS* Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
Claim Types: Compound
Pat. Sub. Date(s): All strengths: Jan 4, 2017
Nov 5, 2025 
Pat. No. 7713938 DS* DP* Crystalline form of 1-chloro-4-(.beta.-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy- )-benzyl]-benzene, a method for its preparation and the use thereof for
Claim Types: New polymorph, salt or hydrate; Composition; Process
Pat. Sub. Date(s): All strengths: Jan 4, 2017
Apr 15, 2027 
Pat. No. 10596120 DP* Pharmaceutical compositions
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): All strengths: Apr 20, 2020
Mar 7, 2032U-2775: Treatment of a Type 2 diabetes mellitus patient with insufficient glycemic control despite metformin therapy using a composition comprising an extended release core comprising metformin and an outer coating comprising empagliflozin
U-2792: Treatment of a treatment-nȁve patient with inadequately controlled type 2 diabetes using a composition comprising an extended release core comprising metformin and an outer coating comprising empagliflozin
Pat. No. 10258637 Pharmaceutical composition, methods for treating and uses thereof
Claim Types: Method of improving a treatment; Method of use
Pat. Sub. Date(s): All strengths: Apr 30, 2019
Apr 3, 2034U-2290: Method of treating Type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=EGFR<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin
Pat. No. 9949998 Pharmaceutical composition, methods for treating and uses thereof
Claim Types: Method of use
Pat. Sub. Date(s): All strengths: May 16, 2018
Jun 11, 2034U-2290: Method of treating Type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=EGFR<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin

TECFIDERA (CAPSULE, DELAYED RELEASE) (ORAL) DIMETHYL FUMARATE
NDA Applicant: BIOGEN IDEC INC      NDA No.: 204063  Prod. No.: 001 RX (120MG); 002 RX (240MG)
PatentsExpirationPatented Use
Pat. No. 7619001 Utilization of dialkylfumarates
Claim Types: Method of use
Pat. Sub. Date(s): All strengths: Apr 24, 2013
Jun 20, 2020U-1384: Method of treating multiple sclerosis
Pat. No. 8399514 Treatment for multiple sclerosis
Claim Types: Method of use
Pat. Sub. Date(s): All strengths: Apr 24, 2013
Feb 7, 2028U-1384: Method of treating multiple sclerosis
ExclusivityExpirationExclusivity Description
Exclusivity Code: M - MiscellaneousFeb 5, 2023M-260: Information added to the labeling describing a randomized, open-label study that examined the concomitant use of dimethyl fumarate and several non-live vaccines in adults 27-55 years of age with relapsing forms of multiple sclerosis

TRIJARDY XR (TABLET, EXTENDED RELEASE) (ORAL) EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE
Drug Classes: sodium-glucose co-transporter 2 (SGLT2) inhibitor; dipeptidyl peptidase-4 (DPP-4) inhibitor; biguanide
NDA Applicant: BOEHRINGER INGELHEIM      NDA No.: 212614  Prod. No.: 001 RX (5MG;2.5MG;1GM); 002 RX (10MG;5MG;1GM); 003 RX (12.5MG;2.5MG;1GM); 004 RX (25MG;5MG;1GM)
PatentsExpirationPatented Use
Pat. No. 6488962 DP* Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
Claim Types: Composition
Pat. Sub. Date(s): All strengths: Feb 18, 2020
Jun 20, 2020 
Pat. No. 8119648 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Claim Types: Method of use
Pat. Sub. Date(s): All strengths: Feb 18, 2020
Aug 12, 2023U-1652: Method of treating Type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin and metformin
Pat. No. 8178541 DP* 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): All strengths: Feb 18, 2020
Aug 12, 2023U-1652: Method of treating Type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin and metformin
Pat. No. 7407955 DS* DP* [Extended 629 days (1.7 years)]
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Claim Types: Compound; Composition
Pat. Sub. Date(s): All strengths: Feb 18, 2020
May 2, 2025 
Pat. No. 7579449 DS* Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
Claim Types: Compound
Pat. Sub. Date(s): All strengths: Feb 18, 2020
Nov 5, 2025 
Pat. No. 8883805 DP* Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
Claim Types: Compound; Process; Product-by-process
Pat. Sub. Date(s): All strengths: Feb 18, 2020
Nov 26, 2025 
Pat. No. 7713938 DS* DP* Crystalline form of 1-chloro-4-(.beta.-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy- )-benzyl]-benzene, a method for its preparation and the use thereof for
Claim Types: New polymorph, salt or hydrate; Composition; Process
Pat. Sub. Date(s): All strengths: Feb 18, 2020
Apr 15, 2027 
Pat. No. 9415016 DP* DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Claim Types: Formulation
Pat. Sub. Date(s): All strengths: Feb 18, 2020
Apr 2, 2029 
Pat. No. 10022379 DP* DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Claim Types: Method of use
Pat. Sub. Date(s): All strengths: Feb 18, 2020
Apr 2, 2029U-2732: Method of treating Type 2 diabetes using a pharmaceutical composition comprising linagliptin, metformin, empagliflozin and a basic amino acid
Pat. No. 8551957 DP* Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate
Claim Types: Composition; Method of use; Formulation; Method of administration
Pat. Sub. Date(s): All strengths: Feb 18, 2020
Oct 14, 2029U-2730: Method of treating Type 2 diabetes mellitus using a pharmaceutical composition comprising empagliflozin, linagliptin and metformin
Pat. No. 9155705 DP* DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Claim Types: Composition; Formulation
Pat. Sub. Date(s): All strengths: Feb 18, 2020
May 21, 2030 
Pat. No. 10406172 DP* Pharmaceutical composition, methods for treating and uses thereof
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): All strengths: Feb 18, 2020
Jun 15, 2030U-2733: Method of treating a Type 2 diabetes mellitus patient with insufficient glycemic control despite therapy with metformin using a pharmaceutical composition comprising empagliflozin, linagliptin and metformin
Pat. No. 10596120 DP* Pharmaceutical compositions
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): All strengths: Apr 21, 2020
Mar 7, 2032U-2776: Treatment of a Type 2 diabetes mellitus patient with insufficient glycemic control despite metformin therapy using a composition comprising an extended release core comprising metformin and an outer coating comprising empagliflozin and linagliptin
U-2790: Treatment of a treatment-naive patient with inadequately controlled type 2 diabetes using a composition comprising an extended release core comprisingmetformin and an outer coating comprising empagliflozin and linagliptin
Pat. No. 10258637 Pharmaceutical composition, methods for treating and uses thereof
Claim Types: Method of improving a treatment; Method of use
Pat. Sub. Date(s): All strengths: Feb 18, 2020
Apr 3, 2034U-2731: Method of treating Type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 M2<=egfr<60 ml/min/1.73 M2) by once daily administration of 10 mg or 25 mg of empagliflozin in combination with linagliptin and metformin
Pat. No. 9949998 Pharmaceutical composition, methods for treating and uses thereof
Claim Types: Method of use
Pat. Sub. Date(s): All strengths: Feb 18, 2020
Jun 11, 2034U-2731: Method of treating Type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 M2<=egfr<60 ml/min/1.73 M2) by once daily administration of 10 mg or 25 mg of empagliflozin in combination with linagliptin and metformin

XARTEMIS XR (TABLET, EXTENDED RELEASE) (ORAL) ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE
Drug Classes: opioid agonist
NDA Applicant: MALLINCKRODT INC      NDA No.: 204031  Prod. No.: 001 DISC (325MG;7.5MG)
PatentsExpirationPatented Use
Pat. No. 6488962 DP* Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
Claim Types: Composition
Pat. Sub. Date(s): 001: Apr 3, 2014
Jun 20, 2020 
Pat. No. 7976870 Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
Claim Types: Method of administration; Method of use
Pat. Sub. Date(s): 001: Apr 3, 2014
Jun 1, 2027U-1498: Method of treating patients with gastric retentive dosage form
Pat. No. 8372432 DP* Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): 001: Apr 3, 2014
Mar 11, 2029U-1499: Management of acute pain in patients requiring opioid analgesia
Pat. No. 8394408 DP* Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
Claim Types: Formulation
Pat. Sub. Date(s): 001: Apr 3, 2014
Mar 11, 2029 
Pat. No. 8668929 Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
Claim Types: Method of use
Pat. Sub. Date(s): 001: Apr 3, 2014
Mar 11, 2029U-1499: Management of acute pain in patients requiring opioid analgesia
Pat. No. 8377453 DP* Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
Claim Types: Formulation; Process
Pat. Sub. Date(s): 001: Apr 3, 2014
Nov 19, 2029U-1499: Management of acute pain in patients requiring opioid analgesia
Pat. No. 8597681 DP* Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
Claim Types: Formulation; Product-by-process
Pat. Sub. Date(s): 001: Apr 3, 2014
Dec 21, 2030 
Pat. No. 8980319 DP* Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
Claim Types: Formulation
Pat. Sub. Date(s): 001: Apr 3, 2015
Dec 21, 2030 
Pat. No. 8658631 DP* Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
Claim Types: Formulation
Pat. Sub. Date(s): 001: Apr 3, 2014
May 16, 2032 
Pat. No. 8741885 DP* Gastric retentive extended release pharmaceutical compositions
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): 001: Jun 17, 2014
May 16, 2032U-1499: Management of acute pain in patients requiring opioid analgesia
Pat. No. 8992975 DP* Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
Claim Types: Formulation
Pat. Sub. Date(s): 001: Apr 3, 2015
May 16, 2032 
Pat. No. 9050335 DP* Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
Claim Types: Formuation
Pat. Sub. Date(s): 001: Jun 25, 2015
May 16, 2032 
Pat. No. 9468636 Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
Claim Types: Method of use
Pat. Sub. Date(s): 001: Nov 16, 2016
May 16, 2032U-1499: Management of acute pain in patients requiring opioid analgesia

XYREM (SOLUTION) (ORAL) SODIUM OXYBATE [GENERIC AA]
Drug Classes: central nervous system depressant
NDA Applicant: JAZZ PHARMS      NDA No.: 021196  Prod. No.: 001 RX (500MG/ML)
PatentsExpirationPatented Use
Pat. No. 7851506 Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
Claim Types: Method of use
Pat. Sub. Date(s): 001: None
Jun 22, 2020 *PEDU-1101: Method of treating excessive daytime sleepiness in patients with narcolepsy
U-1102: Method of treating cataplexy in patients with narcolepsy
Pat. No. 8263650 DP* Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
Claim Types: Formulation; Method of use; Kit
Pat. Sub. Date(s): 001: Sep 20, 2012
Jun 22, 2020 *PEDU-1101: Method of treating excessive daytime sleepiness in patients with narcolepsy
U-1102: Method of treating cataplexy in patients with narcolepsy
Pat. No. 8324275 Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
Claim Types: Method of use
Pat. Sub. Date(s): 001: Dec 5, 2012
Jun 22, 2020 *PEDU-1101: Method of treating excessive daytime sleepiness in patients with narcolepsy
U-1102: Method of treating cataplexy in patients with narcolepsy
Pat. No. 8859619 DP* Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
Claim Types: Formulation; Drug in a container
Pat. Sub. Date(s): 001: Oct 28, 2014
Jun 22, 2020 *PED 
Pat. No. 8952062 Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
Claim Types: Method of administration
Pat. Sub. Date(s): 001: Feb 19, 2015
Jun 22, 2020 *PEDU-1101: Method of treating excessive daytime sleepiness in patients with narcolepsy
U-1102: Method of treating cataplexy in patients with narcolepsy
Pat. No. 9539330 DP* Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
Claim Types: Formulation; Drug in a container
Pat. Sub. Date(s): 001: Feb 8, 2017
Jun 22, 2020 *PED 
Pat. No. 6780889 DP* Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
Claim Types: Formulation
Pat. Sub. Date(s): 001: None
Jan 4, 2021 *PED 
Pat. No. 7262219 DP* Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
Claim Types: Formulation
Pat. Sub. Date(s): 001: None
Jan 4, 2021 *PED 
Pat. No. 8731963 Sensitive drug distribution system and method
Claim Types: Method of improving a treatment
Pat. Sub. Date(s): 001: May 30, 2014
Jun 17, 2023 *PEDU-1110: Method of treating a patient with a prescription drug using a computer database in a computer system for distribution
Pat. No. 7668730 DLR* Sensitive drug distribution system and method
Claim Types: Method of distribution
Pat. Sub. Date(s): 001: None
Dec 16, 2024 *PEDU-1110: Method of treating a patient with a prescription drug using a computer database in a computer system for distribution
Pat. No. 10213400 Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Claim Types: Method of improving a treatment
Pat. Sub. Date(s): 001: Mar 28, 2019
Mar 15, 2033U-2499: Method of reducing adverse effects in patients suffering from excessive daytime sleepiness and/or cataplexy in narcolepsy who are concomitantly administered sodium oxybate and divalproex sodium
Pat. No. 8772306 Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Claim Types: Method of use
Pat. Sub. Date(s): 001: Jul 9, 2014
Sep 15, 2033 *PEDU-1532: Method of treating excessive daytime sleepiness and/or cataplexy in narcolepsy patients with sodium oxybate when divalproex sodium is concomitantly administered.
Pat. No. 9050302 Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Claim Types: Method of administration; method of improving a treatment
Pat. Sub. Date(s): 001: Jul 8, 2015
Sep 15, 2033 *PEDU-1532: Method of treating excessive daytime sleepiness and/or cataplexy in narcolepsy patients with sodium oxybate when divalproex sodium is concomitantly administered.
Pat. No. 9486426 Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Claim Types: Method of use
Pat. Sub. Date(s): 001: Dec 6, 2016
Sep 15, 2033 *PEDU-1532: Method of treating excessive daytime sleepiness and/or cataplexy in narcolepsy patients with sodium oxybate when divalproex sodium is concomitantly administered.
ExclusivityExpirationExclusivity Description
Exclusivity Code: NPP - New patient populationApr 26, 2022 PED 
Exclusivity Code: ODE - Orphan drug exclusivityOct 26, 2025ODE-231: Indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in pediatric patients 7 years of age and older with narcolepsy

OLEPTRO (TABLET, EXTENDED RELEASE) (ORAL) TRAZODONE HYDROCHLORIDE
Drug Classes: selective serotonin reuptake inhibitor (SSRI)
NDA Applicant: ANGELINI PHARMA      NDA No.: 022411  Prod. No.: 001 DISC (150MG**); 002 DISC (300MG**)
PatentsExpirationPatented Use
Pat. No. 6607748 DP* Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture
Claim Types: Formulation; Product-by-process; Process
Pat. Sub. Date(s): All strengths: None
Jun 29, 2020 
Pat. No. 7829120 DP* Trazodone composition for once a day administration
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): 001: Dec 6, 2010; 002: None
Mar 27, 2027U-796: Method of treating depression
Pat. No. 8133893 DS* DP* Trazodone and trazodone hydrochloride in purified form
Claim Types: Formulation; Process
Pat. Sub. Date(s): 001: Mar 16, 2012; 002: None
Mar 13, 2029 

RYZOLT (TABLET, EXTENDED RELEASE) (ORAL) TRAMADOL HYDROCHLORIDE
Drug Classes: opioid agonist
NDA Applicant: PURDUE PHARMA      NDA No.: 021745  Prod. No.: 001 DISC (100MG**); 002 DISC (200MG**); 003 DISC (300MG**)
PatentsExpirationPatented Use
Pat. No. 6607748 DP* Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture
Claim Types: Formulation; Product-by-process; Process
Pat. Sub. Date(s): All strengths: None
Jun 29, 2020 
Pat. No. 7988998 DP* Sustained-release tramadol formulations with 24-hour efficacy
Claim Types: Formulation
Pat. Sub. Date(s): 001: Sep 1, 2011; 002: None; 003: None
Oct 27, 2023 

STALEVO 50; STALEVO 100; STALEVO 150; STALEVO 200; STALEVO 75; STALEVO 125 (TABLET) (ORAL) CARBIDOPA; ENTACAPONE; LEVODOPA [GENERIC AB]
Drug Classes: aromatic amino acid decarboxylation inhibitor; catechol o-methyl transferase (COMT) inhibitor
NDA Applicant: ORION PHARMA      NDA No.: 021485  Prod. No.: 001 RX (12.5MG;200MG;50MG); 002 RX (25MG;200MG;100MG); 003 RX (37.5MG;200MG;150MG); 004 RX (50MG;200MG;200MG); 005 RX (18.75MG;200MG;75MG); 006 RX (31.25MG;200MG;125MG)
PatentsExpirationPatented Use
Pat. No. 6500867 DP* Pharmaceutical composition comprising entacapone, levodopa, and carbidopa
Claim Types: Formulation; Method of use
Pat. Sub. Date(s): All strengths: None
Jun 29, 2020U-219: Treatment of Parkinson's disease
Pat. No. 6797732 DP* Pharmaceutical composition comprising entracapone, levodopa, and carbidopa
Claim Types: Composition; Formulation
Pat. Sub. Date(s): All strengths: None
Jun 29, 2020 

INLYTA (TABLET) (ORAL) AXITINIB
Drug Classes: kinase inhibitor
NDA Applicant: PF PRISM CV      NDA No.: 202324  Prod. No.: 001 RX (1MG); 002 RX (5MG)
PatentsExpirationPatented Use
Pat. No. 7141581 Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
Claim Types: Method of use
Pat. Sub. Date(s): 001: Feb 16, 2012; 002: None
Jun 30, 2020U-1220: Treatment of renal cell carcinoma
Pat. No. 6534524 DS* DP* [Extended 1764 days (4.8 years)]
Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
Claim Types: Compound; Composition; Method of use
Pat. Sub. Date(s): 001: Feb 16, 2012; 002: None
Apr 29, 2025 
Pat. No. 8791140 DS* Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyondazole suitable for the treatment of abnormal cell growth in mammals
Claim Types: New polymorph, salt or hydrate
Pat. Sub. Date(s): All strengths: None
Dec 14, 2030 
Pat. No. 10570202 Combination of a PD-1 antagonist and a VEGFR inhibitor for treating c